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Abstract 
 
Background 
There is increasing evidence that low vitamin D levels are implicated in 
paediatric asthma 
 
Hypotheses 
Children with severe, therapy resistant (STRA) have low serum vitamin D 
levels which are associated with worse asthma control and airway pathology. 
In vitro, steroid responsiveness of peripheral blood mononuclear cells 
(PBMCs) from STRA is improved by vitamin D. 
 
Methods 
Serum 25-hydroxyvitamin D (25[OH]D3) was measured in 36 STRA, 26 
mild/moderate asthmatics (MA) and 24 non-asthmatic controls, and related to 
asthma control and exacerbations. 22/36 children with STRA underwent 
bronchoscopy with assessment of airway inflammation and remodelling. The 
in vitro steroid responsiveness of PBMC was assessed, in the absence or 
presence of dexamethasone and vitamin D.  
 
Results 
Median 25[OH]D3 levels were significantly lower in STRA (28nmol/L) than MA 
(42.5nmol/L) and controls (56.5nmol/L). There were positive relationships 
between 25[OH]D3 levels and %predicted first second forced expired volume 
(r=0.4, p<0.001) and forced vital capacity (r=0.3, p=0.002). 25[OH]D3 levels 
were positively associated with asthma control test (ACT) (r=0.6, p<0.001) 
and inversely associated with exacerbations (r=-0.6, p<0.001) and inhaled 
steroid dose (r=-0.39, p=0.001) in asthmatics. Airway smooth muscle (ASM) 
mass was inversely related to 25[OH]D3 levels (r=-0.6, p<0.01). Asthmatic 
children had diminished levels of bronchoalveolar lavage IL-10 (p<0.001). 
Their PBMC also demonstrated significantly impaired capacity to secrete IL-
10 in culture (p<0.001) and the inclusion of vitamin D, enhanced 
dexamethasone-induced IL-10 (p<0.05), production. Furthermore vitamin D 
status correlated with airway IL-10 (r=0.6, p<0.01) and CD4+ FoxP3 T 
regulatory cells (r=0.6, p<0.01). Children with STRA had significantly higher 
vitamin D binding protein (VDBP) levels in BAL compared to MA (p<0.05) and 
controls (p<0.01) and these were positively associated with symptoms (ACT) 
(r=0.5, p=0.01) and inhaled corticosteroid usage (r=0.6, p=0<0.01)."
 
Summary 
Lower serum vitamin D levels in STRA children were associated with 
increased ASM mass, worse asthma control, lung function and reduced BAL 
IL-10 and T regulatory cells. In vitro vitamin D enhanced dexamethasone-
induced IL-10 production. These data suggest vitamin D supplementation may 
be useful in STRA and support the need for a clinical trial.  
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Chapter 1 Introduction 
 
Asthma is the most common chronic disease of childhood and its prevalence has 
increased dramatically over the past few decades.2 It is one of the leading causes of 
morbidity in children worldwide3 and has a significant social and financial burden on 
the individuals and families affected.4, 5 It can affect virtually all ages, and varies 
greatly in severity. Increasingly, the vitamin D pathways, that were thought to be 
predominantly related to bone health, have been implicated in the pathophysiology 
of asthma.  
 
The work of this thesis concerns the role of vitamin D in paediatric severe, therapy 
resistant asthma (STRA). This chapter begins by reviewing the immunopathology of 
asthma, and then the problem of severe asthma and steroid resistance. There 
follows a review of current knowledge of the important vitamin D pathways and their 
role in asthma, and concludes by formulating the hypotheses, aims and objectives of 
the thesis. A review article based on this chapter has been published in Paediatric 
Respiratory Reviews.6 
 
1.1 Immunopathology of asthma 
1.1.1 Asthma  
Asthma is a heterogeneous disease that is characterised by airway hyper-
responsiveness, recruitment of inflammatory leukocytes to the lung and tissue 
remodelling, including excess mucus production and airway smooth muscle 
hypertrophy and hyperplasia.7 It is largely a disease of the conducting airways, which 
in response to a wide range of exogenous and endogenous stimuli undergo 
exaggerated constriction, leading to airway hyper-responsiveness, the hallmark 
feature of the condition. It is classically driven by allergic responses (summarised in 
Figure 1.1), with enhanced activity of T helper (Th) 2 cells (discussed in the next 
section), leading to B-cell isotype switching to IgE production, and eosinophilic 
airway inflammation and airway hyperresponsiveness.7, 8 Submucosal eosinophilia 
has been described in paediatric asthma and preschool wheeze9, 10 and de Blic et 
al11 showed marked increase in epithelial eosinophils in symptomatic difficult  
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Figure 2.1 Allergic mechanisms in asthma. Reproduced from ‘Treatment 
strategies for allergy and asthma’12 
 
Abbreviations: Antigen-presenting cells (APCs), T helper 2 (TH2), Interleukin (IL), 
Regulatory T (TReg), High-affinity receptor for IgE (FcεRI), Interferon (IFN), T-cell receptor 
(TCR), Tumour-necrosis factor (TNF) 
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asthmatic as compared with non-symptomatic patients.  
 
Interactions between multiple factors including early allergen exposure and 
sensitization, tobacco smoke exposure, infections, diet, genetic predisposition, and 
pollution result in the development of chronic airway inflammation.13, 14 A number of 
different T cell subsets and the cytokines that they secrete are thought to influence 
the nature and magnitude of the allergic immune response in asthma (summarised in 
Figure 1.2).7 
 
 
Figure 1.2 T cells involved in the allergic asthma. Reproduced from ‘Functions of 
T cells in asthma: more than just Th2 cells’ 7 
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1.1.2 T helper cells in asthma 
Chronic airway inflammation in asthma is a multicellular process thought to be driven 
by CD4+ T lymphocytes. More CD4+ T cells are present in adult asthmatic 
bronchoalveolar (BAL) and bronchial biopsies as compared to controls.15, 16 Naïve 
CD4+ Th0 cells differentiate into subsets of CD4+Th cells on recognition of the 
specific signals from antigen presenting cells and dendritic cells.  Several subsets of 
CD4+ T cells are defined on the basis of their cytokine production exist but Th1 cells 
(involved in cell mediated immunity) and Th2 cells (antibody mediated immunity) are 
best described. Th1 cells are critical in cellular defence mechanisms to intracellular 
pathogens and viruses and produce interleukin (IL)-2, interferons (IFN) and tumor 
necrosis factor (TNF). In contrast, Th2 cells mediate responses to extracellular 
agents and secrete several mediators including IL-4, IL-5, IL-6, IL-9 and IL-13,17 and 
drive the response to allergen. The Th2 cytokines IL-4 and IL-13 induce B cells to 
undergo immunoglobulin class switching to produce IgE. During this mechanism, the 
constant region portion of the antibody heavy chain is changed, but not variable 
region.  "
There is now persuasive evidence that Th2 cells are important mediators of asthma 
and dominate the T cell infiltrate in the airways.18 Elevated levels of Th2 cytokine 
mRNA and protein are expressed in CD4+ T cells from asthmatic BAL.19-21 IL-5 
mediates eosinophil recruitment to inflammatory sites, survival and 
eosinophilopoiesis.22 IL- 5 may also be important in the production of an immune 
response in asthma since it mediates eosinophil priming, expansion, recruitment and 
prolonged tissue survival in response to allergens.23 IL-4 drives the differentiation of 
Th2 cells and promotes B cell class switching to IgE production, mast cell 
proliferation and recruitment of eosinophils.24-26 IL-13 promotes B cell IgE production, 
airway hyperreactivity and mucus production.27-29 IL-4 and IL-13 direct the migration 
of T lymphocytes, monocytes, basophils and eosinophils to sites of inflammation and 
stimulate B cell class switching (above).30 IgE activates mast cells. In animal models 
of allergic airway disease, antibodies that block the action of Th2 cytokines reduce 
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pulmonary eosinophilia and airway hyperreactivity (anti-IL-5 blocks eosinophils and 
anti-IL-13 blocks airway hyperresponsiveness).31, 32  
 
Th2 cells orchestrate the inflammatory response in asthma via the release of 
cytokines. A large number of studies, both mouse and human, document the 
expression of Th2-type cytokines, such as IL-4, IL-5, and IL-13, in the allergic lung.33 
Experimental models of asthma indicate that these Th2 cytokines, are critical in 
driving key pathologic features of the allergic response, including eosinophilic 
inflammation, airway mucus production, airway remodelling, and airway hyper 
responsiveness.33 However, clinical trials of drugs designed to modulate Th2 
cytokines have not been universally successful in asthmatic patients. Initial human 
trials with anti-IL-5 monoclonal antibody were not as successful in adult 
mild/moderate asthmatics(MA).34 However, more recently, double blind placebo 
controlled trials in adults with severe asthma have shown that anti-IL-5 antibody is 
effective in reducing exacerbations, specifically in the sub group of patients with 
sputum eosinophilia.35 This is very important as it suggests only a sub-set of patients 
are likely to respond to such therapy. 
 
The common effects of IL-4 and IL-13 are mediated via the IL-4 Rα receptor.30 IL-4 
also promotes the differentiation and proliferation of Th2 lymphocytes. IL-13 by 
activating STAT6 in the airway epithelium36 mediates airway hyper responsiveness 
and mucus hyperproduction.30 The IL-4 analogue pitrakinra binds to IL-4Rα, thus 
blocking IL-4 and IL-13. This has been shown to reduce the late phase response 
following allergen challenge compared with placebo in randomised, double-blind, 
placebo-controlled, phase 2a clinical trials in adults with atopic asthma.37 Recently it 
has been shown that patients with moderate to severe asthma who had specific IL-4 
receptor α gene polymorphisms were more likely to have reduced exacerbations, 
reduced nocturnal awakenings and improved activity following treatment with 
pitrakinra compared with those without the polymorphisms.38 This also reinforces 
that only a sub-set of patients will respond to such therapy, and possibly tests for 
such polymorphisms should be performed prior to initiation of this treatment."
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It has been proposed that severe asthma may in fact represent a spectrum of 
different pathophysiological subphenotypes.39 These appear to have a greater or 
lesser-extent of Th2 activity40 and may therefore explain inconsistencies in clinical 
response to both existing and novel pharmacotherapies targeting this axis.40, 41 In 
severe asthma, regulation of Th1/Th2 cytokine production has been shown to be 
different from MA and Th17 related cytokines (discussed in the next section) might 
be responsible for mediating inflammation.42 Bossley and colleagues43 have recently 
shown that children with STRA have airway eosinophilia without neutrophilia or 
increased mast cell counts. Importantly, in this cross-sectional study signature Th2 
cytokines (IL-4, IL-5 and IL-13) were absent in the majority of children and present 
only in a small subgroup, suggesting phenotypic heterogeneity.43 High-dose steroid 
treatment might have effectively suppressed the signature Th2 cytokines.33 Similarly 
Fitzpatrick and colleagues have shown that severe asthma in children is 
characterized by a distinct airway molecular phenotype that does not have a clear 
Th1 or Th2 pattern.44, 45 They found a mixture of Th1 and Th2 type inflammation in 
BAL and alveolar macrophages, with BAL IL-13 and IL-6 differentiating severe 
paediatric asthma from adult controls and RANTES, IL-10, IL-12, chemokine ligand 
(CXCL) 1 and IFNγ discriminated between STRA and MA in children.44, 45 In 
summary, it is evident that severe asthma can no longer be considered simply a Th2 
mediated disease but involves a more complex interplay between different T-cell 
subsets and mediators determined in individual patients by genetic and 
environmental influences.33 
 
1.1.3 Th17 cells in asthma  
Recently, additional subsets of Th cells have been described including Th17 cells.46-
51 The Th17 phenotype is defined by the expression of retinoic acid–related orphan 
receptor ã as a transcription factor and is characterized by secretion of the cytokines 
including IL-17A, IL-17F, IL-21 and IL-22.52, 53 Their differentiation is controlled by IL-
6, IL-21, IL-23, IL-1β and TGFβ (Figure 1.3).52, 53 In addition to Th17 cells, other cell 
types express and produce IL-17A, including hematopoietic cells and structural cells, 
such as epithelial cells, vascular endothelial cells, fibroblasts, CD8+ T cells, γδ T 
cells, invariant natural killer T cells, and lymphoid tissue inducer-like cells.54 
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Therefore the precise function of IL-17A may be determined by its cellular source.33 
IL-17 is involved in granulopoiesis; it is a key cytokine for the recruitment, activation, 
and migration of neutrophils; and has been shown to regulate neutrophil migration in 
the lung.55 It is postulated that the primary function of Th17 cells is to promote the 
clearance of certain infections (in particular extracellular bacteria and fungi) at 
mucosal surfaces.56  
 
Figure 1.3 Th17 differentiation and maturation. Reproduced from ‘The Basics of 
Th17 and Interleukin-6 in Transplantation’ 57 
 
 
More recently, elevated IL-17A has been implicated in asthma.58, 59 IL-17A mRNA 
and protein are upregulated in lung tissue of adults with asthma compared with 
healthy control subjects.58, 60 Using an immunofluorescence assay, Al-Ramli et al 
have shown the number of IL-17A and IL17F cells are associated with disease 
severity in endobronchial biopsies (EB) of adult asthmatics.61 In addition, the 
percentage of peripheral Th17 cells and the plasma concentrations of IL-17A and IL-
22 increase with disease severity.62 Elevated IL-17A levels correlate with increased 
hyperresponsiveness in patients with asthma.63 Overexpression of IL-17F in mouse 
lung tissue results in enhanced recruitment of neutrophils.64 IL-17A is also reported 
to modulate airway structural cells, leading to tissue remodelling.54 IL-17A may also 
alter airway structural cell function, by promoting smooth muscle motility and 
contractility.65, 66 In mouse models Th17 cells can upregulate Th2 cell-mediated 
eosinophilic airway inflammation and can enhance airway smooth muscle 
contraction, proliferation, and airway epithelial permeability to allergen.65 IL-17A 
expression is also reported to correlate with neutrophilic influx in severe adult 
asthma,60 but Bossley and colleagues43 and unpublished data (Bossley et al) have 
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recently shown absence of neutrophilic inflammation in paediatric STRA, thus calling 
into question the relevance of this mechanism at least in children. In a murine model 
of ovalbumin-induced allergic inflammation IL-17-producing γδT cells have been 
shown to mediate the resolution of allergic airway inflammation and airway 
hyperreactivity while adoptive transfer of Th17 cells had no such effect.67 The 
conflicting evidence in mouse models could be due to different mouse strains and 
allergen sensitization protocols.52 However, it is now known that IL-17A can be 
secreted by other cells besides Th17 cells and importantly, IL-17A may play different 
roles in the airway, depending on its cellular source and context.52 Specifically, it is 
not possible to conclude whether in human disease, IL-17A is causative, protective 
or has mixed roles in different circumstances. 
 
1.1.4 Regulatory T cells (Tregs) in asthma  
Allergic inflammation has been hypothesised to represent an abnormal response to 
harmless airborne particles.68 These reactions are normally suppressed by a 
complex series of mechanisms, including regulatory cells and cytokines, which 
maintain airway tolerance.33, 68 In asthmatic patients there is a breakdown in these 
regulatory mechanisms, leading to development of pulmonary inflammation on 
exposure to innocuous proteins, such as grass, pollens or cat dander.33, 68 Thus, 
Tregs are a subset of T cells that are thought to suppress the activity and 
inflammatory capacity of the innate and adaptive immune system.  
 
CD4+ Tregs (“naturally occurring Tregs”) are derived from the thymus and are 
characterized by expression of the forkhead winged transcription factor FoxP3 
(forkhead box P3).69, 70 In addition to the naturally occurring Treg, CD4+ Tregs may 
also be induced peripherally. Induced Tregs may be FoxP3 positive (FoxP3+) or 
FoxP3 negative (FoxP3-) and play an important role in the moderation of 
autoimmune, infectious, inflammatory and allergic responses to antigens.71 Tregs 
control immune responses through several mechanisms72 including secretion of the 
anti-inflammatory cytokines IL-1073 and TGF-β.74 They also have a role in the 
organization and regulation of recruitment of effector T cells to sites of 
inflammation.68, 75, 76 The most convincing support for a role of Tregs in preventing 
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the development of atopic disease stems from studies of the X-linked autoimmunity 
allergic dysregulation syndrome, also termed immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome.77 This is a rare 
multisystem disorders caused by a genetic abnormality (mutations in the gene 
coding for the transcription factor Foxp3 which is on the X chromosome). Young 
boys affected by mutations in this gene present with multisystem problems including 
enteropathy, endocrinopathy, severe infections, autoimmune disorders and severe 
allergic manifestations (including food allergies, atopic dermatitis, hyper IgE and 
eosinophilia) and infants and children with more severe forms of the disease tend to 
die without bone marrow transplantation or immunosuppression.77 
 
The manipulation of the Treg cell population in the allergic mouse lung by transfer of 
Tregs (CD4+CD25+FoxP3+) results in abrogation of allergic inflammation and 
airway hyperresponsiveness.78 The defective suppression of Treg is shown in 
children with moderate asthma. Treg cells isolated from BAL fluid or peripheral blood 
of asthmatic children were less effective in suppressing proliferation and production 
of Th2 cytokines and chemokines by CD4+CD25- responder T cells than Treg cells 
isolated from control subjects.79 Treg function may be impaired in asthma68, 80, 81 and 
pivotal human studies describing the role of Tregs in asthma are summarized in 
Table 1.1 
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Table 1.1 Pivotal human studies describing role of regulatory T (Treg) cell 
function in asthma and allergies 
Author  Type 
asthma 
Control 
group 
Compart-
ment 
tested  
Results 
Ling et 
al 82  
2004 
Atopic  
 
Adults 
Healthy & 
atopic 
adults with 
no 
symptoms 
Peripheral 
blood 
The suppressive activity of Treg cells 
from the peripheral blood of allergic 
patients during the hay fever season 
was reduced 
Hartl et 
al 79  
2007 
MA 
Children 
Children 
without 
lung 
diseases 
BAL CD4+CD25 high T cells are enriched 
in BAL compared with peripheral 
blood. Pulmonary (BAL), but not 
blood, CD4+CD25high T cells were 
decreased in number; however, this 
was restored following inhalation of 
corticosteroids. The number of 
CD25high cells correlated with 
clinical parameters such as lung 
function (r = 0.85). 
Lower level of Foxp3 mRNA in 
peripheral blood from asthmatics as 
compared with control. 
Akdis 
et al 
83 2004 
Atopic  
Adults 
Healthy 
controls 
Peripheral 
blood 
Reduced numbers of IL-10+ T cells 
in the allergic patients 
Lee et 
al84  
2007 
Allergic 
(allergic 
rhinitis or  
asthma) 
Children 
Healthy 
controls 
Peripheral 
blood 
Decrease in CD4+CD25+ T cells in 
the paediatric patients with allergic 
disease. These findings relate to the 
use of the CD25 marker to identify 
Treg. 
Lower level of Foxp3 mRNA in 
peripheral blood from asthmatics as 
compared with control subjects 
Provoo
st et al 
85 2009 
MA 
Adults 
Healthy 
adults 
Peripheral 
blood 
Asthmatics have normal numbers of 
FoxP3+ cells but reduced FoxP3 
expression  
Niemin
en et al  
201086 
 
Scaddi
ng et al 
87 
2010 
Atopic  
Children 
 
 
 
Atopic  
 
Adults 
Atopic 
children 
 
 
 
Healthy 
controls 
Peripheral 
blood 
 
 
Oral 
mucosal 
immune 
cells 
Successful allergen immunotherapy 
is associated with the induction of 
both FoxP3+ and IL-10 secreting 
Treg cells 
MA: moderate asthma, BAL: bronchoalveolar lavage, IL: interleukin 
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The consequence of sustained or dysregulated inflammation or ineffective resolution 
is chronic airway inflammation in asthma.67 The resolution of inflammation in airways 
is an active coordinated process, which prevents unnecessary tissue damage after 
clearance of inflammatory stimuli and promotes homeostasis. It depends on the 
actions of various anti-inflammatory and pro-resolving mediators including IL-10 
(below) and clearance of inflammatory cells. The capacity to mount a controlled 
inflammatory response is central to host defence. However, should inflammation 
proceed unrestrained, unwanted tissue damage may result.88-90 In summary, airway 
inflammation in asthma may be due to an excessive pro-inflammatory drive or 
insufficient anti-inflammatory resolution mechanisms, or both. 
 
IL-10 is a pleiotropic cytokine with broad anti-inflammatory and also 
immunosuppressant effects on both innate and adaptive immune cells (summarized 
in Text box 1.1.).91 IL-10 is synthesized and secreted by B cells, mast cells, 
eosinophils, macrophages and DCs, and all Th cell subsets including CD8+, 
CD4+FoxP3+ T cells and IL-10-secreting regulatory CD4+ T cells.73, 92-97 Strategies 
designed to increase the production of regulatory cells might be an effective 
treatment for asthma.33 Proof of this concept comes from studies of non-allergic 
beekeepers who are continually exposed to high doses of bee venom antigens. 
Allergen re-exposure suppressed allergen-specific T-cell proliferation and Th1/Th2 
cytokine secretion and was also associated with an in vivo switch to an IL-10 
secreting phenotype during the beekeeping season. In summary, the allergen re-
exposure each year was able to maintain clinical tolerance associated 
immunologically with restoration of the IL-10 response in culture.98 Allergen-specific 
immunotherapy is also associated with the development of allergen-specific Treg 
cells, which are able to control allergic immune responses, and suppressive 
cytokines, such as IL-10 are thought to play a pivotal role.86, 87 Thus a greater 
understanding of how immune responses are regulated in the allergic lung may 
enable manipulation of these regulatory mechanisms to develop novel and improved 
therapies for asthma.68 
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Text box 1.1 Immunomodulatory properties of IL -10  
• IL-10 inhibits mast cell activation and cytokine production.99-101  
• IL-10 inhibits eosinophil survival and function.102   
• IgG4 is an immunoglobulin isotype generally considered to be 
protective in allergic disease, whereas IgE is an important mediator of the 
allergic cascade.103 IL-10 appears to increase levels of circulating IgG4 relative 
to IgE.104   
• IL-10 inhibits the ability of antigen presenting cells to sustain adaptive 
immune responses by suppressing macrophage and dendritic cell production of 
inflammatory cytokines and expression of MHC class II and co-stimulatory 
molecules.105-111  
 
1.1.5 Airway remodelling in asthma  
Airway remodelling was defined by Peter Jeffrey112 as ‘the alteration in size, mass or 
number of tissue structural components that occurs during growth or in response to 
injury and/or inflammation'.112 Remodelling encompasses changes in the epithelium, 
reticular basement membrane (RBM), extracellular matrix, airway smooth muscle 
(ASM), blood vessels and mucous glands. This was first described more than 85 
years ago by Huber and Koessler in their classic paper on fatal asthma.113 Airway 
remodelling occurs in children with severe asthma114-116 and is characterized by 
increased thickness of the reticular basement membrane (due to an increase in 
reticulin deposition),117 ASM hypertrophy and hyperplasia, extracellular matrix 
deposition, epithelial shedding, hypertrophy of mucus-secreting glands and increase 
in size and number of the bronchial vessels within the airways (summarized in Text 
box 1.2). It is thought that airway remodelling worsens the clinical picture of asthma 
but some aspects of remodelling may be protective.114, 118 For example, a thickened 
airway wall may be less compliant and better able to resist dynamic compression.  
 
The submucosal eosinophilia is present in paediatric asthma and preschool wheeze9, 
10 but the presence of submucosal eosinophilia is not itself sufficient to cause 
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symptoms.9 In children, Bossley et al119 and Payne et al120 found no difference in 
submucosal neutrophils between subjects with difficult asthma and controls. de Blic 
et al11 showed marked increase in epithelial eosinophils and neutrophils in 
symptomatic difficult asthmatic as compared with non-symptomatic patients. T 
Lymphocytes are central to the pathogenesis of asthma and it may be that these 
cells also modulate airway remodelling. However, the relationship between 
inflammation and remodelling is unclear, but they are likely parallel processes, rather 
than remodelling being driven by inflammation. This hypothesis is supported by the 
paediatric work of Saglani and colleagues10, 121 that appeared to show inflammation 
and remodelling developing in parallel and also no relationship between eosinophils 
and remodelling was noted by Payne and colleagues.115 This is also supported by 
recent evidence from a novel neonatal mouse model of allergic airways disease 
which has shown that bronchial responsiveness, eosinophilic inflammation and 
remodelling occur in parallel during inhaled house dust mite sensitization.122 
 
The bronchial epithelium acts as a barrier separating the external environment and 
the lung parenchyma. The bronchial epithelium and underlying RBM have a close 
spatial and functional inter-relationship and are considered an epithelial-
mesenchymal trophic unit.123 The airway epithelium also plays a central role in the 
pathogenesis of asthma and the epithelium is emerging as an area of interest as 
new research shows interactions between the epithelium and the immune system 
are crucial in driving asthma.123 There is evidence that dysregulated epithelial repair 
originates in childhood asthma and is a critical determinant of disease 
progression.124 Genetic studies also suggest that the epithelium plays a significant 
role in the allergic response. Bronchial epithelial cells from asthmatic children 
function abnormally even in the absence of inflammation with decreased production 
of TGF-β and the release of anti-inflammatory mediators.124 There is also some in 
vitro evidence that an injured airway epithelium stimulates ASM cell hyperplasia.125 It 
is therefore possible that children with STRA have inherently functionally different 
epithelial cells, which thus respond abnormally to infectious, dietary, or 
environmental stimuli leading to ASM hyperplasia. The identification of key 
modulators regulating the contribution of ASM function to asthma may provide new 
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opportunities for therapeutic intervention. 
 
Text box 1.2 Airway remodelling in children  
Changes in reticular basement membrane (RBM) 
• Increased thickness of the RBM present in children with asthma and preschool 
wheeze.115 
• Increased RBM thickness is not present at a year of age,121 but appears as 
early as 3 years in preschool wheeze.10  
• Increased RBM thickness has been shown in children with mild9 and severe115 
asthma  
• No correlation between RBM thickness and lung function in children. 
• Increased thickness of the RBM is an important pathological feature of asthma 
but not related to the duration of asthma, or to treatment.115 
 
Changes in epithelium 
• Functional changes in epithelium are considered important in the pathogenesis 
of asthma.123 
• In children with mild asthma more epithelial shedding than in controls.9  
• Epithelial height is increased in asthmatics.126 
 
Changes in airway smooth muscle (ASM) 
• ASM mass (hypertrophy and hyperplasia) is increased in children with severe 
asthma.116  
• Positive correlation between ASM mass and bronchodilator reversibility.116 
• Increased ASM mass in children and adult with persistent obstructive 
pattern.127 
• Inverse relationship between forced expired volume (FEV1) and ASM mass in 
adults.127 Thus, ASM mass may be related to function.  
 
Changes in bronchial vessels  
• Increase in size and number of the bronchial vessel size within the airways 
have been shown in children with mild/moderate asthma.9 
• Dilated and congested blood vessels have been associated with fatal disease in 
adults.128 
• Study of childhood severe asthma showed the density of the vascular network 
to be more pronounced in children with fixed airway obstruction.129 
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1.2 Problematic severe asthma in children  
For most children with access to healthcare, asthma can be controlled with low 
doses of inhaled corticosteroids, sometimes in combination with long-acting β-2 
agonist, if regularly and properly administered.130 There remain, however, a 
substantial number of children with asthma, who, despite what appears to be 
appropriate treatment, continue to be symptomatic and at risk of acute 
exacerbations. Most assessments have proposed that this difficult-to-treat population 
represents 5-10% of all asthmatics.131-133 However, it is difficult to be certain of 
prevalence as definitions differ between studies. Although this high risk cohort only 
represents a small portion of all asthmatics, they suffer the greatest morbidity and 
mortality including exacerbations, admissions to intensive care, need for healthcare 
utilization and days lost in absence from school or work.134  
 
Entry criteria to our paediatric problematic severe asthma clinic at Royal Brompton 
Hospital (RBH) 134 are one or more of: 
1. Persistent (most days, for at least 3 months) chronic symptoms (the 
requirement because of symptoms for short-acting β-2 agonists at least three 
times/week) of airways obstruction despite high dose inhaled corticosteroids 
(Beclomethasone equivalent 800 mcg/day) and trials of add-on medications 
(these would include long acting β-2 agonist, leukotriene receptor antagonist, 
oral theophylline in the low, anti-inflammatory dose).  
2. Recurrent severe asthma exacerbations despite attempts with medication 
including trials of allergen avoidance, daily inhaled corticosteroids or 
intermittent high dose inhaled corticosteroids to abort exacerbations, that 
have required: either at least one admission to an intensive care unit, or at 
least two hospital admissions requiring intravenous medication/s, or> 2 
courses of oral steroids during the last year, despite the above therapy.  
3. Persistent airflow obstruction: post steroid trial, post-bronchodilator Z score < 
-1.96 or <80% predicted for forced expiratory volume in one second (FEV1) 
using appropriate reference equations 135 despite the above therapy.  
4. The necessity of prescription of alternate day or daily oral steroids to achieve 
control of asthma.  
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At RBH, these children with problematic asthma undergo a staged investigation 
protocol (Figure 1.4) to exclude a wrong diagnosis, asthma with critical co-
morbidities and difficult asthma (in which potentially modifiable factors have not been 
identified and remedied).136 The RBH protocol, including a formal assessment in the 
home (stage 1), results in almost half the referrals being classified as difficult 
asthmatics, in whom basic management needs to be optimized rather than therapy 
escalated.134, 136 The remaining children with STRA have persistent symptoms, acute 
severe exacerbations and/or fixed airflow obstruction unresponsive to high-dose 
steroid therapy and in whom all aspects of basic management have been assessed 
in detail and found to be satisfactory.134 Once the multidisciplinary team is satisfied 
that the basic management is right but the child is still symptomatic, we use a two 
stage (stage 2 & 3), invasive investigations protocol (Figure 1.4). This involves 
performing an assessment of asthma control (using the asthma control test [ACT]), 
spirometry, exhaled nitric oxide, measured at flow 50ml/s (FeNO50) and sputum 
induction, bronchoscopy, BAL and EB prior to the steroid trial. Triamcinolone is given 
intramuscularly in theatre while the child is anaesthetised for the bronchoscopy to 
ensure compliance with the steroid trial. Assessment of asthma control (using the 
ACT), spirometry, FeNO50 and sputum induction are then repeated 4 weeks later. 
The aims of the invasive investigations are to134 1) exclude an additional 
unsuspected diagnosis; 2) identify discordance between symptoms and lung function 
or airway pathology; 3) identify evidence of eosinophilic or neutrophilic inflammation; 
4) determine whether the child has persistent airflow limitation; and 5) assess the 
response to a single dose of intramuscular depot triamcinolone to determine whether 
there is at least partial steroid resistant airway inflammation. The over-arching aim is 
to try to produce an individualized treatment plan for the child; for example, it would 
seem illogical to give ever more potent anti-inflammatory medication to a child who is 
symptomatic but has no evidence of airway inflammation.134 
 
1.2.1 Assessment of steroid responsiveness in children  
The adult definition of steroid resistance is <15% increase in FEV1 after 2 weeks of 
oral prednisolone (40mg/day) in a patient with an abnormal FEV1 at baseline and 
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who can bronchodilate more than 15% with acute use of β2 agonist134, 137 This 
definition is not appropriate for children, who can have normal spirometry despite 
severe asthma134, 138-140 and Bossley and colleagues have recently shown that adult 
criteria of steroid responsiveness cannot be applied to 50% of children with STRA 
(manuscript submitted). Unlike adults, there is no universally agreed definition of 
steroid responsiveness in children or any consensus on the dose, duration and route 
of administration of treatment, or what end-points of steroid responsiveness to 
use.134  
 
Bush et al134 recently suggested the following non-evidence-based criteria for steroid 
responsiveness in children after intra-muscular (IM) triamcinolone134 and acute 
administration of inhaled β-2 agonist (Figure 1.4) 
1. Symptom response - Improvement in ACT score to at least 20 out of 25 or by 
at least 5 points141 
2. Lung function response - FEV1 rises to normal (>80% predicted) or >15% rise 
in FEV1% with no residual bronchodilator response (BDR))142, 143 
3. Inflammatory response (if paired induced sputum samples available)  - Return 
of sputum eosinophils to normal levels (eosinophils < 2.5%)144  
4. Inflammatory response (if paired induced sputum samples not available) - Fall 
in FeNO50 to normal (<24 parts per billion)145, 146  
 
Complete response is normalization in all three domains 
Partial response is improvement in one or two domains   
Non-response is classified as no improvement in any domain. 
 
This proposal is not evidence based and requires validation. Also, the magnitudes of 
the changes proposed as defining response are arbitrary. The work of this thesis is 
on children who have been evaluated with this protocol, and are thought to have 
genuine STRA, rather than difficult asthma. A major strength is the very detailed 
evaluation of potentially reversible factors to ensure as far as possible that the 
children had truly severe therapy resistant disease.136 Adherence was assessed by 
checking for prescription pick up and respiratory nurses checked the location and 
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availability of medications in the home (Text box 1.3). Respiratory nurses also 
checked for allergen and environmental tobacco smoke exposure in the home and 
asked the children and family to fill in psychosocial questionnaires, and referred 
those with significant morbidity for professional help. All these assessments had to 
be completed prior to invasive assessments. If all patients referred with difficult 
asthma had invasive assessment then children with difficult asthma would have 
contaminated the cohort. The thorough evaluation, as far as is possible, prevented 
this contamination of data. This is one of the novel features of this work. 
Text box 1.3 The nurse–led assessment136 (Stage 1 of the protocol) 
Hospital assessment 
• Patient history including triggers, environmental exposures, exacerbations in the 
past year and family history 
• Skin prick tests (food and aeroallergens, including moulds) 
• Exposure to tobacco smoke using urinary cotinine assay 
• Inhaler technique assessed and corrected 
• Semi-structured psychosocial questionnaire 
• Asthma control test 
• Sweat test (if this had not been previously performed) 
• Spirometry (including bronchodilator reversibility) 
• FeNO50 
• Chest X-ray 
• Consent to contact GP and pharmacies regarding medication pick up, and this is 
performed following the hospital assessment 
Home visit 
• Allergen exposure checked for including presence of allergens patient sensitised 
to, looking for house dust mite avoidance measures, and advice on exposure 
reduction 
• Evidence of smoke exposure 
• Adherence assessment; all medications checked including location, ease of access 
and if they were within their use-by-date 
• Discuss any issues raised by the psychosocial questionnaire 
• Attention to asthma education 
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Figure 1.4 The Royal Brompton Hospital paediatric problematic severe asthma 
investigation protocol134  
                     Stage 1  
Complete history 
Psychological questionnaire 
Spirometry (including BDR)  
FeNO50  
Sputum induction 
Skin prick tests 
Chest x ray (if not already 
performed 
Sweat test (if not already 
performed) 
Home and school visit 
Evaluation of medication pick 
up (compliance) 
 
 
     
 
If still symptomatic despite addressing issues in home visit 
Stage 2 
Asthma control test 
Non invasive markers of inflammation 
Spirometry (including BDR) 
FeNO50 
Sputum induction 
Invasive testing 
Fibreoptic bronchoscopy 
EB/BAL cytology 
BAL microscopy 
Immune function testing, atopy testing (RAST and total 
IgE) 
pH study 
 
DOSE OF IM TRIAMCINOLONE GIVEN IN THEATRE 
WHILE CHILD ANAESTETISED 
 
 
 
 
 
 
 
 
 
 
Stage 3 
Asthma control test 
Non invasive markers of inflammation 
Spirometry (including BDR) 
FeNO  
Sputum induction (
Individualized management plan 
 
Remediable 
factors are 
addressed, 
compliance 
improved, 
psychological 
referrals made 
(>50% of those 
assessed) 
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1.3 Steroid resistance  
Steroid resistance in asthma represents a major concern, since those patients are 
most at risk of hospitalization and death from asthma. The molecular mechanisms of 
glucocorticoid resistance in children are unclear and there is no accepted definition 
of steroid resistance (see above).147 Congenital steroid resistance due to mutations 
in the glucocorticoid receptor (GR) is rare.148 By definition children with STRA are 
steroid resistant and acquired steroid resistance is a spectrum and often can be 
overcome by high steroid doses, albeit at the risk of increased side-effects.147 The 
vast majority of studies investigating the potential mechanisms of steroid resistance 
have been performed in adults147, 149 and novel therapies aimed at overcoming 
clinical steroid resistance are pioneered in adult asthmatics.150-154 However it is 
increasingly recognized, both immunologically and in the development of novel 
therapies, that adult responses cannot be used to accurately predict those of 
children.155 This next section describes possible mechanisms of steroid resistance in 
asthma.  
 
1.3.1 Mechanism of corticosteroid action  
Corticosteroids bind with high affinity to GR to form a complex in the cytoplasm, 
activating the translocation of GRs into the nucleus. The cortisol-GR complex moves 
swiftly into the nucleus and inhibits inflammation by three molecular mechanisms156:- 
 
 (1) Direct genomic effect - binding with specific DNA sequences and influencing 
nuclear gene expression, thereby decreasing or increasing gene transcription.156 
  
(2) Indirect genomic effect - via blockade of the activity of nuclear factor-kB(NF- kB), 
a transcription factor for pro-inflammatory chemokines, cytokines, cell adhesion 
molecules, and receptors for these molecules.156 
 
(3) Non genomic effect - activates glucocorticoid signaling through membrane 
associated receptors and second messengers.156 There are three main non-genomic 
mechanisms  
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(a) Induction of the production of annexin I, which, by inhibiting the synthesis of 
cytosolic phospholipase, blocks the release of arachidonic acid from membrane 
phospholipids and its subsequent conversion to eicosanoids.156 
  
(b) Induction of the mitogen-activated protein kinase (MAPK) phosphatase 1 that 
dephosphorylates and inactivates members of MAPK cascades, thereby inhibiting 
the transcription of inflammatory proteins or indirectly inhibiting phospholipase A2-
alpha activity.156 
 
(c) Antagonism of the transcriptional activity of NF-kB, thereby inducing repression of 
cyclooxygenase 2.156  
 
1.3.2  Molecular mechanisms of steroid resistance  
The molecular mechanisms of steroid resistance in asthma have been studied 
mainly in adults and animals and include reduced glucocorticoid binding to GR, 
reduced GR expression, enhanced activation of inflammatory pathways or lack of 
corepressor activity. The molecular basis of steroid resistance is summarized in Text 
box 1.3 and Figure 1.5. 
 
Text box 1.3 Possible mechanisms of steroid resistance in asthma  
 
Reduced glucocorticoid receptor (GR) function  
• Reduced quantity and binding capacity of the GR alpha subunit.157, 158  
• Increased levels of the inhibitory receptor subunit GRβ and of pro-
inflammatory transcription factors such as activator protein-1 (AP-1) and nuclear 
factor of activated T cells (NFAT), both of which undermine GR from DNA-binding, 
and also inhibit histone acetyl transferase (HDAC) promoter activity in turn causing 
reduction of glucocorticosteroid effects. 152, 159, 160 
 
Impaired induction of anti- inflammatory genes and/or repression of pro-
inflammatory genes 
• Mitogen–activated protein kinase (MAPK) phosphatase-1 dephosphorylates 
and inactivates MAPK which are pro-inflammatory and are induced by steroids bound 
to GR. Impaired induction of MAPK phosphatase-1 by dexamethasone results steroid 
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resistance.161 
 
Cytokines 
• PBMC (peripheral blood mononuclear cells) from adult steroid resistant 
asthmatics fail to secrete IL-10 when treated in vitro with dexamethasone, as 
compared to PBMC from healthy individuals or steroid-sensitive asthmatics.162 IL-10 
has also been proposed to increase GR alpha.163 This suggests that induction of IL-10 
is an important part of the anti-inflammatory effect of corticosteroids in asthma. 
• PBMC cultures from steroid refractory adult asthmatics synthesise 
significantly higher levels of IL-17A than steroid sensitive patients and nonasthmatic 
control cultures.164 IL-17 has been associated with steroid resistance in adults.54 
Recently, IL-17A is also proposed to upregulate GRβ, a dominant negative receptor 
for steroids and this is proposed to drive steroid resistance.165  
• Combination of IL2/IL4 has also been attributed to induce steroid 
resistance.166 
 
Increase in free oxygen radicals /oxidative stress 
• Oxidative stress and smoking reduces HDAC2 expression and activity, in turn 
affecting inflammatory gene induction and repression leading to altered corticosteroid 
sensitivity. HDAC2 activity has been shown to inversely correlate with steroid 
sensitivity.167 
• Reduced HDAC2 expression in bronchial biopsies and BAL of asthmatics 
who smoke compared to non-smokers.167 
 
Obesity  
• Obese asthmatics do not have the same amount of airway inflammation as 
non-obese severe asthmatics.168  
• Response to ICS reduces with increasing BMI.169 
• In vitro, dexamethasone induced PBMCs and BAL MAKP-1 expression was 
reduced in overweight/obese compared with lean asthmatic adults. 170 
 
Vitamin D (discussed in detail in next section) 
• Vitamin D appears to maintain expression levels of GR in CD4+ T cells and 
thereby sensitivity to steroids by preventing corticosteroid-induced down-
regulation.163 
 "" "
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Figure 1.5 Mechanism of glucocorticoid action by the glucocorticoid receptor 
and sites of regulation in glucocorticoid insensitivity. Note that this figure is 
based on adult and animal, not paediatric, data. Reproduced from ‘Molecular 
Mechanisms of Corticosteroid resistance’152 "
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1.3.3 Steroid resistance in asthma and vitamin D in asthma 
Vitamin D, once thought mainly to be important for bone metabolism, is now known 
to interact with a large number of immunological pathways, and has been implicated 
as being important in many inflammatory respiratory diseases including steroid 
resistant asthma in adults. However, very little is known about the role of vitamin D in 
paediatric STRA.147  
 
Corticosteroids in vitro induce IL-10 synthesis by peripheral immune cells and CD8+ 
T cells depleted PBMC stimulated with anti-CD3 antibody, IL-2, IL-4 in the presence 
of steroids show a dose dependent induction of IL-10 synthesis.162 Also, CD8+ T 
cells depleted PBMC from steroid resistant adult asthmatics fail to show increased 
IL-10 synthesis following in vitro stimulation in the presence of glucocorticoids,162 
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implying that induction of IL-10 is an critical part of the anti-inflammatory effect of 
glucocorticoids. Importantly, this defect in corticosteroid-induced IL-10 synthesis was 
overcome by the addition of vitamin D to the CD4+ T cell culture.171  Following on, a 
small pilot study was carried out which demonstrated that oral ingestion of 0.5 mcg 
vitamin D3 (calcitriol) daily for 7 days by steroid-resistant asthmatic patients restored 
the  CD4+ T cell response to dexamethasone in terms of induction of IL-10 in vitro. 
Vitamin D also appears to maintain expression levels of GR in CD4+ T cells and 
thereby sensitivity to steroids.163  !
 
Sutherland et al172 have reported an association between lower serum vitamin D 
concentrations and impaired lung function (reduced FEV1), increased airway hyper-
responsiveness, and decreased in vitro steroid response in a small cohort of adults 
with mild or MA, whilst higher serum vitamin D concentrations associated with 
enhanced dexamethasone-induced expression of MAPK phosphatase-1 by PBMC in 
an apparently IL-10–independent fashion.172 Another interaction between Vitamin D 
and glucocorticoid resistance involves the ability to regulate inflammatory gene 
expression and GR. In vitro, physiologic concentrations of vitamin D added to 
dexamethasone significantly enhanced MAPK phosphatase-1 expression in PBMCs 
compared with dexamethasone alone, suggesting that the addition of vitamin D 
could decrease the dexamethasone dose requirement for steroid response by more 
than 10-fold.173 This relationship was stronger in patients who were steroid naïve.173  
 
As discussed previously, reduction in Treg numbers has been linked with 
corticosteroid resistance.174, 175 Vitamin D has been shown to increase the number of 
Tregs in peripheral blood and cell culture163, 171, 176-179 and in the absence of vitamin 
D both the number and function of Tregs are reduced.162, 179-181"Thus it is possible 
that the mechanism of the reversibility effect of vitamin D on steroid resistance is via 
an up-regulation of Treg cells. In a recent adult study of moderate and severe 
asthmatic individuals who were vitamin D insufficient (defined as less than 75 
nmol/l), those who exhibited steroid resistance had a significantly lower numbers of 
CD4+CD25+FOXP3+ Treg cells in the peripheral blood as compared to the adults 
with steroid sensitive asthma.181 Furthermore, in these individuals serum 25[OH]D3 
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level was strongly associated with FOXP3+ Treg cell number. Thus these data 
support the hypothesis that vitamin D deficiency in adults hinders the expression of 
FOXP3 in CD4+ Treg cells, subsequently lowers the steroid-induced IL-10 
production by these cells and diminishes the anti-inflammatory effects of 
glucocorticoids.  
 
It could be postulated that such synergistic effect of vitamin D on corticosteroids in 
adults observed in vitro might translate to clinical outcomes. In a childhood cohort of 
mild to moderate persistent asthmatics who received inhaled corticosteroid, lung 
function (pre-bronchodilator FEV1) improvement, was the greatest in the vitamin D 
sufficient group (defined as >30 ng/ml) as compared to the vitamin D-deficient group 
(defined as ≤ 20 ng/ml).182 Another study, in 616 Costa Rican asthmatic children, 
showed an inverse association between vitamin D levels and the use of anti-
inflammatory medication (either inhaled corticosteroids or leukotriene inhibitors)183 
and Searing et al173 also found that low levels of vitamin D were significantly 
associated with inhaled and oral steroid use and total steroid dose173 in children with 
asthma. The authors concluded that vitamin D supplementation might potentiate the 
anti-inflammatory function of corticosteroids in asthmatic patients.173  
 
In summary, these studies suggest that insufficient serum vitamin D levels might 
increase asthma severity, thus requiring increased treatment, or that down-regulation 
of glucocorticoid pathways due to insufficient vitamin D leads to a need for increased 
steroid doses. Hence, the next section reviews the current understanding of vitamin 
D physiology, deficiency and insufficiency.   
 
1.4 Vitamin D 
1.4.1 Sources of vitamin D  
Vitamin D is derived from skin exposure to ultraviolet B (UVB) rays and the diet. 
Dietary sources include fish oil, fish, liver, egg yolk and many dietary 
supplements.184, 185 As very few foods contain vitamin D, sunlight exposure is the 
primary determinant of vitamin D status in humans. In a fair skinned person, 20 to 30 
minutes of sunlight exposure of the face and forearms at midday is estimated to 
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generate the equivalent of around 2000 IU of vitamin D. Two or three such sunlight 
exposures a week are sufficient to achieve healthy vitamin D levels in summer in the 
UK.186 In the absence of adequate sun exposure, at least 800–1000 IU (20–25 µg) 
vitamin D in the diet per day may be needed to achieve this.187 
 
1.4.2 Vitamin D metabolism 
Vitamin D synthesis is initiated in the skin by solar UVB radiation (wavelength 290 to 
315 nm), activating the precursor 7-dehydrocholesterol, which then circulates in the 
bloodstream to the liver, where it is converted into its main metabolite, 25-
dihydroxyvitamin D (25[OH]D3), which has blood levels about 1000 times higher 
than the active metabolite, 1α,25VitD3. A summary of vitamin D metabolism is 
depicted in Figure 1.6. Until recently, it was thought that the conversion to 
1α,25VitD3 occurred only in the kidneys, but increasing evidence indicates that the 
cells of most organs express the vitamin D receptor and have the capacity to 
synthesize 1α,25VitD3 locally.185 This synthesis of 1α,25VitD3 is dependent on 
serum 25(OH)D3 levels, the primary circulating form of vitamin D.185 
 
Systemic 25[OH]D and 1α,25VitD3 may enter into the cells unbound or complexed 
with vitamin D binding protein (VDBP) via diffusion or endocytosis.188 Once in the 
cytoplasm, 1α,25VitD3 binds to its receptor (vitamin D receptor). 1α,25VitD3 acts 
through the vitamin D receptor, a nuclear hormone receptor which is expressed in a 
variety of cell types, including those of the innate and adaptive immune system.189 
The binding of vitamin D to vitamin D receptor activates the receptor, forms a 
heterodimer with retinoid-X receptor and the heterodimer subsequently translocates 
to the nucleus.188, 189 In the nucleus the vitamin D receptor – retinoid-X receptor 
complex binds to a specific DNA sequence on a gene promoter region called vitamin 
D response elements to transactivate expression of the target genes.189 Coactivators 
of the vitamin D receptor further regulate transcription of vitamin D–dependent innate 
immune target genes. The genomic effects of vitamin D usually take hours or days to 
be noticed and are considered the slow effects of vitamin D.188 
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Figure 1.6 Metabolism of Vitamin D. A) Bone metabolism B) Non-skeletal 
functions. Reproduced from ‘Vitamin D deficiency’ ( Holick NEJM 2007)185   
A) Vitamin D – bone metabolism  
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B) Vitamin D – non-skeletal functions  
 
 
1.4.3 Definition of vitamin D deficiency and insufficiency 
Serum 25[OH]D3 is the best indicator of overall vitamin D status because this 
measurement reflects total vitamin D from dietary intake and sun exposure, as well 
as the hepatic conversion of vitamin D from adipose stores. There are no consensus 
guidelines available on optimal levels of serum 25[OH]D3. Vitamin D deficiency is 
defined by most experts as a 25[OH]D3 level of less than 50 nmol/L (20 ng per 
millilitre).185, 190-194 The 25[OH]D3 levels are inversely related to parathyroid hormone 
levels until the former reach 75 to 100 nmol/L (30-40 ng per millilitre), at which point 
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parathyroid hormone levels begin to level off (at their nadir).193, 195, 196  Intestinal 
calcium transport increases by 45 to 65% when vitamin D levels increase from an 
average of 50 to 80 nmol/L  (20 to 32 ng per millilitre).197 25[OH]D3 levels between 
50-75 nmol/L (20-30 ng per millilitre ) are considered indicative of vitamin D 
insufficiency on the basis of the above data and their association with health 
outcomes.194, 198, 199 25[OH]D3 levels of 75 nmol/L (30 ng per millilitre) to 100 nmol/L, 
are indicative of normal vitamin D levels.200, 201 Excessive levels or vitamin D 
intoxication are rare.185, 202 The current Institute of Medicine (IOM) guidelines from 
2011 recommended a lower limit of 50 nmol/L (20 ng per milliliter) and an upper limit 
of 125 nmol/L (50 ng/ml).203 It should be noted that these values are based entirely 
on the levels required to maintain bone health,185, 190-194 and may be totally different 
to those needed for immunological and pulmonary health. 
 
Table 1.2.  Serum 25-hydroxyvitamin D (25[OH]D3) concentrations 
Vitamin D 
status 
Serum 25-[OH]D3 
concentration in nmol/l 
Serum 25-[OH]D3 
concentration in mcg/l or ng/ml 
Deficient <50  <20 
Insufficient 50-75  20-30 
Optimal >75  >30 
*To convert to µg/l divide by 2.5. 
 
1.4.4 Prevalence of vitamin D deficiency and insufficiency  
Vitamin D deficiency is one of the most common medical conditions worldwide with 
more than 1 billion children and adults at risk.204 A recent survey of 7437 adults from 
across the UK showed 60% had serum 25(OH)D3 concentrations below 75 nmol/L 
(30 ng per millilitre) in the summer months and 87% were insufficient in the winter.205 
This survey also demonstrated a gradient of prevalence across the UK, with highest 
rates of insufficiency in Scotland, northern England, and Northern Ireland.205 People 
living at higher latitudes are known to be at greater risk for vitamin D deficiency.206 
Depending on the levels used to define vitamin D deficiency, 57% to 93% of the 
general hospital inpatient population is deficient193 and a recent meta-analysis 
52" "
concluded that use of vitamin D supplements is associated with decrease in total all-
cause mortality rates.207 
 
Children and young adults are also potentially at high risk of vitamin D deficiency; 44 
(12%) of 365 infants and toddlers from Boston,208 and 129 (42%) of 307 adolescents 
from Boston 209 had 25(OH)D3 concentrations below 50 nmol/L (20 ng per millilitre). 
A recent large, cross-sectional survey210 (US National Health and Nutrition 
Examination Survey from 2001-2004) showed that 61% of 6275 children aged 1 to 
21 years had insufficient levels of vitamin D.210 The prevalence of vitamin D 
deficiency is also reflected in the several hundred children with rickets treated each 
year in the UK.211 However, these children represent a small proportion of all 
individuals with suboptimal vitamin D levels in the UK population.205, 212  
 
1.4.5 Risk factors for vitamin D deficiency and insufficiency 
Vitamin D skin metabolism is influenced by age, skin pigmentation (melanin content 
of the skin), sun exposure (latitude, season, time outdoors, and clothing), body fat 
and sunscreen use (for example, use of sun protection factor (SPF) 8 reduces 
vitamin D production by 92.5% and SPF 15 by 99%).185, 187 Risk factors for vitamin D 
deficiency and insufficiency are summarized in Table 1.3 
 
Table 1.3 Risk factors for Vitamin D Deficiency/Insufficiency in children147 
Risk factors  
1. Lack of sunlight exposure (very little vitamin D is produced in 
people living in areas at beyond a latitude of 35° from October 
to March) 
2. Non-white ethnicity (pigmented skin)  
3. Concealing clothing (for example use of veil, headscarf) 
4. Use of sun screen  
5. Obesity 
6. Institutionalized individuals who spend relatively large amount 
of time indoors.  
7. Liver disease, malabsorption, short bowel, drugs such as 
phenobarbitone, cholestyramine, orlistat 
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The next section reviews the epidemiological evidence of the association between 
vitamin D and asthma. 
 
1.4.6 Epidemiological evidence of an association between vitamin D and 
asthma  
Vitamin D deficiency and asthma are both common, and share risk factors such as 
urban residence,213, 214 black ethnicity215-217 and obesity.218, 219 This has generated 
interest in exploring a link between vitamin D deficiency and asthma.220  
 
Black et al reported a positive correlation between serum vitamin D and FEV1 and 
forced vital capacity (FVC) in a cross sectional study of 14,000 adults.221 An 
association between lower serum vitamin D concentrations and impaired spirometry 
is also reported in children173, 222 and adults172 with mild to moderate asthma. A high 
prevalence of vitamin D deficiency (54%, 46 out of 85) and insufficiency (86%, 73 out 
of 85) was noted in a recent cross sectional case control study of inner-city African-
American children with asthma. Significantly lower vitamin D levels were also noted 
in asthmatic children compared to healthy controls.223 A study of 616 Costa Rican 
asthmatic children between the ages of 6 and 14 years showed an inverse 
association between serum vitamin D and total IgE levels, and peripheral blood 
eosinophil counts.183 A high frequency of vitamin D insufficiency (35%) in 1024 North 
American children with mild-to-MA has also been reported. In addition, vitamin D 
insufficiency was associated with a lower FEV1 compared with children with sufficient 
levels.222 Vitamin D levels are known to change with demographic and lifestyle 
variables and this study did not report repeated vitamin D measurements over time, 
an issue that limits our ability to understand the extent to which fluctuations in 
vitamin D levels over time influence asthma.222 
 
Recently, Searing et al173 have shown the prevalence of vitamin D insufficiency was 
47% (47 / 100) in children with asthma who were primarily from latitudes above 
35°N, and 17% (17/100) of asthmatic children were vitamin D deficient. These 
percentages were higher than those in the equatorial population from Costa Rica, in 
which 175 (28%) of asthmatic children were vitamin D insufficient.183 The differences 
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between these studies support the association of an increased risk of vitamin D 
deficiency in populations living at higher, northern latitudes. Searing et al173 also 
found that vitamin D levels were positively correlated with FEV1 percent predicted 
and the FEV1/FVC ratio.173 Total IgE and the number of positive aeroallergen skin 
prick test responses showed a significant inverse correlation with vitamin D levels. 
More recently a positive association between vitamin D levels and asthma control 
(assessed by childhood ACT)224 and negative association with exercise induced 
bronchoconstriction has also been shown in Italian asthmatic children.225   
 
Although these studies suggested a role for vitamin D in asthma control, some 
authors have also suggested that vitamin D may promote, rather than ameliorate the 
asthmatic phenotype.226 Although these studies suggested a role for vitamin D in 
improving asthma control, Wjst et al have suggested that vitamin D may promote, 
rather than ameliorate the asthmatic phenotype.227 In many studies, it is uncertain 
whether vitamin D is critical in airway inflammation or is just an indirect biomarker for 
asthma morbidity. A large, population-based, cross-sectional survey found that 
corticosteroid therapy of any kind (not just for asthma) is associated with low levels 
of vitamin D, possibly because exogenously administered corticosteroids accelerate 
degradation of vitamin D.228 The potential relationship between vitamin D deficiency 
and asthma is further confounded by the strong association with physical activity, 
which is linked to an individual’s level of exposure to sunlight229 and disease severity, 
which means that it is unclear whether vitamin D is simply an indirect marker of 
physical activity or disease severity and, therefore, is an innocent spectator in 
disease pathogenesis.Also, whether there is a direct effect of airway inflammation in 
asthma on circulating vitamin D levels is not known. Given that there is local 
upregulation of the conversion of 25(OH)D to 1,25(OH)2D during infection or 
inflammation one might predict that immediate circulating levels / store of 25(OH)D 
would be depleted. It is possible that in the setting of chronic airway inflammation 
systemic vitamin D levels may be reduced as a direct result of the inflammatory 
response, which further confounds the positive association between vitamin D 
deficiency and disease severity.230-232  In summary, associations between asthma 
and vitamin D could represent causality, reverse causation, or be a consequence of 
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inflammation or treatment.  
 
Regular vitamin D supplementation (2000 IU/day) in the first year of life increased 
the risk of developing atopy, allergic rhinitis, and asthma when assessed at age 31 
years.233 However, this study was limited by the absence of data on maternal intake 
of vitamin D and assessment of childhood asthma or atopy. Mothers reported the 
frequency and dose of vitamin D supplementation and daily dose was calculated 
based on this information.  Furthermore, this finding may be related to the very high 
dose of vitamin D supplementation.202 Another study from the United Kingdom has 
shown that pregnant women with higher levels of vitamin D have offspring with an 
increased risk of eczema at 9 months and asthma at 9 years of age,234 however, this 
study also has important limitations (only 30% [178 out of 596] follow-up at age 9 
years and relatively small numbers [n=596]). In another study of 922 newborns, low 
cord blood vitamin D levels were associated with an increased risk of respiratory 
infections at three months of age and wheeze by five years of age, but again were 
not associated with doctor diagnosed asthma.235 This study was limited by 
unavailability of vitamin D status during pregnancy and childhood and information 
regarding respiratory infections and wheeze were captured from interviews with 
mother rather than medical evaluation. In summary, the evidence to suggest that 
higher vitamin D levels reduce the incidence of asthma is conflicting and 
observational studies of vitamin D and asthma are summarized in Table 1.4. These 
variable results may be secondary to differences in the absolute amount of vitamin D 
exposure, the baseline vitamin D status (vitamin D deficiency versus insufficiency) 
and the timing of exposure (naive immune cells versus mature cell lines). 
Furthermore, the effect of vitamin D status on asthma and allergic diseases may only 
exist among a subgroup of subjects with particular genotypes. This is supported by a 
recent study,236 investigating the effect of low cord blood vitamin D and gene 
interactions on the development of food sensitization using a prospective birth cohort 
design. They noted vitamin D deficiency alone, was not associated with food 
sensitization, however, when individual genetic susceptibility was also considered, 
vitamin D deficiency increased the risk of sensitization among children with certain 
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high-risk genotypes. This underscores the need to consider individual genetic 
susceptibility in assessing effects of vitamin D deficiency.  Polymorphisms exist in 
the genes encoding the vitamin D receptor, VDBP and enzymes involved in vitamin 
D metabolism. Some genetic studies have reported associations between vitamin D 
status and asthma. Genome scans for asthma have identified possible linkages on 
17 different chromosomes, including chromosome 12, region q13-23. Because the 
vitamin D receptor gene spans 63kb of the long arm of chromosome 12, some 
geneticists have postulated an association between vitamin D receptor 
polymorphisms and genetic susceptibility for asthma and allergy,237-239 and more 
specifically an area towards the centromeric end of chromosome 12q, which includes 
the vitamin D receptor gene.  Other potential candidate asthma genes map to this 
region, including STAT-6 (a signaling molecule in Th2 cells), IRAK3 (involved in IL-1 
signaling) and c-kit (mast cell growth factor receptor). However, studies of a number 
of single nucleotide polymorphisms (SNPs) in these genes have not identified a link 
with asthma237 
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Table 1.4 Vitamin D and asthma in children and adults. Updated from Vitamin D 
and asthma in children6!
Effect of vitamin D Study 
Limitations  
Population 
studied 
Children / 
adults 
Study 
type  
Authors  
Log10  ↑in serum vitamin D 
level associated with ↓ 
hospitalizations, ↓ anti-
inflammatory medication, 
and ↓ markers of allergy 
Cross 
sectional 
study 
(inability to 
exclude 
reverse 
causation) 
Costa Rica 
 
Asthma 
616 
children, 
aged 6-14  
Cross 
sectional 
Brehm et 
al 183 
Vitamin D insufficiency is 
common in children with 
mild-to-moderate asthma 
and is associated with higher 
odds of severe exacerbation 
over a 4-year period 
Lack of 
repeated 
measures of 
vitamin D 
North 
American  
 
Severe 
Asthma 
1024 
Children 
Sub study 
of 
Childhood 
Asthma 
Managem
ent 
Program 
(CAMP) 
study 
Brehm et 
al 222  
Vitamin D insufficiency is 
associated with reduced 
asthma control  
Inability to 
exclude 
reverse 
causation, 
small sample 
size 
Italian  
 
Asthma 
75 
children 
(5-11yrs) 
Cross 
sectional 
Chinellato 
et al 240  
Lower serum Vitamin D 
levels associated with 
reduced lung function and 
increased airway reactivity to 
exercise  
Inability to 
exclude 
reverse 
causation, 
small sample 
size 
Italian  
 
Asthma 
45 
children 
(5-11yrs) 
Cross 
sectional 
Chinellato 
et al 225  
Vitamin D level was 
positively correlated with 
lung function and inversely 
correlated with total IgE, 
atopy and steroid use 
Inability to 
exclude 
reverse 
causation, 
lack of 
adjustments 
to 
confounders.  
 
 
 
 
 
 
Denver, 
Colorado 
 Asthma 
 
100 
children  
Cross 
sectional  
Searing et 
al 241 
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Vitamin D level at 6 years 
was associated with asthma 
in boys at 14 years of age.  
Children (particularly males) 
with inadequate vitamin D 
are at increased risk of 
developing atopy, and 
asthma 
Significant 
loss to follow 
up  
Australia 
 
Asthma 
989 - 6 yrs 
old,  
1380 14 
yrs old  
(689 
children 
were seen 
longitudin
ally at 
both 6 and 
14 years) 
Longitudin
al and 
Cross-
sectional 
Hollams et 
al 242 
Vitamin D deficiency 
associated with asthma 
Small sample 
size 
Washington
, DC 
Asthma 
106 
children 
(6-20 yrs) 
Case 
control 
study 
Cross 
sectional 
design  
Freishtat 
et al 215 
Regular vitamin D 
supplementation (2000 
IU/day) in the first year of life 
increased the risk of 
developing atopy, allergic 
rhinitis, and asthma by age 
31 years 
Lack of 
serum 
vitamin D 
levels in 
infancy, no 
study visits 
between 4-31 
year of age 
and 29% 
were lost to 
follow up 
Finland 
 
General 
Population  
7648 
adults 
Cross 
sectional 
study at 
31 years 
of age 
Hypponen 
et al 243 
Vitamin D deficiency 
associated with decreased 
lung function in newly 
diagnosed asthmatics 
Inability to 
exclude 
reverse 
causation 
Chinese 
 
Asthma 
Adults Cross 
sectional  
Li et al 244 
No association  Low vitamin 
D level in all 
subjects,  
United 
Kingdom 
 
Asthma  
160 Adults Case 
control 
study 
Cross 
sectional 
design 
Devereux 
et al 245 
Vitamin D level was 
positively correlated with 
lung function and 
glucocorticoid response  
Small sample 
size, Inability 
to exclude 
reverse 
causation 
Denver, 
Colorado 
 
Asthma 
54 adults Cross 
sectional 
Sutherlan-
d et al 246 
Severe and uncontrolled 
asthma in adults is 
associated with vitamin D 
insufficiency and deficiency  
Inability to 
exclude 
reverse 
causation 
Germany  280 Adults Cross 
sectional 
design 
Korn et 
al247 
Association between vitamin 
D receptor polymorphisms 
and asthma 
Small sample 
size 
Tunisia 155 
children 
225 
control 
Case 
control 
study 
 
Maalmi et 
al248 
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No association Inability to 
exclude 
reverse 
causation.   
Worcester, 
USA 
263 
children 
with 
asthma 
284 
controls 
Retrospec
tive, Case 
control 
study 
 
Menon et 
al249 
No association between 
maternal late pregnancy 
vitamin D status and either 
asthma or wheeze at age 6 
years.  
Only single 
serum 
measuremen
t, incomplete 
follow up 
Southampto
n, United 
Kingdom 
451 
children 
Prospectiv
e  
Pike et 
al250 
Vitamin D insufficiency is 
associated with severe 
asthma exacerbations, 
independently of racial 
ancestry, atopy and time 
spent outdoors. 
No 
information 
on 
adherence to 
prescribed 
steroids  
Puerto Rico 560 
childen 
Cross 
sectional 
study 
Brehm et 
al251 
Low serum vitamin D levels 
were associated with asthma 
atopy and asthma, 
predominantly in boys, at 
age 6 and 14. 
Inability to 
exclude 
reverse 
causation.   
Western 
Australia 
689 
children 
were 
assessed 
at both 
ages 
Longitudin
al cohort 
study 
Hollams et 
al252 
Serum vitamin D levels were 
inversely associated with 
asthma 
Inability to 
exclude 
reverse 
causation.   
Iran 50 
asthamtic 
children 
and 50 
controls 
Cross-
sectional 
study  
Alyasin et 
al253 
Cord Vitamin D levels are 
inversely associated with risk 
of wheezing but no 
association with asthma at 5 
years.  
Short 
duration of 
follow up 
New 
Zealand  
 
1105 
children, 
823 
assessed 
at 5 years  
Population 
based 
birth 
cohort 
studies 
Camargo 
et al 235 
Vitamin D levels were 
inversely associated with 
wheeze and asthma 
Inability to 
exclude 
reverse 
causation 
US 6857 
children & 
adults 
Cross 
sectional 
study 
(NHANES 
2005-6) 
Keet et 
al254 
Vitamin D concentration at 
age 4 years was inversely 
associated with asthma at 4-
8, whereas vitamin D 
measurement at age 8 was 
positively associated with 
asthma at age 8.  
Small sample 
size, 
diagnosis of 
severe 
asthma was 
based on 
parental 
questionnaire  
Netherlands 372 at 4yr 
and 
different 8 
year sub 
group of 
328 
Cohort 
study – 
cross 
sectional 
as well as 
longitudin
al  
PIAMA 
birth 
cohort of 
4146 
pregnant 
women. 
Oeffelen 
et al 255 
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Importantly, the observational nature of these studies precludes an assessment of 
cause and effect. Epidemiological cross-sectional studies suggest an association but 
do not prove causality. Longitudinal and interventional studies in children and adults 
are needed to elucidate any relationship more clearly. 
 
1.4.7 Epidemiological evidence of a link between vitamin D and preschool 
asthma / wheeze 
Prenatal vitamin D status is thought to affect the development of the fetal lung and 
immune system.256, 257 Thus it is possible that vitamin D deficiency/insufficiency in 
early life predisposes individuals to asthma. A birth cohort (n=2000) in Scotland 
showed children of healthy mothers who had lower vitamin D intake had an 
increased risk of recurrent wheeze at age 5 years. However, there was no 
association with spirometry or FeNO50.258 In another epidemiological study of 1194 
mother-child pairs, children born to healthy women living in an inner city who had 
vitamin D deficiency during pregnancy were at increased risk for recurrent wheeze at 
3 years of age.259  A limiting factor to all these studies was the use of food frequency 
questionnaires and not serum levels of vitamin D. Observational studies of vitamin D 
and preschool wheezing are summarized in Table 1.5 
 
In summary, in utero and early life vitamin D deficiency/insufficiency is associated 
with an increased risk of wheezing. However, association does not prove causation, 
and further evaluation needs to be undertaken to clarify the exact role of vitamin D in 
the pathogenesis of wheeze and asthma.  
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Table 1.5 Vitamin D and wheeze in preschool children Updated from Vitamin D 
and asthma in children6 
Effect of vitamin D Limitations Age group  Study type  Authors 
Low serum vitamin D is 
associated with 
increased risk of viral co-
infection in wheezing 
children 
Cross sectional 
study, uncertain 
diagnosis 
284 
Preschool 
children (1-
2.8 years) 
Substudy of 
the VINKU 
project, 
Finland 
Jartti et al 
260  
Cord blood levels of 
vitamin D are inversely 
associated with risk of 
respiratory infections and 
childhood wheezing but 
no association with 
asthma at 5 years.  
Short duration 
of follow up 
Birth 
cohort of 
1105 
children, 
823 
assessed 
at 5 years 
of age 
New 
Zealand 
birth cohort  
Population 
based 
cohort 
studies 
Camargo 
et al 235  
Mothers in highest 
quartile of vitamin D 
intake had lower risk for 
recurrent wheeze in child 
at age 3 years  
Short duration 
of follow up 
Birth 
cohort 
study of 
2128 
children, 
1194 
children 
assessed 
at 3  
Mother-child 
pre-birth 
cohort 
Camargo 
et al 259 
Mothers in highest 
quintile of vitamin D 
intake had lower risk for 
child at age 5 years to 
have ever wheezed, 
wheezing in the previous 
year, and persistent 
wheezing. No association 
of vitamin D levels with 
asthma, spirometry, or 
atopic sensitization 
No maternal 
serum vitamin D 
levels during 
pregnancy 
2000, 
mother & 
child pair 
1335, 
aged 2 
years 
1212, 
aged 5 
years 
Mother-child 
pre-birth 
cohort 
Devereux 
et al 258 
Maternal 25-
hydroxyvitamin D 
concentrations >30 
ng/mL associated with an 
increased risk of eczema 
at 9 months and 
increased risk of asthma 
at 9 years 
70% lost to 
follow up, no 
study visits 
between 9 
month and 9 
years 
596 
mother & 
child pair  
440 
children 
aged 9 
months 
178 
children 
aged 9 yrs 
Mother-child 
pre-birth 
cohort 
Gale et al 
234 
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Maternal vitamin D intake 
from foods during 
pregnancy is negatively 
associated with risk of 
asthma and allergic 
rhinitis  
No maternal 
serum vitamin D 
levels 
Birth 
cohort 
study of 
3565 
children, 
1669 
children 
assessed 
at 5 yrs 
Finnish birth 
cohort study 
Erkkola 
et al 261 
Atopic manifestations 
were more prevalent in 
the group with higher 
intake of vitamin D 
Small n 
numbers  
No vitamin D 
levels  
123 
children, 
aged 6 
years 
Postal 
questionnair
e 
Back et al 
262  
Maternal intake of 
vitamin D associated with 
reduced risk of wheeze 
No maternal 
serum vitamin D 
levels during 
pregnancy 
1002 
mother 
and child 
pairs, 763 
assessed 
at 16-24 m 
Birth cohort 
study 
Miyake at 
al 263 
Cord serum vitamin D 
levels were inversely 
associated with the risk 
of transient early 
wheezing by the age of 5 
yeas but no association 
with asthma 
Parental 
questionnaires 
could result in 
misclassification  
No vitamin D 
levels during 
childhood  
239 
newborns  
EDEN birth 
cohort 
Baiz et 
al264 
No difference between 
supplemented and 
control groups in risk of 
wheeze atopy, eczema 
and lung function or 
FeNO50 between 
supplemented groups 
and controls. 
Possibility of 
insufficient dose 
(even after 
supplementation
, only a small 
percentage of 
offspring (13% 
daily group, 3% 
bolus group) 
had cord vitamin 
D levels in the 
sufficient range) 
Supplementatio
n only started at 
27 weeks of 
gestation (? 
late).  
Risk of 
reporter’s bias 
(not blinded) 
180 
pregnant 
women at 
27 weeks 
gestation  
Randomise
d controlled 
trial to either 
no vitamin 
D, 800 IU 
ergocalcifer
ol daily until 
delivery or 
single oral 
bolus of 
200,000 IU 
cholecalcifer
ol,  
Goldring 
et al265 
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1.4.8 Immunomodulatory effects of vitamin D  
Vitamin D may be important for maintenance of pulmonary health through its 
influence on innate and adaptive immune responses and the promotion of 
regulatory T cells (summarized in Figure 1.7) Recent immunological and 
epidemiological studies have shown that vitamin D has numerous cytokine-
modulating effects through multiple different cells of the immune system and 
airway (summarized in Table 1.6).  
 
Table 1.6 Response of different target cells to vitamin D  
Target Cells 
of vitamin D!
Effector function of vitamin D!
All T cells ! Inhibit T cell proliferation266!
Th1 ! Inhibit Th1 cytokine release267-269!
Th2! Conflicting evidence for enhancement 268 and inhibition 270 of 
Th2 responses, which may pertain to dose.178 !
Th17 ! Inhibit Th17 cytokine release271, 272!
Tregs!
!
Induces IL-10 synthesis163, 171, 178!
Increase in the frequency of FoxP3 cells177, 273 !
Enhance TGF β synthesis274!
B cells!
!
Nonlinear association between serum vitamin D levels and 
IgE202!
Enhanced production of the immunomodulatory cytokine IL-
10275!
Dendritic cells ! Renders monocyte derived dendritic cells more immature 
and tolerogenic276!
Induces IL-10 synthesis276!
Bronchial 
smooth 
muscle cells !
Inhibit cytokine synthesis and release277  
Decrease lung inflammation268, 278   
Inhibit bronchial smooth muscle cell proliferation and 
remodelling (eg, matrix metalloproteinase-9 [MMP-9]) 279-281!
Mast cells! Inhibit the differentiation, maturation, and homing of mast 
cells to allergic airways282 
Induce IL-10 synthesis283!
!
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Figure 1.7 Immunological effects of vitamin D.  Reproduced from ‘The 
impact of vitamin D on Regulatory T cells’ (Chambers and Hawrylowicz, 
2011)179   
!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ILT3 - Immunoglobulin-like transcript 3, PD-L1- programmed cell death ligand 1, 
CTLA 4- cytotoxic T-lymphocyte antigen 4, TLR—Toll-like receptor 
 
 
Vitamin D appears to influence T cell function. Essentially all studies using 
mouse or human cells agree on the capacity of vitamin D to inhibit T cell 
proliferation and production of Th1 associated cytokines.284-287  However the 
effect of vitamin D on Th2 cytokines is less clear and there are contradictory 
reports.269, 288-290 Inconsistent results may be due to the differences in target 
cell types, and timing and dose of vitamin D administration.220, 289, 291  For 
example a study on whole human PBMC responses to allergen with high 
concentration of vitamin D (10-6M) found that Th1 cytokines were suppressed 
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while Th2 cytokine secretion (IL-5 and IL-13) was enhanced.292 However, 
studies using 10-7M to 10-9M (lower) concentrations of vitamin D showed 
suppression of both Th1 and Th2 cytokines.178, 293, 294 A counterpart to this 
probably exists in vivo in humans. Hypponen et al202 recently showed that a 
significant, but nonlinear relationship exists between serum vitamin D and IgE, 
where a very high and very low serum vitamin D associated with higher levels 
of  IgE.  More recently vitamin D has been shown to inhibit IL-17A production 
in animal models 272, 295 and moderate to severe adult asthmatics35 which may 
be important in steroid resistant airway disease.296 
    
Vitamin D also appears to promote the function of Tregs. Vitamin D enhances 
the production of the anti-inflammatory cytokine IL-10 by human T cells in 
vitro and in vivo both directly178 and synergistically with corticosteroids.163 
Vitamin D can also increase IL-10 gene expression178 Enhancement of IL-10 
synthesis in B cells275 by vitamin D has also been reported. Studies by Adorini 
and colleagues demonstrate the capacity of vitamin D to induce IL-10 
production by dendritic cells.284 Taher et al demonstrated a beneficial effect of 
vitamin D administration to mice post allergic sensitization, but prior to 
allergen challenge, when delivered together with allergen immunotherapy.297 
Moreover, using antibodies (anti-IL-10receptor and anti-TGFβ-neutralizing 
monoclonal antibodies) to block TGFβ and IL-10 reversed these beneficial 
effects.297   
 
1.4.9 VDBP  
The vitamin D axis not only includes vitamin D but also incorporates VDBP 
and the vitamin D receptor.  VDBP is a glycosylated α-globulin, with 458 
amino acids folded into a disulfide-bonded, triple-domain structure (Figure 
1.8).298 Most of the vitamin D in the circulation is bound to VDBP with high 
affinity. Vitamin D is taken up into cells by diffusion of unbound vitamin D 
across cell membranes, and by endocytosis of that bound to VDBP.299 
Circulating vitamin D is also bound to albumin. Since the affinity of albumin for 
vitamin D is lower than that of VDBP 300 the vast majority is bound to VDBP.  
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Figure 1.8 The crystal structure of vitamin D binding protein. 
‘Reproduced from The vitamin D axis in the lung: a key role for vitamin D-
binding protein’.299  
 
 
The diagram shows the structure of VDBP. Domain I, which binds vitamin D, is 
shown in purple, II in blue and III in brown. Actin binds to elements within zones II 
and III. The arrow like elements within each structure represent alpha helices, and the 
disulphide bonds linking elements within the structure can just be seen in orange. 
 
 
 
 
 
 
"
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VDBP is a multifunctional protein. The major functions of VDBP are the 
binding, solubilization and serum transport of vitamin D. The relationship of 
VDBP and vitamin D concentrations is not yet clear. Low vitamin D 
concentrations were reported in the VDBP knockout mouse model but VDBP 
does not influence vitamin D’s biologically active pool (vitamin D available to 
enter cells and tissues. 301 
 
VDBP also possesses direct functions independent of vitamin D binding,302, 303 
that may be of particular relevance in airway inflammation.299, 302, 304 VDBP is 
expressed in the plasma membrane of neutrophils,305, 306 contributes to 
macrophage activation,303 augments monocyte and neutrophil chemotaxis to 
C5-derived peptides307, 308 and acts as a scavenger protein to clear 
extracellular G-actin released from necrotic cells.309, 310 (The functions of 
VDBP are discussed further in chapter 6 and summarised in table 6.1) 
Recently VDBP has also been identified in BAL.302, 304 Wood and 
colleagues304 recently noted that circulating VDBP levels inversely correlate 
with FEV1 in an adult cohort with COPD, and that sputum VDBP contributes to 
macrophage activation.304 They used an innovative in vitro assay to assess 
alveolar macrophage phagocytic capacity (efferocytosis) by engulfment of 
fluorescently-labelled apoptotic neutrophils. They showed that exogenous 
VDBP in culture enhanced macrophage activity in a dose-dependent manner, 
and that sputum from adults with COPD increased macrophage phagocytic 
activity to an extent that positively correlated with the amount of VDBP 
present. The anti-inflammatory role of VDBP, together with the relationship 
with serum vitamin D, may therefore be important in children with asthma but 
there have been no reports comparing VDBP levels of healthy children and 
those with asthma. Despite the wealth of serum vitamin D studies, there has 
been relatively little work concerning the role of VDBP in children with asthma.  
 
1.4.10 Vitamin D and airway remodelling  
As discussed earlier in this chapter, increased ASM mass is a feature of 
airway remodelling and in vitro studies have shown that vitamin D may 
influence airway remodelling by inhibiting ASM proliferation in adult asthma280, 
281, 311 and COPD312 and alter expression of genes (such as MMP9  and 
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ADAM metallopeptidase domain 33 [ADAM33]) involved in airway 
remodelling. In vitro Damera et al 255 have shown that in primary human ASM 
culture, twice as many asthmatic ASM cells entered into S phase of the cell 
cycle as compared to non-asthmatic cells. 255 They also showed that 
stimulation with platelet-derived growth factor increased DNA synthesis in 
asthmatic ASM cells as compared to normal ASM cells and importantly, 
treatment with vitamin D decreased the platelet-derived growth factor induced 
DNA synthesis and reduced the number of ASM cells in the S-phase in both 
asthmatic and non-asthmatic cells.255 In another in vitro study of human 
primary ASM cells isolated from adult asthmatic and non-asthmatic subjects 
using flow cytometry, immunocytochemical staining and colorimetric 
proliferation Song et al311, 313 demonstrated that asthmatic ASM cells had 
greater proliferation rate as compared to the controls, as determined by 
proliferating cell nuclear antigen staining. In the presence of vitamin D, 
asthmatic ASM cells in vitro inhibit ASM proliferation rate to normal.288, 290 
Additionally, vitamin D reduced the mRNA and protein expression of MMP9 
and ADAM33 genes (both involved in airway remodelling) to a level 
comparable to that of non-asthmatic ASM cells.311, 313 Bosse et al279 have 
shown in vitro that vitamin D increases glucocorticoid bioavailability in 
bronchial smooth muscle cells  suggesting a further beneficial role for vitamin 
D in the treatment of asthma.  
 
A recent study has shown that in a mouse model vitamin D receptor deletion 
upregulated matrix metalloproteinases, which are critically involved in the 
airway remodelling process, in BAL and whole lung homogenates.314 Further, 
in vitro vitamin D has been shown to inhibit the profibrotic effects of TGFβ on 
lung fibroblasts and epithelial cells in cell culture.315 Recently, Lai et al316 have 
also shown that in a mouse model, vitamin D treatment reduced pulmonary 
inflammation and attenuated established structural changes of the airways. 
They showed that vitamin D treatment could efficiently reduce ASM mass, 
subepithelial collagen deposition, epithelial thickening and prevent goblet cell 
hyperplasia.316 In another recent study, Agrawal and colleagues317 examined 
the effects of dietary supplementation with vitamin D on a murine model of 
allergic airways inflammation. Evidence of severe airway remodelling (airway 
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thickening, smooth muscle cell thickening, collagen deposition, epithelial 
hyperplasia with abundant cytoplasmic as well as airway lumen filled with 
mucin) was noted in the vitamin D deficient group compared to vitamin D-
sufficient and Vitamin D supplemental groups.317, 318 In summary, in vitro and 
animal work suggest vitamin D may have an impact on airway remodelling in 
asthma. 
 
1.4.11 Vitamin D and lung development 
If vitamin D is important in disease onset then it is most likely to exert its effect 
in utero or early in post-natal life. Vitamin D has been shown to stimulate 
alveolar type II cells319 and surfactant production320, 321 and may regulate 
alveolarization.322, 323 Gaultier et al have shown reduced lung compliance in 
pups born to vitamin D deficient rats.324 These data are consistent with a 
recent study that showed decreased lung function (as assessed by 
plethysmography and the forced oscillation technique) and altered lung 
structure without changes in somatic growth in mice born to mothers with 
vitamin D deficiency.325 Given the effect of vitamin D on lung growth in vivo 325 
and the role that structural deficits are likely to play in the onset of chronic 
lung disease and the prognosis of an individual who is genetically susceptible 
to the development of obstructive lung disease, it may be that vitamin D 
deficiency may predispose to pulmonary morbidity by altering early lung 
development. 
 
1.4.12 Vitamin D and asthma exacerbations 
Viral respiratory infections are the commonest cause of asthma exacerbations 
in children and adults.326, 327 Increasing evidence has suggested that viruses 
may cause more than just simple respiratory infections.153 In humans, 
rhinovirus infection induces airway inflammation, increases asthma 
exacerbation severity, and results in more severe infections in asthmatics 
when compared to normal subjects.326, 328 There is emerging evidence that 
low serum vitamin D levels are associated with more upper respiratory 
infections, especially among patients with asthma,329 and with increasing 
asthma severity.183 A prospective cohort study that measured serial 
concentrations of vitamin D in 198 healthy adults observed that individuals 
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with a 25(OH)D3 concentrations > 95 nmol/L (38 ng/ml) had a twofold 
reduced risk of acute viral respiratory tract infections.330  
 
Emerging evidence indicates that vitamin D mediated effects on innate 
immunity, particularly through enhanced expression of the human cathelicidin 
(hCAP-18) antimicrobial peptide, is important in host defence against 
respiratory tract pathogens.331-334 In particular, hCAP-18 enhances microbial 
killing and acts as a chemoattractant for neutrophils and monocytes. Other 
antimicrobial products regulated by vitamin D are defensin-β-2 and -4. In vitro, 
the induction of hCAP-18 in respiratory epithelial cells by vitamin D enhances 
antimicrobial activity against respiratory pathogens.334, 335 Vitamin D can 
potentially modify the signaling pathways that bind respiratory viruses. Vitamin 
D decreases the expression of ICAM-1, the major cellular receptor for human 
rhinovirus in human PBMC.336 Both cathelicidins and defensins have a broad 
spectrum of antimicrobial activity and kill bacteria by disruption of microbial 
membranes and also act as chemoattractants for other inflammatory cells and 
contribute to wound repair. A study of Mycobacterium tuberculosis infection in 
human monocytes found that activation of toll-like receptors (responsible for 
recognizing microbial ligands) led to upregulation of the vitamin D receptor 
and cytochrome P450 enzyme 27 B1 (CYP27B1), the enzyme responsible for 
converting 25[OH]D3 to active form of vitamin D.332 The endogenous 
production of active form of vitamin D by CYP27B1 and subsequent action 
through the vitamin D receptor led to the induction of cathelicidin, thus 
demonstrating a mechanism of the antimicrobial activity of vitamin D.332 In 
addition to enhancing antimicrobial peptide expression, vitamin D also 
induces autophagy in human macrophages.337  Autophagy is the ingestion of 
sequestered material inside phagosomes, which is important in the defense 
against infections. Natural killer cells also play a critical role in the innate 
immune system and are able to kill infected cells. Vitamin D induced 
cathelicidin was required for cytotoxic activity of natural killer cells against 
tumor cells in a transplantable mouse melanoma model.338 As discussed 
earlier in this chapter, vitamin D can also enhance IL-10 production in adults, 
thus providing a potential mechanism by which vitamin D can decrease 
inflammation while increasing antimicrobial action.  
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The association of vitamin D with asthma exacerbations triggered by acute 
viral respiratory infections is supported by intervention trials demonstrating 
decreased respiratory tract infections in children receiving vitamin D 
supplementation.339-341 Majak et al341 in a double blind, placebo controlled 
study assessed the effect of vitamin D supplementation in the time period 
from September to July on asthma symptom score, lung function and the 
number of exacerbations in 48 vitamin D sufficient Polish children (aged 5-18 
yrs) with newly diagnosed asthma.341 Despite the lack of any significant 
differences between the study groups as far as the absolute changes of 
vitamin D levels were concerned, vitamin D supplementation decreased the 
number of asthma exacerbations triggered by acute respiratory tract 
infections. Findings from this small clinical trial must be interpreted with 
caution due to non-standardized assessment of asthma exacerbations and 
lack of significant improvement in symptom score. In another multi-centre, 
randomized, double blind placebo-controlled clinical trial in 430 Japanese 
school children, vitamin D supplementation appeared to have a stronger effect 
in the sub-cohort with underlying asthma. Vitamin D supplements (1200 IU 
daily for 4 months) led to a relative risk reduction in asthma exacerbations of 
93% compared with children given placebo.339 These observations are 
supported by a study by Brehm et al in 1,024 children with mild to MA in which 
vitamin D insufficiency was associated with higher odds of any hospitalization 
or emergency department visit (odds ratio 1.5) 222 and a Costa Rican study 
which showed that asthmatic children with higher vitamin D levels had fewer 
hospitalizations in the previous year (odds ratio =0.05, 95% confidence 
interval =0.004-0.71, P=0.03).183 A recent systematic review of clinical studies 
investigating the association between vitamin D deficiency and susceptibility 
to acute respiratory infection in humans was published. A total of 39 studies (4 
cross-sectional studies, 8 case-control studies, 13 cohort studies and 14 
clinical trials) were evaluated. Observational studies predominantly reported 
statistically significant associations between low vitamin D status and 
increased risk of both upper and lower respiratory tract infections, However, 
results from randomised controlled trials were conflicting, reflecting 
heterogeneity in dosing regimens and baseline vitamin D status in study 
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populations.342 The potential for vitamin D to increase pulmonary defence 
against respiratory infections may reduce the triggering of asthma 
exacerbations caused by respiratory tract infections.343  
 
1.5 Summary  
Vitamin D deficiency and insufficiency are increasingly being recognized in 
the general population, and have been largely attributed to lifestyle changes 
(reduced exposure to sunshine due to working indoors or the use of protective 
clothing and sunscreen; and changes in diet) over the last few decades. 
There is growing appreciation of the likely importance of vitamin D as a 
pleiotropic mediator that contributes to pulmonary health by inhibiting 
inflammation, in part through maintaining regulatory T cells, direct induction of 
innate antimicrobial mechanisms and by altering lung development in early 
life. 
 
Vitamin D deficiency and asthma are common conditions that share risk 
factors such as urban residence, black ethnicity and obesity. Epidemiologic 
data suggest that low serum vitamin D in children with asthma is associated 
with more symptoms, exacerbations, reduced lung function, increased 
medication usage and severe disease. In vitro studies have demonstrated that 
vitamin D enhances steroid responsiveness in adult asthmatics.  
 
An increasing amount of data has now shed light on the role of vitamin D in 
asthma. However, there are several areas about which little is known. First, 
the prevalence of vitamin D deficiency and insufficiency in children with STRA 
and the relationship between vitamin D levels and markers of asthma severity, 
including clinical and therapeutic disease variables has not been explored. 
Secondly, we know little about the relationship between vitamin D levels and 
airway inflammation and remodelling in children and adult with STRA, nor 
about the relationship between steroid resistance and vitamin D in these 
children. The aims of this thesis are to try and address some of these gaps in 
our understanding.  
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1.6 Research Hypotheses, Aims and Objectives 
1.6.1 Research hypotheses 
i. Children with STRA have lower serum vitamin D levels than MA and 
non-asthmatic controls, and these are associated with worse clinical 
parameters of asthma control including lung function and symptoms, 
and worse pathological markers of asthma severity and airway 
remodelling. 
ii. In vitro, steroid responsiveness of PBMCs from children with STRA can 
be improved by addition of Vitamin D 
 
1.6.2 Aims 
i. To compare serum vitamin D levels in children with STRA, MA and 
age-matched non-asthmatic controls, and to investigate the 
relationship between serum vitamin D levels and markers of asthma 
severity. 
ii. To investigate the relationship between vitamin D levels and airway 
inflammation and remodelling in BAL and EB from children with STRA. 
iii. To assess the differences in glucocorticoid response between STRA, 
MA and control PBMC and BAL cells in cell culture and to ascertain 
whether vitamin D modulates the effects of glucocorticoids; and to 
determine whether addition of vitamin D restores steroid sensitivity in 
children with STRA.  
 
1.6.3 Specific objectives  
i. To recruit children with STRA, MA and non-asthmatic controls 
attending the Royal Brompton Hospital, and assess their asthma 
control (measured by the ACT), exacerbations, lung function, 
medication usage, and serum vitamin D levels.  
ii. To obtain BAL and EB from children with STRA undergoing clinically 
indicated bronchoscopy as part of investigations to assess steroid 
responsiveness and to use BAL and EB to study cellular content and 
markers of airway inflammation (BAL cell counts, cytokine 
measurements, mucosal eosinophils and neutrophils) and remodelling 
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(RBM thickness and ASM mass) and correlate with concurrent serum 
measurements of vitamin D status. 
iii. To use BAL whole cell and PBMC cultures to evaluate the effects of 
vitamin D and dexamethasone alone and in combination on IL-10 
production and to correlate the responses with evidence of steroid 
responsiveness in STRA. 
 
The following chapter describes the clinical protocols and laboratory 
methodological techniques that are common to several sections of this thesis. 
Laboratory techniques unique to each study are described in the relevant 
results chapter. Details of the some clinical methods used, including subject 
selection and recruitment are also described in the individual results chapters. 
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Chapter 2 Methods 
 
The main aims of this thesis were to investigate the relationship between 
serum vitamin D levels and markers of asthma severity, airway inflammation 
and remodelling in children with STRA, as well as to assess whether in vitro 
addition of vitamin D to PBMC in cell cultures restores steroid sensitivity in 
these children. This chapter reports those methods which are common to all 
of the results chapters in this thesis (clinical assessment, non-invasive 
measurement of inflammation, bronchoscopy). Detailed immunological 
methods which were used to generate the results are reported in the 
subsequent chapters with the corresponding results, for ease of reference. 
 
2.1 Study plan and subjects 
Three subject groups, aged 5-16 years were studied: 
 
Non-asthmatic controls comprised either children with no respiratory 
disease whose parents had consented for a small (<1 ml/kg, maximum 20 ml) 
blood sample to be taken during an elective cardiac surgical procedure or 
children undergoing a clinically indicated bronchoscopy for upper airway 
symptoms. The actual indication for flexible bronchoscopy in each child is 
presented in Table 5.1, chapter 5  
 
 MA - mild/moderate asthmatics well controlled on low dose (<800mcg/day 
beclomethasone equivalent) inhaled corticosteroids and were free of 
exacerbation for 3 months.   
 
STRA - were defined as previously described in chapter 1 section 1.2 and 
flow diagram summarizing stage 1-3 in Figure 1.4. Briefly, persistent (≥ 3 
months) symptoms (requiring rescue bronchodilator ≥ 3 days per week) 
despite treatment with high dose inhaled corticosteroids (> 800 
microgram/day of beclomethasone equivalent) and trials of add on drugs (long 
acting β2 agonists, leukotriene receptor antagonists and oral theophylline in a 
low, anti-inflammatory dose) and / or recurrent severe asthma exacerbations 
and / or persistent airflow obstruction (post oral steroid, post-inhaled 
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bronchodilator Z score < -1.96 for FEV1 despite above therapy); all children 
had poor control despite high-dose therapy, and had been through a detailed 
assessment to exclude wrong diagnosis, important co-morbidities, and to 
optimize adherence and other aspects of basic management, as far as 
possible.134  
 
Subjects were excluded from the study if they were taking vitamin D 
supplements.  
 
2.2 Clinical methods  
Since not all children participated in every study, the demographic details of 
the groups studied are described in their appropriate results chapters. 
 
2.2.1 Study consent 
The study was approved by the Royal Brompton and Harefield Research 
Ethics Committee (09/H07008/48). Informed consent was obtained from 
parents and age-appropriate assent from children. 
 
2.2.2 Height and weight  
The child’s height without shoes was measured in centimeters to one decimal 
place using a calibrated wall-mounted Harpenden stadiometer (Chasmor, 
London, UK). Weight was measured in kilograms to one decimal place with 
calibrated electronic scales (Marsden, Taiwan) with the child wearing minimal 
clothing. 
 
2.2.3 Exacerbations and medication usage 
Regular medications and doses were recorded for the asthmatics. Acute 
exacerbations were defined as episodes necessitating physician or parent 
initiated high dose oral steroids for at least 3 days, and the number of 
exacerbations in the previous six months was recorded.  
 
2.2.4 Pulmonary function testing 
Spirometry was performed using Vitalograph Compact (Vitalograph 
Buckingham, UK). The spirometer was calibrated on the day of the study with 
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a one litre syringe. If it was the subject’s first attempt at spirometry (healthy 
controls) a period of training was given. The child was familiarised with the 
equipment which was then demonstrated. The child was observed closely to 
ensure the manoeuvre was performed optimally. Manoeuvres were rejected if 
the subject was thought to use sub-optimal effort, if a full inspiratory breath 
was not taken, if there was coughing during the first second, if a plateau was 
not reached, or if the blow was terminated prior to full expiration. If the child 
had difficulty performing the manoeuvre then interactive computerised 
incentive spirometry was used (Vitalograph Pneumotrac, Spirotrac IV 
software). As this machine was situated in another room and was often in use 
for busy outpatient clinics it was not possible to use it routinely. The highest 
sum of FVC and FEV1 of the 3 manoeuvres was recorded to define the best 
flow volume loop, as per ATS/ ERS guidelines.344 All spirometry results were 
compared to appropriate recent reference populations.345  The procedure was 
repeated in order to achieve 3 satisfactory measurements. Spirometry was 
required to meet ATS criteria for acceptability and reproducibility.344  
 
2.2.5 BDR 
Spirometry was performed at baseline and 15 minutes after the administration 
of 1mg (10 puffs) of salbutamol via a large volume spacer in subgroup of 
children with STRA undergoing stage 2 & 3 assessment (Figure 1.4). BDR 
was defined as change in percentage predicted FEV1 from baseline: 
100 X (FEV1post bronchodilator-FEV1pre bronchodilator) 
FEV1pre bronchodilator 
 
A positive BDR was defined as FEV1 improvement of >12% of baseline.347 
This formula is used in our institution on children on a daily clinical basis, as 
do other lung function laboratories over the country. A relatively high dose of 
salbutamol was used to ensure as far as possible the top of the dose 
response curve had been reached, and also to protect against hypertonic 
saline induced bronchoconstriction during subsequent sputum induction. 
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2.2.6 Symptom Questionnaire 
All parents, and when age-appropriate, the children with asthma also 
completed the childhood ACT questionnaire.348 The ACT is a 5 point 
questionnaire, marked out of a total of 25. Low score is reflective of 
suboptimal asthma control and a score of 20 and above was taken to 
represent adequate control.  It is a simple tool to assess control and is used to 
document asthma control over a 4 week period.  This scoring system has 
been validated 141, 348, 349 and correlates well with specialists’ evaluation of 
asthma control.141  
 
2.2.7 FeNO50  
FeNO50 was measured prior to lung function using a chemiluminescence 
analyser (NIOX Aerocrine AB, Solna, Sweden). A constant temperature of 
22°C was maintained in the room in which the analyser was stored to ensure 
optimal operating conditions. The ambient nitric oxide (NO) was recorded 
prior to each reading and was always <300ppb in accordance with the 
manufacturer’s recommendations. FeNO50 was always measured before 
forced expiratory manoeuvres such as spirometry as they may affect FeNO50 
levels.350 
 
The procedure was explained and demonstrated to the child and all 
measurements were made with the child sitting with the disposable 
mouthpiece held in their hand in front of them. A nose clip was not used. 
Children had several practise runs to optimise their technique before 
proceeding to actual measurement. For the measurement, NO-free air 
(generated by the NIOX module internally from ambient air) was inhaled to 
near total lung capacity over a period of 2 to 3 seconds through the mouth-
piece of the instrument. Then the child was asked to exhale slowly, being 
encouraged to maintain a constant flow by a visual display on a screen 
(blowing a little girl in a balloon between 2 cliffs). There was automatic control 
of exhaled flow rate to a constant 50 ml/s, making it easier for the child to 
comply. The exhaled NO value is the mean NO level during a 3 second NO 
plateau. Three acceptable readings (defined as agreement to within 10%) 
were performed with at least 30-second intervals between manoeuvres and 
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FeNO50 was calculated as the mean of three correctly performed exhalations. 
Normal FeNO50 is less than 24 parts per billion.146 
 
2.3 Laboratory Methods  
 
2.3.1 Serum 25-hydroxyvitamin D  
Serum 25-hydroxyvitamin D level was measured in all subjects using a 2 
dimensional high performance liquid chromatography system - tandem mass 
spectrometry (2D LC-MS-MS), by the biochemistry department at the RBH. 
Serum 25-hydroxyvitamin D levels are considered the best circulating 
biomarker of vitamin D metabolic status because this form has a longer half-
life (2-3 weeks) than 1α,25VitD3 (6-12 hours) and reflect contributions from all 
sources of vitamin D (i.e. diet and sun exposure).351 Serum 25-hydroxyvitamin 
D levels were measured in duplicate and the lowest limit of detection was 3 
nmol/L and upper limit of detection was 100nmol/L. 
 
Vitamin D deficiency was defined as serum 25-hydroxyvitamin D <50nmol/L 
(20ng per milliliter)185, 352 and serum levels between 50-75 nmol/L (20-30 ng 
per millilitre) were defined as vitamin D insufficiency.185, 352 Based on changes 
in parathyroid hormone levels and intestinal calcium transport values of less 
than 75nmol/L have been suggested as insufficient.185 The date the 25-
hydroxyvitamin D level was measured was recorded to assess seasonal 
variation between subjects. Subjects were grouped as follows; winter 
(December to February), spring (March to May), summer (June to August) or 
autumn (September to November).  
 
2.3.2 Serum total and allergen specific IgE 
Serum IgE was analyzed by Beckman Access 2 immunoassay analyser and 
allergen-specific IgE levels (normal <0.35 IU/ml) to cat, dog, tree pollen, 
Dermatophagoides pteronyssinus, Aspergillus fumigatus, grass, egg, milk and 
peanut were analyzed by Phadia Immunocap 250 analyser in the 
biochemistry department at the RBH. Recently it has been postulated that it is 
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useful to quantify atopy rather than just reporting it as present or absent. This 
was done by summing the results of specific IgE for food and aeroallergen.353  
 
2.3.3 Sputum induction 
For subjects with a post-bronchodilator FEV1 > 65% predicted, sputum 
induction was performed using 3.5% saline inhalation for four 5 min periods 
as part of clinical investigations. For subjects with a post-bronchodilator FEV1 
< 65% predicted, sputum induction was performed with 0.9% saline. I 
performed sputum induction and processing in 10 patients and in the 
remaining 12 patients was performed by Ms Adesimbo Sogbesan, sputum 
technician at RBH.  
 
Children were asked to blow their nose and rinse their mouth to reduce 
squamous cell contamination before sputum induction was started. The 
children were instructed how to cough and clear their throat in order to obtain 
the best sample. The recorded baseline FEV1 was the highest manoeuvre 
from 3 satisfactory spirometric curves. Children were seated comfortably and 
asked to inhale the saline solution for periods of increasing duration from an 
ultrasonic nebuliser (De Vilbliss 2000, Somerset). FEV1 was measured after 
each inhalation period and the higher of 2 readings was selected. After each 5 
minute nebulisation period children were encouraged to cough and 
expectorate sputum into a falcon tube. If the FEV1 had not fallen below 10-
15% of the baseline value, further aliquots of 3.5% saline were nebulised. 
Symptoms such as cough or wheeze were recorded at each stage. If an 
inadequate sample of sputum was produced the process was continued for up 
to a maximum of 15 minutes. 
 
Children whose FEV1 had decreased by more than 15% were given 
salbutamol (1000µg) through a large volume spacer and spirometry was 
repeated 10 minutes later to ensure return to baseline values before 
discharge.  
 
Sputum processing 
81" "
Sputum samples were stored on ice until ready for processing. All samples 
were processed in less than 4 hours. The sample was poured into a petri dish 
and sputum was selected by identifying mucoid plugs and gelatinous portions. 
A selected rather than whole sample processing method was used to reduce 
salivary contamination because this improves intra-observer repeatability of 
differential cell counts.119 The selected sputum was returned to a clean pre-
weighed tube and weighed using a microbalance. A stock dithiothreitol (DTT) 
(0.1%) was then added to the sputum in the ratio of 4 ml DTT to 1g sputum. 
The mixture was gently aspirated with a 3ml disposable wide bore plastic 
pipette and then gently agitated on a rolling mixer (DenleySpiramix 5, Denley 
Instruments, Colchester, UK) for 15 minutes. The sample was filtered using a 
48µm pore nylon mesh filter. Phosphate buffered saline (PBS) (in the ratio of 
4 ml PBS to 1g original sputum weight) was used to wash out the tube and 
added to the filtrate (through the filter). The filtrate was centrifuged at 4°C for 
10 minutes at 400g (1500rpm). The remaining pellet was re-suspended in 1ml 
PBS and mixed by gentle vortexing. 20µl of sputum cell suspension was 
added to 20µl trypan blue (1 in 2 dilution factor). 10µl of the mixture was 
placed on a haemocytometer and examined using a light microscope (Leitz, 
Wetzlar, Germany) (improved Neubauer, BDH, Leicestershire, UK). All 
leukocytes (viable stained yellow and dead stained blue) and squamous cells 
were counted in the bottom left middle and top right quadrants of the 
haemocytometer grid. The total leukocyte count per ml was calculated using 
the following formula: 
 
Total count = no of viable & dead leukocytes X trypan blue dilution factor X104 
 
After calculation of the total leukocyte count the sputum cell suspension was 
adjusted to 200,000 cells/ml by diluting with PBS. The mixture was 
centrifuged (Shandon Cytospin Preparation System, Thermo Shandon, 
Cheshire, UK) at 450rpm for 3 min. If the total leukocyte count was less than 2 
x 105 /ml aliquots of 200µl or 400µl of sputum cell suspension were loaded. 1- 
4 slides were left to air dry for 30 minutes and then fixed with methanol. The 
slides were then stained with a modified Wright Giemsa stain Reastain® 
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Quick-Diff staining kit (Reagena Ltd. Toivala, Finland). Characteristic images 
of cells are shown in Figure 2.1  
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Figure 2.1 Characteristic appearances of sputum cytology shown under 
light microscopy (magnification x400) (a) normal count showing 
macrophages (b) eosinophilic (c) neutrophilic.  
A" " " " B" " " " C"
 
Photograph taken by Dr Cara Bossley. 
   
Cell counts 
The 400 cells were counted and expressed as % total inflammatory cells and 
total cell counts. Eosinophilia was defined as ≥2.5% eosinophils; neutrophilia 
as ≥54% neutrophils.354  
 
The intra-observer sputum eosinophil variability, percentage of eosinophils 
counted in the same slides on 3 separate occasions from 3 different subjects 
(blinded to previous results) is shown in Table 2.1 
 
Table 2.1. Intra-observer sputum eosinophils repeatability. This show 
acceptable coefficient of variation (CoV) of less than 10% 
 
Slide Count 1 Count 2 Count 3 Average CoV 
1 4 3.7 4.3 4 7.5 
2 11 9.8 10.4 10.4 5.8 
3 2 2 2.2 2.1 5.6 
Mean CoV 6.2 
    CoV-Coefficient of variation  
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2.4 Fibreoptic bronchoscopy 
This was performed under general anaesthetic (GA)355 administered by a 
consultant anaesthetist, and the procedure was undertaken by a paediatric 
respiratory consultant as part of clinical investigations. The anaesthetic 
technique was at the discretion of the individual anaesthetist, and usually a 
laryngeal mask was preferred.356 Intravenous access was obtained and a 
blood sample was taken in all subjects. Standard monitoring included a 
continuous electrocardiogram, oxygen saturation, end tidal carbon dioxide 
and systemic arterial blood pressure. 
 
An Olympus BF-XP40 BF-MP60 (4.0 mm videobronchoscope) or BF-P20D 
(4.9 mm) bronchoscopes (KeyMed, Southend-on-Sea, Essex, UK) were used 
as appropriate to the size of the child. BAL was performed using 3 aliquots of 
1ml/kg 0.9% sterile saline (to a maximum of 40mls per aliquot) instilled into 
the right middle lobe and the returns pooled. BAL fluid was sent to the Royal 
Brompton Hospital pathology laboratory for cytology, bacterial culture and 
viral immunofluorescence. The larger single use 2mm disposable cupped 
forceps (FB-231D, Olympus, KeyMed, UK) were used to take up to 4 EB 
under direct vision from the subsegmental bronchi of the right lower lobe.  
 
2.4.1 BAL cytology 
Quantification of inflammatory cells in BAL was performed by the 
histopathology department at the RBH. BAL was centrifuged at 2000 rpm 
(400g), 4ºC for 10 minutes. The cell pellets were re-suspended in 1ml PBS 
and mixed for 15 seconds using vortex.  Cell viability was then assessed 
using the trypan blue exclusion method.  50µl of cell suspension was added to 
50 µl of trypan blue. 20 µl of this suspension was then put onto an improved 
Neubauer Haemocytometer.  Number of live cells (white), dead cells (blue) 
and squamous cells were noted.  A total cell count could then be calculated 
by multiplying the average number of live and dead cells by the dilution used.  
A suspension of approximately 100,000 cells per ml was made up using PBS.   
Eosinophilia was defined as eosinophil percentage > 1.19.357 Neutrophilia was 
defined as neutrophil percentage >3.5.358   
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2.4.2 Processing of endobronchial biopsy 
Biopsies were fixed in formal saline, and processed to paraffin within 24 hours 
by the histopathology department at the RBH. The 5µm sections were stained 
with haematoxylin and eosin (H&E) to determine biopsy quality. Sections were 
examined under a light microscope (Leica microsystems, Milton Keynes, UK). 
To be categorized as “evaluable”, a biopsy had to fulfill the following criteria: 
(i) presence of identifiable epithelium, RBM with associated submucosa; 
(Figure 2.2) (ii) good orientation; (iii) minimal crush, edema or blood within the 
biopsy. Biopsies were evaluated by Mr T Oates. Assessments of tissue 
remodelling were performed on H&E stained sections by Mr T Oates and Ms 
A Sjoukes using computer aided image analysis and equations from design-
based stereology,359, 360 as described previously.116  
 
Morphometry of airway remodelling 
Evaluable H&E stained sections were used to quantify airway remodelling, 
including RBM thickness,361 epithelial shedding9 and smooth muscle mass.116 
 
Figure 2.2 An example of endobronchial biopsy stained with H & E; 
showing epithelium, reticular basement membrane and sub-mucosa.  
 
Photograph taken by Dr Cara Bossley. 
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RBM thickness 
RBM was measured in sections stained with H&E using computer aided 
image analysis at x 400 magnification by Ms. A Sjoukes. Forty point-to-point 
repeated measurements were taken of RBM thickness at right angles to the 
basement membrane, at regular intervals of 20 micrometer (µm) in randomly 
selected sections.361 Results are the mean of the 40 measurements per 
patient in µm.  
 
Epithelial shedding 
The length of incomplete epithelium was measured as a percentage (%) of 
the total epithelial length (assessed by the length of basement membrane) at 
x 200 magnification by Ms A Sjoukes. The epithelium was considered 
incomplete when the basement membrane was completely denuded or when 
it was only covered by a single layer of basal cells with no intact ciliated cells 
or goblet cells.9 A minimum length of 1mm epithelium was assessed.   
 
Smooth muscle volume fraction 
Smooth muscle quantification was performed by Ms Sjoukes using equations 
from design-based stereology. The volume fraction of smooth muscle (sm) 
was measured using a weibel grid at x 200 magnification.  Stereological data 
were calculated as follows:116  
Volume fraction of sm indexed to volume of submucosa tissue:  
Vv (sm/submucosa) =          ∑ points on sm     
∑ points on sm + points on submucosa 
 
Proliferating Cell Nuclear Antigen (PCNA) – for smooth muscle 
proliferation 
PCNA is a sensitive marker of smooth muscle proliferation.362 It has been 
demonstrated to detect ASM hyperplasia, and an associated change in 
muscle mass. PCNA staining was performed in paraffin sections by T Oates 
and A Sjoukes as previously described.119 Positively stained smooth muscle 
nuclei were counted in every biopsy at x 400 magnification and divided by the 
total number of smooth muscle nuclei and expressed as a percentage (%).  
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Quantification of tissue inflammation 
Mucosal inflammation was quantified in sections stained with congo red 
(eosinophils), and immunohistochemistry was used to assess neutrophils 
(neutrophil elastase)363 and mast cells (mast cell tryptase).364 All cells with 
positive nuclear staining were counted in the submucosa in every biopsy at x 
400 magnification. Mast cells were also counted within the smooth muscle in 
every biopsy by A Sjoukes. The data is presented in mm2 per area of 
submucosa or smooth muscle (for mast cells alone).  
 
2.5 Cytokine Analysis by Cytometric Bead Array (CBA) 
Cytokines were analysed using the CBA kit (CBA, Human Inflammation kit, 
BD Biosciences, Pharmingen, San Diego). This is a commercial, flow 
cytometer based immunoassay that allow for simultaneous multiple analyte 
measurements to be made from small serum, BAL and tissue culture 
supernatant samples. It uses a matched antibody pair that permits analysis of 
multiple cytokines simultaneously within a sample (Figure 2.3). The lower limit 
of detection was 1.5pg/ml for all cytokines. CBA was performed as per the 
manufacturer’s instructions and by Mr David Richards in BAL. I also 
performed CBA in serum samples under the close supervision of David 
Richards. For beads to be identified and analysed separately each analyte 
bead is labelled with a unique combination of the fluorochromes 
allophycocyanin (APC) and allophycocyanin-cyano dye 7 (APC-Cy7). Multiple 
analyte measurement is possible because the beads are tandem conjugated 
with 2 fluorescent dyes. By varying the labelling concentration of these dyes, it 
is possible to distinguish between the analyte beads based on the their 
fluorescence when measured in the APC and APC-Cy7 channels. The 
sample/standard are incubated with antibody coated beads, which capture 
secreted cytokines. The detection antibodies fluoresce within the 
phycoerythrin (PE) emission spectrum at a frequency determined by the 
quantity of detection antibody bound to captured cytokine. A 16-point standard 
curve containing all relevant cytokines was prepared in CBA sample buffer 
(BD Biosciences) from the top standard, which was 50000 pg/ml for all 
cytokines. 
 
88" "
Figure 2.3 Overview of CBA. Reproduced from Reynolds et al 
‘Quantification of cytokines using  cytometric bead array. 
http://www.bdbiosciences.com’ 
 
 
 
 
 
 
 
 
Test steps 
Samples (50µl) were added to a 96-well plate and incubated with 50µl of 
capture beads 10% Bovine Serum Albumin (BSA, Fischer Scientific), 0.5% 
TWEEN-20 (Sigma) and 2mM EDTA (Sigma)) with gentle shaking (500rpm) 
for the first 15 minutes and then incubated for 3 hours at room temperature in 
the dark.  After 3 hours the plate was then centrifuged at 500g for 5 minutes at 
4°C and then beads were resuspended with 200µl of CBA buffer.  The plate 
was again centrifuged for 5 minutes at 500g / 4°C.  The beads were then 
incubated with 50µl antibody-detection reagent with gentle shaking (500rpm) 
for the first 15 minutes and then incubated for a further 2 hours at room 
temperature in the dark. Finally, beads were washed twice and resuspended 
in 150µl FACSflow for analysis using a BD Fortessa flow cytometer with high-
throughput sampler plate-reader platform.  Data were read off as mean 
fluorencesnce intensity (MFI) values, which were analysed using FlowJo 
(version 9.2, TreeStar Inc) and GraphPad Prism (version 5 for Mac OS X, 
GraphPad Software Inc.). 
 
2.6 FoxP3 intranuclear analysis by flow cytometry 
FoxP3 staining was performed with a PE conjugated FoxP3 antibody and the 
FoxP3 staining buffer set, (Ebiosciences, San Diego, USA) according to 
manufacturer’s instructions. BAL cells were first stained for surface 
expression of CD4 and CD25 or the matched isotype control antibody. BAL 
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cell pellets were resuspended in 1ml FACS Flow containing 1% Mouse 
serum. A 50ul of cell suspension was taken to count cells on a 
haemocytometer and cell concentration was adjusted to 1x106/ml and specific 
antibodies were added at 20µg/ml (2microlitre per 105 cells) according to 
manufactures instructions and were incubated in the dark on ice for 30 
minutes. Samples were then washed twice at 200g for 5 minutes at 4oC in 
250 microlitres of FACSflow. The cells were resuspended in 250 microlitres 
FACSflow and 10,000 live cells were analysed for fluorescence on a 
FACSCalibur, following compensation, using the CellQuest software. Dead 
cells were excluded by forward and side scatter gating. Quadrant markers 
were based upon background staining of matched isotype control antibodies. 
For the FoxP3 staining, BAL cells were washed twice in ice-cold FACS flow 
(200g at 4oC for 5 minutes). The cell pellet was resuspended by pulse vortex, 
1 ml of FoxP3 fixative (freshly diluted, 1:4) was added and incubated in the 
dark at room temperature for 45 mins. Cells were washed twice in 1 ml of 
FoxP3 permeabilisation buffer (diluted 1:10 times) and centrifuged at 200g for 
5 mins. Fluid was decanted and 5µl mouse serum was added to each sample 
and then incubated at room temperature for 10 minutes. Five µl of PE rat 
IgG2a control antibody was then added to the appropriate tube and 5µl PE 
conjugated anti-human FoxP3 antibody to another tube. After mixing the 
contents of each tube by vortex, they were incubated in the dark at room 
temperature for 45 minutes. Cells were then washed with 1 ml of FoxP3 
permeabilisation buffer (diluted 1:10 times), and centrifuged at 200g for 5 
mins. Liquid was decanted and cell pellets were washed again with FACSflow 
and centrifuged at 200g for 5 mins. Liquid was again decanted and 500µl of 
FACSflow was added to the cells. Resuspended cells were analyzed by flow 
cytometry using FACScan (Becton Dickinson, Abingdon, GB). Forward scatter 
was increased for the FoxP3 analysis to 2.5 to compensate for cell shrinkage 
(as a result of the staining process). Quadrant markers were set according to 
the matched isotype control antibody staining (Figure 2.4). The gating and 
instrument settings were controlled in every experiment and maintained 
throughout the whole study in all samples analyzed. Calculations were 
performed with Cell Quest software (Becton Dickinson). 
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Figure 2.4. An example of gating for FoxP3 intracellular staining  
Flow cytometry density plots to demonstrate the gating strategy employed to analyse 
the frequency of FoxP3 in BAL cells. BAL lymphocytes were identified according to 
forward (FSC) and side scatter (SSC). Cells were next gated on the basis of positive 
expression of CD3 and CD4. Quadrant markers were set according to the isotype 
matched isotope control (rat IgG2a) 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
2.7 Statistical Analyses   
For the clinical relationship (discussed in chapter 3) again there are 
insufficient published data with which to inform a power calculation, however a 
retrospective power calculation was performed (the limitations of this 
approach are acknowledged365). The mean vitamin D levels for the controls, 
MA and STRA were 59.9, 46.5 and 29.8 respectively and the within group 
mean square was 304.66 giving a pooled standard deviation of approximately 
17.5. Based on these means and SD, the power to achieve the effect size 
reported in this study is greater than 90%. The clinical study was therefore 
adequately powered for the data relating to serum vitamin D and clinical 
status. The laboratory studies were novel studies therefore the previous work 
was not relevant to power calculations. Also, laboratory studies were 
opportunistic and limited by the sample volumes. 
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Categorical data were analyzed using the Chi squared or Fishers exact tests. 
Data were assessed for normality using the D’Agostino and Pearson test. For 
nominal data, between group differences for normally distributed data were 
analyzed using the student’s t test. The Mann-Whitney U test was used for 
skewed (non-normally distributed) variables. Differences between 3 groups 
were assessed using one way analysis of variance (normal data) or Kruskal-
Wallis test (non-normal distribution) followed by a Bonferroni correction to 
compare differences between groups. Correlations were assessed using the 
Pearson correlation (normal data) or the Spearman's rank correlation (skewed 
data). To assess the association between serum vitamin D levels and severity 
of disease, linear regression was used for continuous variables and logistic 
regression was used for categorical variables. When a non-normal variable 
remained skewed even after log transformation, this variable was 
dichotomized and used in the logistic regression. For both types of regression 
analyses, 2 models (an unadjusted and a multivariable model were 
constructed). To assess the effect of two factors simultaneously repeated 
measures two way analysis of variance (ANOVA) test was used. Statistical 
significance was reported at p<0.05.  
 
Linear regression, logistic regression and power calculations were performed 
by Mr. Winston Banya, Hospital statistician using Stata version 10.1 
(Statacorp Texas, USA). AG performed the rest of the statistical analysis 
using GraphPad Prism 5.02 under the guidance of Mr. Winston Banya. 
  
The next chapter compares serum vitamin D levels in children with STRA, MA 
and non-asthmatic controls and describes the relationship between serum 
vitamin D levels and clinical markers of asthma severity, airway inflammation 
and remodelling. 
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Chapter 3. Relationship between serum vitamin D, disease severity, 
airway inflammation and remodelling in children with asthma 
 
3.1 Introduction "
In the previous chapter, methods common to all chapters of this thesis were 
described. The overarching aim of this thesis is to investigate the relationship 
between vitamin D and childhood STRA. This chapter compares serum 
vitamin D levels in children with STRA, MA and non-asthmatic controls and 
describes the relationship between serum vitamin D levels and clinical 
markers of asthma severity, airway inflammation and remodelling. Some of 
these finding have been reported in the American Journal of Respiratory and 
Critical Care Medicine.366 
 
Little is known about vitamin D levels and their impact on disease control and 
airway pathology in children with STRA. As discussed in chapter 1 section 
1.1.5 an increase in ASM mass is a key feature of airway remodelling in 
asthma.116, 367-369 Importantly, increased ASM hypertrophy and hyperplasia 
has been demonstrated in EB from children with severe asthma and is 
significantly related to bronchodilator responsiveness.116  However, to date, 
there is little evidence that any asthma therapies affect airway remodelling. In 
vitro studies have shown that vitamin D may influence ASM remodelling by 
exerting an inhibitory effect on ASM growth and contractility.280, 281, 311 The 
relationship between airway pathology in asthmatics and serum vitamin D 
levels has not been reported.  
 
3.1.1 Hypothesis 
 
The hypothesis tested in this chapter was that the children with STRA have 
lower serum vitamin D levels than MA and non-asthmatic controls, and these 
are associated with worse clinical parameters of asthma control including lung 
function and symptoms, and worse pathological markers of asthma severity 
including airway remodelling. 
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3.1.2 Aims 
 
i. To compare serum vitamin D levels in children with STRA, MA and 
age-matched non-asthmatic controls, and to investigate the 
relationship between serum vitamin D levels and markers of asthma 
severity. 
ii. To investigate the relationship between serum vitamin D levels and 
airway inflammation and remodelling in BAL and EB from children with 
STRA. 
 
3.2 Methods  
3.2.1 Subjects 
Children aged 5-16 years with STRA (n=36), MA (n=26) and non-asthmatic 
controls (n=24) were recruited prospectively (Table 3.1). A sub-group of STRA 
(n=22/36) underwent stage 2 and 3 investigations according to the severe 
asthma protocol at RBH (as described in chapter 1 Figure 1.4). This includes 
performance of fibreoptic bronchoscopy under general anaesthesia, with BAL 
and EB. The other 14/36 children with STRA had previously undergone 
flexible bronchoscopy and stage 2 and 3 investigations. MA had doctor 
diagnosed asthma being managed at the RBH treated at steps 2-3 of the 
British Thoracic Society guidelines. Non-asthmatic controls comprised either 
children with no respiratory disease whose parents had consented for blood 
tests during an elective surgical procedure (n=18) or children undergoing a 
clinically indicated bronchoscopy for upper airway symptoms (n=6).  
 
3.2.2 Sputum eosinophils and neutrophils 
Sputum induction, processing and cell counts were performed in children with 
STRA (n=22) as described in chapter 2 section 2.3.3. Sputum induction was 
not undertaken in MA and controls, as it was not clinically indicated.  
 
3.2.3 Bronchoscopy, BAL and EB 
All bronchoscopies, BAL & EB were performed under general anaesthesia in 
children with STRA (n=22) as part of their clinical investigations as described 
in chapter 2. The histopathology department at the RBH performed 
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quantification of inflammatory cells in the BAL for clinical purpose. BAL fluid 
was centrifuged at 300 g at 4oC for 10 minutes. The supernatant was 
removed and stored at – 80 C and the cell pellets were resuspended in RPMI-
1640 medium (Sigma) with 10% fetal calf serum. Slide preparations for 
differential percentage counting of cells were made in a Shandon 
cytocentrifuge (Cytospin II; Shandon Ltd, Runcorn, Cheshire, UK) using 
aliquots of the lavage cell suspension, adjusted to 0.5 x 106 cells/ml. 
Preparations were stained with May-Grunewald Giemsa. Differential counts 
were made from a minimum of 400 cells. EB were fixed in formal saline and 
processed to paraffin blocks within 24 hours by the histopathology department 
at the RBH as previously described.355 5µm thick sections were cut at 25-
50µm intervals.  Sections were stained with H&E and were assessed for 
morphology and quality. Adequate sections were used to assess airway 
remodelling (RBM361, epithelial shedding9 and smooth muscle mass116). 
Mucosal inflammation was quantified using specific stains; congo red for 
eosinophils, neutrophil elastase for neutrophils363 and mast cell tryptase for 
mast cells.364 All biopsies were cut and stained by Mr. Timothy Oates, and 
analyzed by Ms. Alies Sjoukes, Imperial College London.  
 
3.3 Results  
3.3.1 Subject demographics 
The demographic data of the children in whom serum vitamin D levels were 
measured are presented in Table 3.1. There were no significant differences 
between children with MA, STRA, and non-asthmatic controls in age, 
ethnicity, gender distribution or BMI. As expected, children with STRA were 
on higher doses of ICS, had poor asthma control, worse lung function and had 
more frequent exacerbations. 
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Table 3.1. Demographic characteristics of subjects✪ No significant 
differences between children with MA, STRA, and non-asthmatic controls in 
age, ethnicity, gender distribution or BMI. As expected, STRA had worse lung 
function and more symptoms and exacerbations, and were more 
bronchodilator responsive, despite being on more treatment. The normal 
controls were less likely to be atopic and had a lower IgE than the asthmatics. 
 
 
STRA 
(n=36) 
MA 
(n=26) 
Controls 
(n=24) 
P value 
Age  
(years) 
11.5 (9.5, 14) 12.5 (11,13) 10.5 (9-13) 0.24a 
Male  21 (58%) 11 (42%) 15 (62%) 0.17£ 
BMI 
(Kg/m2) 
19.5 (16, 24)  19 (16, 25) 18 (15.7, 23) 0.16a 
Ethnicity  
White 
Non-white  
 
23 (64%) 
13 (36%) 
 
22 (84%) 
4 (16%) 
 
21 (88%) 
3 (12%) 
0.056£ 
FEV1  
(%predicted) 
76 (63, 85) 88 (84, 95) 94 (90, 97) <0.001a 
FVC   
(%predicted) 
88 (78, 97) 103 (96,110) 96 (94,108) <0.002 a 
FEV1 / FVC 
ratio 
73 (68, 84) 84 (78, 92) 92 (89, 96) <0.001a 
Atopic+ (%) 32 (88)  20 (77) 3 (12) <0.001£ 
IgE (IU/ml) 530 (196, 645) 717 (254, 
1377) 
12.5 (8, 51) <0.001a  
BDR$ (%) 15 (7, 25) 4 (3.5, 6) 
(n=4) 
- 0.065& 
ACT^ 11 (8.5, 14)  18 (17, 21) - <0.001& 
ICS dose% 
(microgram/day) 
1600 (1000- 
2000) 
600 (500-800) - <0.001& 
Median 
exacerbations ** 
3 (2,4) 1 (0,2) - <0.001& 
 
Definition of abbreviations: BMI = body mass index; FEV1 = forced expiratory 
volume in 1 second; FVC = forced vital capacity; BDR= Bronchodilator response; 
ACT= asthma control test;  
 
✪ Values are given in Median (interquartile range) for continuous variables or as 
number (%) for binary variables.  
+One or more positive allergen-specific IgE responses 
**Median exacerbations in last six months requiring oral steroids 
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$  Rise in FEV1 post bronchodilator (%) 
^ Score out of 25 
% Beclomethasone equivalent  
aP value calculated by  Kruskal-Wallis test;£P value calculated by  Chi-square test; &P 
value calculated by Mann Whitney test;  
 
 
3.3.2 Serum 25[OH]D3 levels in asthmatics and controls 
Serum 25[OH]D3 levels are considered the best circulating biomarker of 
vitamin D metabolic status because this form has a longer half-life (2-3 
weeks) than 1α,25VitD3 (6-12 hours) and reflect contributions from all 
sources of vitamin D (i.e. diet and sun exposure).351 As described in chapter 2 
section 2.3.1 serum 25[OH]D3 level was measured in all subjects using a 2 
dimensional high performance liquid chromatography system - tandem mass 
spectrometry, at the RBH. Serum 25[OH]D3 levels (median [IQR]nmol/L) were 
significantly lower in children with STRA (28[22-38])nmol/l than those with MA 
(42.5[29-63])nmol/L, and non-asthmatic controls (56.5[45-67])nmol/L (p<0.001 
for both) (Figure 3.1A). The prevalence of vitamin D deficiency (25[OH]D3 
level < 50nmol/L) was 94%, 54% & 33% in STRA, MA and controls 
respectively (p<0.001) (Figure 3.1B) and 97% of children with STRA, 92% of 
MA and 83% of controls had insufficient serum 25[OH]D3 levels (25[OH]D3 
level <75nmol/L).  
 
Vitamin D metabolism is affected by season (factors affecting sun exposure). 
The date the 25[OH]D3 level was measured was recorded to assess seasonal 
variation between subjects. Subjects were grouped as follows; winter 
(December to February), spring (March to May), summer (June to August) or 
autumn (September to November). There was no significant impact of season 
of sample collection on serum vitamin D level in the three groups (Figure 3.2).  
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Figure 3.1 Serum vitamin D levels in STRA, MA & controls.  
Figure 3.1A Serum 25-hydroxyvitamin D levels were lower in STRA and MA as 
compared to non-asthmatic controls (Kruskal-Wallis test p<0.0001). Bar represents 
median values. Mann Whitney U test, followed by a Bonferroni correction was used 
to compare differences between groups. Figure 3.1B shows a higher prevalence of 
vitamin D deficiency (serum 25-hydroxyvitamin D levels less than 50 nmol/L) in 
STRA compared to MA and controls (p<0.001, calculated by Chi-square test) 
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Figure 3.2. Serum vitamin D levels and season  
(a) No significant difference in season and sample collection in the three groups when 
combined (p=0.13, measured by Chi-square test). (b) No significant difference in 
season and serum 25[OH]D3 levels (p=0.07, measured by Kruskal-Wallis test) 
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3.3.3 Vitamin D and atopic status 
A history of atopic disorders was taken at recruitment. Food allergies were 
determined by clinical history, formal food challenges were not performed. 
Blood for total IgE and specific IgE was taken at the same time as vitamin D 
levels. Serum 25[OH]D3 was inversely related to serum total IgE (r=-0.3, 
p=0.01) (Figure 3.3), specific IgE to cat (r=-0.27, p=0.01), dog (r=-0.29, 
p=0.01), tree pollen (r=-0.28, p=0.02), Dermatophagoides pteronyssinus (r=-
0.3, p=0.01), and Aspergillus fumigatus (r=-0.36, p=0.009) (Table 3.2). 
Recently it has been postulated that it is useful to quantify atopy rather than 
just reporting it as present or absent. This is done by summing the results of 
specific IgE for several aeroallergens.353 In a post hoc analysis, there was a 
significant inverse relationship between serum 25[OH]D3 levels and sum of 
specific IgE to aeroallergen (cat, dog, tree pollen, Dermatophagoides 
pteronyssinus, Aspergillus fumigatus and grass) (r=-0.28, p=0.009) but not to 
sum of specific IgE to food allergens (egg, milk and peanut). Blood test for 
serum eosinophil count was taken at the same time as serum vitamin D 
levels. There was no relationship between serum 25[OH]D3 levels and serum 
eosinophil and vitamin D levels.  
 
Figure 3.3 Serum vitamin D levels and total IgE levels.  
Significant negative association between serum vitamin D levels and total IgE levels 
(IU/ml) (r=-0.3, p=0.01) Correlation was determined by the Spearman rank 
correlation coefficient.  
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Table 3.2. Association between serum vitamin D levels and IgE levels  
Serum 25[OH]D3 was inversely related to serum total IgE (r=-0.3), specific IgE to cat 
(r=-0.27), dog (r=-0.29), tree pollen (r=-0.28), Dermatophagoides pteronyssinus (r=-
0.3), and Aspergillus fumigatus (r=-0.36). *Correlation (r) was determined with the 
Spearman rank correlation coefficient 
 
 N Correlation (r)* P value 
IgE (IU/ml) 86 -0.3 0.01 
Specific IgE to cat 79 -0.27 0.01 
Specific IgE to dog 
 
75 -0.29 0.01 
Specific IgE to tree pollen 67 -0.28 0.02 
Specific IgE to Dermatophagoides 
pteronyssinus 
73 -0.3 0.01 
Specific IgE to Aspergillus 
fumigatus 
51 -0.36 0.009 
Specific IgE to grass 57 -0.14 0.3 
Specific IgE to egg 37 -0.04 0.7 
Specific IgE to milk 35 -0.09 0.58 
Specific IgE to peanut 34 -0.07 0.7 
Serum Eosinophil count % 84 -0.08 0.4 
 
3.3.4 Spirometry, BDR and serum vitamin D  
There was a positive correlation between serum 25[OH]D3 levels and % 
predicted FEV1 (r=0.43, p<0.001) (Figure 3.4A) and FVC (r=0.32, p=0.002) 
(Figure 3.4B) when the subjects from all the three groups were combined. 
However, correlation analyses within each patient group were not significant 
(controls- r=0.3, p=0.08; MA- r=0.3, p=0.18; STRA - r=0.1, p=0.5), probably 
limited by the low numbers of total participants and the lack of vitamin D sufficient 
STRA. Serum 25[OH]D3 was significantly and inversely associated with % 
BDR (r=-0.4, p=0.003) and positive BDR (Figure 3.5A & 3.5B) 
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Figure 3.4 Relationship between vitamin D levels and lung function.  
Positive association between serum vitamin D levels and %predicted FEV1 (r=0.43, 
p<0.001) (A) and FVC (r=0.32, p<0.002) (B). Lower serum vitamin D levels were 
associated with higher bronchodilator response (BDR), (r=-0.40, p=0.003) 
Correlation was determined by the Spearman rank correlation coefficient.  
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           ***p<0.001 
Figure 3.5 Relationship between vitamin D levels and BDR.  
Lower serum vitamin D levels were associated with higher bronchodilator response 
(BDR), (r=-0.40, p=0.003) (A) and positive BDR (FEV1 improvement of at least 
12%) (p<0.001) (B). BDR (%) = percentage increase of FEV1 after inhalation of 
1,000 µg of salbutamol. Correlation was determined by the Spearman rank correlation 
coefficient. Mann Whitney U test, was used to compare differences between groups 
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3.3.5 Asthma control, exacerbations and serum vitamin D levels 
A positive relationship was found between 25[OH]D3 level and ACT (r=0.6, 
p<0.001) (Figure 3.6), whereby higher serum 25[OH]D3 was associated with 
better asthma control as assessed by ACT in all asthmatics. Lower serum 
25[OH]D3 levels were associated with increased acute asthma exacerbations 
in the previous six months (p<0.001) (Figure 3.7)  
 
The severity of asthma (defined by asthma symptoms [assessed by ACT] and 
frequent exacerbations) was so closely associated with serum vitamin D 
levels it was difficult to separate the two. For example, dividing the STRA 
group into those who were well controlled and those who had poor control as 
shown by an asthma control test of less than 20, left only one patient with 
well-controlled STRA so no meaningful comparisons are possible.
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***p<0.001 
 
Figure 3.6 Relationship between serum vitamin D level and ACT  
Children with higher serum vitamin D levels had less asthma related symptoms 
(r=0.6, p<0.001) Correlation was determined by the Spearman rank correlation 
coefficient.  
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Figure 3.7 Relationship between serum vitamin D level and 
exacerbations.  
Children with lower serum vitamin D levels had more acute exacerbations in the last 6 
months (r=-0.6, p<0.001) Correlation was determined by the Spearman rank 
correlation coefficient. Kruskal-Wallis test and Mann Whitney U test, followed by a 
Bonferroni correction was used to compare differences between groups.  
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3.3.6 Medication dose and serum vitamin D levels 
Of the different therapies received by children with MA and STRA, the use of 
daily maintenance oral steroids (p<0.001), oral theophyllines (p=0.02), and 
leukotriene receptor antagonists (LTRA) (p=0.005) were significantly 
associated with lower 25[OH]D3 levels, but there was no association between 
anti-reflux therapy and serum 25[OH]D3 level (Table 3.3). Moreover, the daily 
dose of ICS (r=-0.39, p=0.001) and oral maintenance corticosteroids (r=-0.43, 
p<0.001) were inversely related to serum 25[OH]D3 levels (Figure 3.8C). 
Because of relatively small numbers in the study population it was not 
possible to control for the potential confounding effects of corticosteroids in 
this work (addressed further in discussion).  
 
Table 3.3. Serum vitamin D levels and medication use in all asthmatics  
Medications used 
 
Median 25-hydroxyvitamin D 
levels (IQR) 
 
p value* 
Oral CS Oral CS: 28 (21-33) 
No Oral CS: 45 (21-61) 
<0.001 
LTRA LTRA: 33.7 (27-39) 
No LTRA: 47 (40-53) 
0.005 
Theophylline  Theophylline: 31 (21.5-39.5) 
No Theophylline: 38.5 (27-59) 
0.02 
Anti-reflux medications  Yes: 39 (33-44)  
No: 44.2 (32-57) 
0.60 
 
CS, Corticosteroid; IQR, interquartile range; LTRA, leukotriene receptor antagonist 
*The Wilcoxon test was used for median value differences for categorical variables.
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(A) 
 
(B) 
 
(C) 
 
 
**p<0.01 ***p<0.001 
 
Figure 3.8 Relationship between serum vitamin D levels and steroids  
(A) Lower serum vitamin D levels were associated with increased oral corticosteroid 
usage (p<0.01) (B) Asthmatics with lower serum vitamin D levels were on higher 
dose of inhaled corticosteroids as compared to those who had higher serum vitamin D 
levels. (C) Daily dose of ICS (r=-0.39, p=0.001) and oral maintenance corticosteroids 
(r=-0.43, p<0.001) were inversely related to serum 25[OH]D3 levels Kruskal-Wallis 
test and Mann Whitney U test, followed by a Bonferroni correction was used to 
compare differences between groups.  
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3.3.7 Serum vitamin D levels and asthma pathology 
Demographic data of the children in whom asthma pathology and serum 
vitamin D levels were measured are presented in Table 3.4. Most children had 
normal airway anatomy at flexible bronchoscopy (all except one were normal, 
one child had tracheobronchomalacia). Macroscopically these children 
showed evidence of inflammation (hyperaemia), oedema and mucus 
plugging.  
 
Table 3.4. Demographic characteristics of STRA children (n=22) in whom 
asthma pathology was assessed.  
 
STRA children 
(n=22) in whom 
asthma pathology 
was assessed 
STRA children 
(n=14) in whom 
asthma pathology 
was not assessed 
P 
value 
Age  
(years) 
11.5 (9, 14) 12 (10, 14) NS 
Ethnicity  
White 
Non-white  
 
14 (64%) 
8 (36%) 
 
7 (50%) 
7 (50%) 
NS 
FEV1  
(%predicted) 
78 (67, 91) 72 (60, 82) NS 
FVC   
(%predicted) 
90 (77, 101) 86 (74, 95) NS 
Atopic+ (%) 19 (86) 13 (92) NS 
IgE (IU/ml) 492 (122, 652) 462 (252, 616) NS 
BDR$ (%) 15 (7, 25) 15 (12, 17) NS 
ACT^ 12.5 (8.7, 15.2)  11.5 (7.7, 14)  NS 
ICS dose* 
(microgram/day) 
1450 (1000- 2000) 1600 (1000- 2400) NS 
Median 
exacerbations ** 
3 (2,4) 3 (2,4) NS 
 
Definition of abbreviations: FEV1 = forced expiratory volume in 1 second; FVC = 
forced vital capacity; BDR= Bronchodilator response; ACT= asthma control test;  
 
Values are given in Median (interquartile range) for continuous variables or as 
number (%) for binary variables.  
+One or more positive allergen-specific IgE responses 
* Daily Inhaled Corticosteroid dose  
**Median exacerbations in last six months requiring oral steroids 
$  Rise in FEV1 post bronchodilator (%) 
^ Score out of 25 
% Beclomethasone equivalent  
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3.3.7.1 Airway and tissue inflammation 
It may be important to know the extent to which inflammation in each 
compartment, airway lumen (represented by sputum & BAL) and airway wall 
(represented by EB), are related to serum vitamin D levels in children with 
STRA. The intra-observer sputum eosinophil variability, percentage of 
eosinophils counted on 3 separate occasions from 3 different subjects is 
addressed in chapter 2, table 2.1. The 18 children with STRA had an 
adequate sample to perform differential cell count in sputum. A high sputum 
eosinophil count (median 3%, IQR 0.9-10) was seen in children with STRA 
(12/18 had sputum eosinophil >2.5%). BAL cytology was available for all 22 
children with STRA. Similarly, a high BAL eosinophil count was also seen 
(median BAL eosinophil % of 4.6, IQR 1.2-8.2).  
 
 Associations between number of inflammatory cells (eosinophils and 
neutrophils) and serum vitamin D levels were assessed. Table 3.5 outlines the 
relationship between serum 25[OH]D3 levels and airway inflammation in 
children with STRA. There was no significant correlation between serum 
25[OH]D3 levels and eosinophils (Figure 3.9 ) or neutrophils (Figure 3.10) in 
induced sputum (n=18), BAL (n=22) or EB (n=19). There was also no 
association between tissue mast cells and serum 25[OH]D3. 
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Table 3.5. Association between serum vitamin D levels and airway 
inflammation in children with STRA.  
 N Correlation (r) 
P value 
Sputum Eosinophils 18 0.1 0.9 
BAL Eosinophils  22 -0.24 0.6 
Mucosal Eosinophil  
 
19 0.05 0.8 
Sputum Neutrophils 18 -0.2 0.6 
BAL Neutrophils  22 0.17 0.24 
Mucosal Neutrophils  19 0.02 0.97 
Mast cells within the smooth 
muscle  
19 -0.02 0.92 
Mucosal Mast cells  19 -0.18 0.61 
 
Correlation was determined by the Spearman rank correlation coefficient. 
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Figure 3.9 No relationship between serum 25[OH]D3 levels and 
eosinophilic inflammation.  
There was no significant correlation between serum 25[OH]D3 and % sputum 
eosinophils (r= 0.1, p-0.9) (A), % BAL eosinophils (r=-0.2, p=0.6) (B) and mucosal 
eosinophils (r= 0.05, p-0.8) (C) Correlation was determined by the Spearman rank 
correlation coefficient. 
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Figure 3.10 No relationship between serum 25[OH]D3 levels and 
neutrophilic inflammation.  
There was no significant correlation between serum 25[OH]D3 and % sputum 
neutrophils (r= -0.2, p-0.6) (A), % BAL neutrophils (r=0.1, p=0.2) (B) and mucosal 
neutrophils (r= 0.2, p-0.9) (C) Correlation was determined by the Spearman rank 
correlation coefficient. 
Sputum Neutrophils
0 20 40 60
0
20
40
60
80
Serum 25[OH]D3  (nmol/L) levels 
N
eu
tr
op
hi
ls
 in
 s
pu
tu
m
 (%
)
(A)
BAL Neutrophils
0 20 40 60
0
10
20
30
40
60
80
Serum 25[OH]D3  (nmol/L) levels 
B
A
L 
 n
eu
tr
op
hi
ls
 (%
)
(B)
0 20 40 60
0
20
40
60
Serum 25[OH]D3  (nmol/L) levels 
N
eu
tr
op
hi
ls
  i
n 
su
bm
uc
os
a
ce
lls
/m
m
2  a
re
a
(C) Mucosal Neutrophils  
113" "
 
3.3.7.2 Airway Remodelling  
EB were deemed evaluable if epithelium, RBM and subepithelium were 
present with a minimum subepithelial area of 0.2mm2 and minimum length of 
RBM of 800µm. EB were of sufficient quality to quantify airway remodelling in 
19 of 21 children with STRA (Table 3.6). Median volume fraction of smooth 
muscle was 0.16 (range 0.07-0.20). There was a significant negative 
correlation between serum 25[OH]D3 and volume fraction of ASM (r=-0.63, 
p=0.007) (Figure 3.11A). Median RBM thickness in children with STRA was 
8.4 (range 7.9-9.7 micrometers). There was no relationship between serum 
25[OH]D3 and RBM thickness (r=-0.12, p=0.62) (Figure 3.11B). Median % 
epithelial shedding in the biopsies was 98 (range 87.4-99.7)%. There was no 
significant relationship between epithelial shedding and serum 25[OH]D3 (r=-
0.09, p=0.69) (Figure 3.11C). Smooth muscle proliferation was assessed by 
quantifying the proportion of PCNA positive smooth muscle cells(Figure 3.12). 
Median myocyte proliferation was 35.3% (range 25.3-64.3)%. There was no 
relationship between serum 25[OH]D3 and  % of smooth muscle cells positive 
for PCNA (r=0.007, p=0.07) (Figure 3.11D).  
 
Table 3.6. Biopsy cell count results, Median (Interquartile range (IQR)).  
 STRA 
Patients with good quality 
biopsies 
19 (out of 21) 
%smooth muscle cells positive 
for PCNA (IQR) 
34.1 (20.8-56.1) 
Epithelial loss  (%) median (IQR) 98 (87 -100) 
RBM thickness in micrometer 
 median (IQR) 
8.4 (7.9 - 9.7) 
Mast cells in submucosa 
cells/mm2 
median (IQR)  
65 (49-106) 
Mast cells in smooth muscle 
cells/mm2 
median (IQR)  
11 (4-40) 
Neutrophils in submucosa 
cells/mm2 
median (IQR)  
5 (0-12) 
Eosinophils in submucosa cells 
/mm2 
median (IQR)  
14 (3 – 78) 
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Figure 3.11. Relationship between serum 25[OH]D3 levels and airway 
remodelling in children with STRA.  
There was a significant negative correlation between serum 25[OH]D3 and volume 
fraction of ASM (r= -0.6, p-0.008) (A). There was no significant correlation between 
serum 25[OH]D3 and RBM thickness (B) or epithelial shedding (C). There was no 
relationship between serum 25[OH]D3 and proliferating cell nuclear antigen (PCNA) 
positive smooth muscle cells (D). Correlation was determined by the Spearman rank 
correlation coefficient. 
 
Vv (smooth muscle (SM)/SM + submucosa) = Volume fraction of smooth muscle 
indexed to volume of submucosa tissue  
 
PCNA SM cells/ total SM cells (%) = Positively stained smooth muscle nuclei were 
counted in every biopsy at x 400 magnification and divided by the total number of 
smooth muscle nuclei and expressed as a percentage (%).  
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Figure 3.12 Endobronchial biopsy sections from a child with STRA  
Endobronchial biopsies were stained with haematoxylin and eosin (A) and 
proliferating cell nuclear antigen (PCNA) (B) (magnification x 200).  Smooth muscle 
volume fraction was quantified by overlaying a weibel grid at x 200 magnification 
over the section and performing point counting. The volume fraction of smooth 
muscle was indexed to volume of submucosal tissue (C).116 Smooth muscle 
proliferation was assessed by quantifying the proportion of PCNA positive smooth 
muscle cells and dividing by the total number of smooth muscle nuclei, expressed as a 
percentage (magnification x400) (D). Arrows indicate a positively stained nucleus 
(dark brown) and a negative nucleus (light blue). 
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3.3.8 Serum vitamin D levels and disease severity  
 
To assess the association between serum vitamin D levels and severity of 
disease, linear regression was used for continuous variables and logistic 
regression for categorical variables (Table 3.7) When a non-normal variable 
remained skewed even after log transformation, this variable was 
dichotomized and used in the logistic regression. For both types of regression 
analyses, 2 models (an unadjusted and a multivariable model were 
constructed). In Table 3.8 all subjects were classified as vitamin D deficient 
(<50 nmol/L) or not, and performed a logistic regression. Multivariable 
analysis was adjusted for confounding factors (age, sex, lung function, body 
mass index and ethnicity).  
 
Even after adjusting for confounding factors including age, sex, body mass 
index, FEV1 and ethnicity, there was still a significant relationship between 
serum vitamin D levels and each of symptoms, exacerbations, inhaled and 
oral steroid use and positive BDR (Table 3.7). 
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Table 3.7. Serum vitamin D levels and disease severity in all asthmatics (mild 
/moderate asthma and severe therapy resistant asthma). (A) Linear 
regression was used for continuous measures of disease severity (B) Logistic 
regression was used for categorical variables. "(A)"
Outcome @Beta coefficient [95% confidence interval] (p value) 
 
 Unadjusted Multivariate model^ 
 
ACT 0.18 [0.13 to 0.24] (<0.001) 0.15 [0.09 to 0.20]           
(< 0.001) 
 
Daily Inhaled 
Corticosteroid 
dose 
(microgram/day) 
-0.006 [-0.01 to -0.003] 
(0.001) 
-0.004 [-0.007 to 0.0001] 
(0.05) 
 "
@ Beta coefficient is for each nmol/L increase in serum vitamin D levels  
^ Multivariate model adjusted for age, sex, BMI, FEV1 and ethnicity. 
ACT= asthma control test "(B)"
Outcome *Odds Ratio [95% confidence interval] (p value) 
 
 Unadjusted Multivariate model^ 
 
Positive BDR% 0.91 [0.84 to 0.98] (0.01) 0.86 [0.76 to 0.97] (0.01) 
 
Oral CS$ 0.92 [0.88 to 0.98] (0.004) 0.92 [0.86 to 0.98] (0.006) 
 
Exacerbation£ 0.87 [0.80 to 0.95] (0.001) 0.79 [0.64 to 0.97] (0.02) 
 ""
* Odds ratio are for each nmol/L increase in serum vitamin D levels  
^ Multivariate model adjusted for age, sex, BMI, FEV1 and ethnicity. 
% Positive Bronchodilator response (BDR) = FEV1 improvement of at least 12% after 
inhalation of 1,000 µg of salbutamol 
$ CS= Corticosteroid; use of maintenance daily oral corticosteroids  
£Exacerbation = any acute exacerbations in the last 6 months requiring oral steroids 
Decimal values were approximated to closed integer for ease of exposition.  
 " "
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Table 3.8. Serum vitamin D status in children with severe therapy 
resistant asthma (STRA), mild /moderate asthma (MA) and controls.   "
 
Vitamin D status 
 
Odds Ratio [95% CI] (p value)  
Not deficient 
(serum 
25[OH]D3 
levels > 50 
nmol/L) 
 
Deficient         
(serum 
25[OH]D3 
levels < 50 
nmol/L) 
 
Unadjusted  Multivariate@ 
Control (n=24)  15 (63%)  9 (37%) 1  
 
 
MA (n=26) 
 
11 (42%)  17 (58%) 2.27 [0.73 to 
7.07] (0.16)  
 
1.51 [0.44 to 
5.14] (0.5) 
 
STRA (n=36) 2 (6%) 34 (94%) 28.33 [5.45 to 
147.25] 
(<0.0001) 
13.15 [2.19 to 
78.82] (0.005) 
"
@ Multivariate model adjusted for age, body mass index (BMI), % predicted FEV1 
(forced expiratory volume in 1 second), % predicted FVC (forced vital capacity), 
ethnicity.  
 
 
 
Serum vitamin D levels were significantly lower in ‘non-White’ children than 
those of ‘White’ ethnic background, (p<0.001 [***] measured by Mann Whitney 
test) (Figure 3.13). However, within the three groups (severe therapy resistant 
asthma, mild/moderate asthma and controls) there was no difference in serum 
vitamin D levels between ‘White’ and ‘non-White’ children (Figure 3.13). Also 
only looking at  ‘white’ children in all groups serum vitamin D levels were 
significantly lower in ‘white’ children with STRA compared to ‘white’ children 
with MA and controls (p<0.01 for both) but the numbers are relatively small. 
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Figure 3.13. (A) Serum vitamin D levels were significantly lower in ‘non-
White’ children than those of ‘White’ ethnic background, (p<0.001 [***] 
measured by Mann Whitney test). (B) Within the three groups (severe therapy 
resistant asthma, moderate asthma and controls) there was no difference in 
serum vitamin D levels between ‘White’ and ‘non-White’ children (Kruskal-
Wallis p<0.001 followed by Mann Whitney test for inter-group differences and 
then a Bonferroni  correction for multiple comparison)  
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3.4 Discussion 
3.4.1 Principle findings  
The main findings are summarized in text box 3.1. The work of this chapter 
reports for the first time that children with STRA have significantly lower 
serum 25[OH]D3 levels than MA. Lower serum 25[OH]D3 levels were 
associated with worse lung function, poorer asthma control and more steroid 
use in MA and STRA. Within STRA, low 25[OH]D3 levels  were associated 
with increased ASM mass, but not with other parameters of airway 
remodelling, nor with airway inflammation despite an association with the 
degree of aeroallergen sensitisation.  
 
In this group with STRA, a significant negative association was present 
between volume fraction of ASM and 25[OH]D3 levels. Of note, however, 
there was no association between RBM thickness or epithelial shedding and 
vitamin D.  Although a negative relationship between ASM mass and lung 
function has been reported in pediatric difficult asthmatics,116 this is the first 
demonstration of an association between low serum 25[OH]D3, poor lung 
function and asthma control, increased BDR and ASM mass. It is therefore 
plausible that the link between ASM mass and lung function in severe asthma 
may partly be explained by low 25[OH]D3 levels. The association between 
increased ASM mass and low 25[OH]D3 is supported by independent in vitro 
studies, which have shown that vitamin D inhibits smooth muscle 
proliferation.280, 281, 311 In contrast to the published in vitro studies, there was 
no relationship between serum 25[OH]D3 levels and ASM proliferation 
assessed by PCNA staining. However, all in vitro work is in adult ASM and 
mechanisms may be different in children. Importantly, ASM mass is still 
increasing as part of normal growth and development in children,370 therefore 
the influence of superimposed pathological abnormalities are likely to be 
different to those in adults. 
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Text box 3.1 Relationship between serum vitamin D and clinical markers 
of asthma severity  
Main findings in children with STRA 
• Serum 25[OH]D3 levels were significantly lower in children with STRA than 
those with MA, and non-asthmatic controls.  
• Most of the children with STRA were vitamin D deficient. 
• Serum 25[OH]D3 levels were inversely related to serum total IgE.  
• There was a positive correlation between serum 25[OH]D3 levels and % 
predicted FEV1  and FVC.  
• Serum 25[OH]D3 was inversely associated with % BDR  
• A positive relationship was found between 25[OH]D3 level and ACT, whereby 
higher serum 25[OH]D3 was associated with better asthma control as assessed 
by ACT.  
• Lower serum 25[OH]D3 levels were associated with increased acute asthma 
exacerbations in the previous six months. 
• Daily prescribed dose of corticosteroids were inversely related to serum 
25[OH]D3 levels. 
• There was no significant correlation between serum 25[OH]D3 levels and 
eosinophils or neutrophils in induced sputum, BAL or EB. 
• Low serum 25[OH]D3 levels  were associated with increased ASM mass, but 
not with other parameters of airway remodelling. 
 
 
   
3.4.2 Strengths and weaknesses  
The children with STRA had been carefully assessed such that their basic 
management had been optimized, and any ‘difficult asthmatics’ (whose 
asthma was uncontrolled because of modifiable factors such as poor 
adherence to treatment) had been excluded as far as possible..  
 
Interestingly, there was no association between any of the inflammatory cells 
quantified (eosinophils, neutrophils or mast cells) and serum 25[OH]D3 levels. 
This remained true for both luminal inflammation (BAL and sputum) and tissue 
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inflammation (EB). This may be related to relatively small numbers, although 
this study is comparable in size with other airway biopsy manuscripts. It is 
also possible that the substantial anti-inflammatory treatment prescribed for 
these children may have masked any relationship between vitamin D and 
airway inflammation in STRA.  ""
The cross-sectional design of this study made it impossible to determine 
whether low 25[OH]D3 levels result in severe asthma in children, or whether 
children with severe asthma have low 25[OH]D3 levels because, for example, 
they are unable to go outside and exercise normally. In addition, correlating 
ASM mass with the results of airway challenge would be of interest. However, 
given the STRA subjects’ disease severity, this was thought to be unsafe and 
therefore unethical. A further limitation of this study was that BDR and ACT 
were not performed in normal controls. The small numbers of children with 
STRA with normal serum vitamin D levels is also a limitation. It could be 
postulated that STRA, low vitamin D levels, high corticosteroid usage, high 
ASM mass and bad outcomes all cluster together. Low serum vitamin D levels 
may contribute to asthma severity in children, or corticosteroid usage might 
result in low serum 25[OH]D3 levels; or that asthma severity, steroid usage, 
and low 25[OH]D3 levels results independently from another as yet 
undetermined factor. By definition, children with STRA will always be on more 
treatment than children with MA. To unpick the interactions between vitamin D 
and asthma severity/ corticosteroid usage, either a prospective study is 
needed, enrolling subjects with asthma before initiation of any treatment to 
see if those who eventually prove to have STRA had lower 25[OH]D3 levels 
from the outset; or, more practically, to show that supplementing children with 
established STRA with vitamin D improves serum vitamin D levels, and with it, 
leads to better asthma control and fewer exacerbations. 
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3.4.3 Strength and weaknesses in relation to other studies 
Even after adjusting for confounding factors including age, sex, body mass 
index, FEV1 and ethnicity, a significant relationship between serum vitamin D 
levels and asthma control, exacerbations, inhaled and oral steroid use and 
positive BDR remained. Some of the findings concur with reports in children 
and adults with much less severe asthma. These include the associations 
found between low 25[OH]D3 levels and asthma control  and 
exacerbations,183, 222, 371 lower lung function,172, 173, 221, 222, 372 increased 
reversibility to bronchodilator183, 372 and greater anti-inflammatory medication 
(ICS, oral steroid & LTRA) usage.173, 183 However association does not prove 
causation and reverse causation (above) remains a possibility.  
 
In terms of ethnicity, because numbers are small the children were divided 
into 'White' and 'non-White' groups, but ethnicity was not further subdivided. 
There was a non-significant trend for more non-White children in the STRA 
group (36%) compared to MA (16%) and controls (12%) (p=0.056). Children 
with non-White skin had lower serum vitamin D levels, as reported by 
others.185 Moreover, non-White children had more severe asthma compared 
to White children.  However the repeated measures ANOVA results have 
shown that there is no interaction between ethnicity and disease severity for 
levels of vitamin D (p=0.20). This could be due to the small number of 
subjects in the study. Importantly, race is a proxy for skin colour, and although 
skin colour is a proxy for low Vitamin D levels, the conclusions relate to the 
relationship between low serum Vitamin D levels, whether driven by diet, 
sunlight, ethnicity or another factor, and asthma severity and pathology. 
 
In recent study, Agrawal and colleagues317 in a murine model of allergic 
airways inflammation, noted that vitamin D supplementation reduces 
eosinophilic inflammation in the BAL as compared to vitamin D deficient 
group.317 Although total serum IgE levels and specific IgE to cat, dog, pollen, 
Dermatophagoides pteronyssinus and Aspergillus fumigatus were inversely 
related to 25[OH]D3 levels, there was no relationship between 25[OH]D3 and 
serum, BAL or biopsy eosinophils. This may be because children with STRA 
are highly atopic, and the majority of STRA patients are vitamin D deficient.   
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Some,173, 183 but not all222 investigators have found correlations between lower 
25[OH]D3 levels and markers of allergy in childhood asthma. An association 
between 25[OH]D3 deficiency and increased sensitization to allergens in 
children, but not in adults was also shown in the National Health and Nutrition 
Examination survey.373 This chapter results are in agreement with this 
report373 that children with low serum 25[OH]D3 levels are more likely to have 
allergic sensitization. Interestingly, there was only an association between 
sensitization to aeroallergens and 25[OH]D3 levels, but not to food allergens, 
and this is also partly in agreement with the work of Sharief et al.373 They did 
not find any association between vitamin D and sensitization to milk and egg 
allergen, however serum vitamin D was inversely associated with peanut 
sensitization. It could be postulated that vitamin D may have a role in 
preventing sensitization (tolerance) to aeroallergen (lung) but not food (gut) 
allergen. Although this chapter does not explain these associations, it is 
hypothesis generating and suggests an important area to validate and extend 
studies. No association with airway eosinophilia in this chapter may be related 
to the substantial anti-inflammatory treatment prescribed for these children 
and may have masked a relationship between vitamin D and airway 
inflammation in STRA.   
 
The relationship between ASM and serum vitamin D levels in children with 
STRA noted in this chapter is supported by two recently published studies (in 
a mouse model).317 316  In both animal studies, vitamin D supplementation 
attenuated evidence of airway remodelling (reduced ASM mass, subepithelial 
collagen deposition, epithelial thickening and prevents goblet cell hyperplasia) 
in murine models of allergic airways disease. The cross-sectional nature of 
the biopsy data prevents certainty as to whether the relationship between 
increased ASM mass and vitamin D is a result of severe asthma, or whether 
the increased ASM mass may have been present before the development of 
disease and caused the asthma. It is possible that a developmental structural 
defect of the airway wall, such as ASM hypertrophy in children with STRA 
results from vitamin D deficiency in-utero, and that may have led to asthma in 
the first place. It may be that exaggerated ASM hypertrophy is a cause of the 
asthma, rather than a consequence, as a result of in-utero 257, 374 and post-
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natal vitamin D deficiency. The effects of vitamin D deficiency in utero 257, 374 
could be in addition to, or independent of, airway remodelling. This is 
especially important as a randomized controlled trial of vitamin D therapy in 
children with STRA could potentially reverse the ASM hypertrophy and 
change the course or natural history of these patients’ asthma. However, if 
vitamin D induces a smooth muscle developmental defect in-utero, then it 
may prove more challenging to reverse.  
 
3.4.4 Meaning of the results  
Having established a link between serum 25[OH]D3 levels and spirometry and 
asthma control, and importantly, having now seen a novel link between serum 
vitamin D levels and asthmatic airway smooth muscle, it is logical to suggest 
that vitamin D supplementation in children with STRA and low 25[OH]D3 
levels, may be a novel therapeutic target directed against some aspects of 
remodelling. It is challenging to propound a unifying hypothesis to account for 
ASM changes being the sole manifestation of vitamin D deficiency. In terms of 
remodelling, this may be due to a heightened sensitivity of ASM to vitamin D 
deficiency as compared to other airway wall components. The lack of any 
association between serum vitamin D and inflammation may in part be due to 
the high dose of inhaled and oral steroid therapy being prescribed. Although 
vitamin D deficiency causes a degree of steroid insensitivity, the high ICS 
doses used in the STRA children may have overcome this. It is possible that 
in the setting of chronic airway inflammation systemic vitamin D levels may be 
reduced as a direct result of the inflammatory response, which further 
confounds the association between vitamin D deficiency and disease severity. 
However, these ideas remain speculative at the present time and the 
determination of the exact mechanism between low 25[OH]D3 and  airway 
inflammation and remodelling in STRA will require intervention studies. 
 
 
3.4.5 Summary  
Children who, as far as could be determined had genuine severe asthma had 
significantly lower serum vitamin D levels than MA and controls. Lower serum 
vitamin D levels were associated with worse parameters of asthma severity, 
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and a contributory mechanism may be via an effect on ASM. As numbers are 
small, and represent a selected population, the conclusions drawn must be 
tentative. However, these findings suggest that detecting and treating low 
serum vitamin D levels in children with STRA may aid in treatment of 
specific structural airway changes as well as of asthma symptoms and 
severity. 
 
Reverting back to the hypotheses, the data have shown that the hypothesis 
tested in this chapter has been proven, albeit in relatively small numbers, a 
selected population of children who as far as could be determined had 
genuine severe asthma; they had significantly lower serum vitamin D levels 
than MA and controls. Lower serum vitamin D levels were associated with 
worse parameters of asthma severity including lung function and symptoms, 
and ASM mass.  As there were few children with STRA with normal vitamin D 
levels, any conclusions must be tentative. To understand the underlying 
mechanisms and elucidate the effect of vitamin D treatment, the next chapter 
describes in vitro responses of peripheral immune cells in cell culture to 
glucocorticoids and vitamin D. 
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Chapter 4  The effects of vitamin D on IL-10 secretion from PBMC in 
vitro from asthmatic children and controls "
4.1 Introduction  
The previous chapter describes the relationship between serum vitamin D 
levels and clinical markers of asthma severity, airway inflammation and 
remodelling. Children with STRA had significantly lower serum vitamin D 
levels than MA and controls. Lower serum vitamin D levels were associated 
with worse parameters of asthma severity. However as discussed, cross-
sectional data does not prove causation nor explain mechanisms. The vast 
majority of studies investigating the potential mechanisms of steroid 
resistance in asthma (discussed in chapter 1 section 1.3) have been 
performed in adults,149 but not yet extensively in children. The well-
characterized cohort of children with STRA included here provides the unique 
opportunity to investigate mechanisms underlying steroid resistance and 
vitamin D levels in asthmatic children. As discussed in chapter 1 section 1.2 
children with STRA had undergone a staged investigation protocol134, 375 and 
this protocol, (Figure 1.4) which includes a formal assessment in the home 
and results in approximately half the referrals being classified as difficult 
asthmatics, in whom basic management needs to be optimized rather than 
therapy escalated. The remaining children (characterised as STRA) have 
persistent symptoms, acute severe exacerbations and/or fixed airflow 
obstruction unresponsive to high-dose steroid therapy.134 I performed in vitro 
experiments in samples from children with STRA to understand responses of 
PBMC in the cell culture to glucocorticoids and vitamin D.  
 
IL-10 is secreted by many cell types including B cells, mast cells, eosinophils, 
macrophages, dendritic cells and many T cell subsets such as CD4+ T cells, 
including CD4+Foxp3 Treg cells.92 IL-10 is a potent immunoregulatory 
cytokine and has multiple immunosuppressive functions376 and anti-
inflammatory effects in adult asthma92, 377 (summarized in Figure 4.1). IL-10 
also regulates the function of innate immune cells and inhibits pro-
inflammatory cytokine production by both Th1 and Th2 cells377 (discussed in 
chapter 1).  
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Figure 4.1 Functions of IL-10 relevant to asthma. Reproduced from 
Hawrylowicz and O'Garra377 
 
 
 
 
Adult studies have shown that there is an inverse association between IL-10 
levels and the incidence and severity of asthma in adults.378, 379 Akdis and 
colleagues showed that there is an increased frequency of IL-4-secreting 
allergen-specific T cells and a reduced frequency of peripheral IL-10-secreting 
allergen-specific CD4+ T cells in atopic patients as compared to healthy 
controls suggesting an imbalance between IL-10-secreting Treg cells and Th2 
cells.83 Adult asthmatic patients prescribed corticosteroid treatment showed 
increased mRNA expression for IL-10 in PBMC as compared to the controls 
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(untreated asthma patients).380 Importantly, corticosteroids are associated 
with a dose dependent induction of IL-10 synthesis in healthy and steroid 
sensitive adult asthmatic adult PBMC in vitro.381,382 However, there is a poor 
response in steroid resistant adult asthmatics,382 suggesting that IL-10 has an 
important role in the anti-inflammatory effect of corticosteroids.382 Hawrylowicz 
and colleagues suggested a potential role for IL-10 in improving steroid 
responsiveness in adult asthmatics.382 Further studies in healthy adult PBMC 
has shown that the combination of dexamethasone and vitamin D potently 
induced IL-10 synthesis and importantly to a greater degree than that 
observed with dexamethasone alone.171 Moreover in another study, vitamin D 
was noted to restore the defective steroid-induced IL-10 synthesis both in vitro 
and ex vivo following vitamin D ingestion (0.5mcg daily for 7 days) in steroid-
resistant asthmatic patients.383 These data from adult studies, using 
peripheral blood, suggest a potential for improving steroid responsiveness 
with vitamin D.  
 
It is increasingly recognized that paediatric asthma is different from adult 
asthma immunologically and this has implications for the development of 
novel therapies; adult responses cannot be used accurately to predict those of 
children.384 Very little is known about the in vitro response of PBMC to vitamin 
D and corticosteroids in children with STRA.  
 
4.1.1 Hypothesis 
 
In this chapter the hypothesis tested is that CD8-depleted PBMCs, from 
children with STRA exhibit a reduction in glucocorticoid-induced IL-10 
synthesis in cell culture, and this is restored by vitamin D.  
 
4.1.2 Aims 
 
i. To assess the differences in PBMC responses from STRA, MA and 
control subjects to glucocorticoids  
ii. To determine whether addition of vitamin D modulates the effects of 
glucocorticoids and restores steroid sensitivity in children with STRA.  
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Some of the findings have been reported in the European Journal of 
Immunology 273 and Thorax.385  
 
4.2 Methods 
4.2.1 Subjects  
Children aged 5-16 years with STRA (n=19), MA (n=16) and non-asthmatic 
controls (n=13) were recruited prospectively from RBH. STRA was defined as 
previously described in chapter 1 section 1.2.134 Non-asthmatic controls 
comprised either children with no lower airway disease whose parents had 
consented for a blood test during an elective surgical procedure (cardiac 
catheterization n=7) or children undergoing a clinically indicated 
bronchoscopy for upper airway symptoms (n=6) at RBH. Parents of 21 non-
asthmatic control children were approached, 13 of these agreed to participate. 
The most common reason for refusal was procedural and general 
anaesthesia anxiety (5/12), the remaining three gave no reason for refusal. 
Parents of 38 MA children were approached, 16 of these agreed to participate 
and the most common reason for refusal was anxiety/phobia for blood test 
(14/22), the remaining eight gave no reason for refusal. Parents of all 19 
STRA children approached agreed to participate.  
 
4.2.2 Steroid responsiveness 
Clinical steroid responsiveness was assessed in children with STRA only, as 
described in chapter 1 section 1.2.1 after a trial of intra-muscular 
corticosteroid (triamcinolone) as suggested by Bush et al134 using lung 
function response (normalisation or improvement of ≥15% in FEV1), symptom 
response (normalisation or improvement by ≥ 50% in ACT) and inflammatory 
response (if paired sputum available - normalisation of sputum eosinophil % 
<2.5% or if paired sputum samples were not available, normalisation of 
FeNO50 <24ppb). Non-response (steroid refractory, SR) was classified as no 
improvement in any of the three domains; partial response (partial 
responders, PR) was improvement in one or two domains; and complete 
response (steroid sensitive, SS) was normalisation in all three domains.134 
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4.2.3 Isolation of cell populations from peripheral blood 
4.2.4 Isolation of total PBMC 
Peripheral blood (10-25 mls, maximum 1ml/kg) was collected from all subjects 
by venepuncture and placed into the anti-coagulant sodium citrate (Sigma-
Aldrich Co. Ltd, Poole, UK) at a ratio of 10:1. Blood was transferred and 
processed immediately (<1hr) at the MRC Centre for Allergic Mechanisms of 
Asthma, Department of Asthma, Allergy and Respiratory Science, Guy’s 
Hospital, London. Blood was diluted 1:1 in Hank’s balanced salt solution 
(HBSS; Life Technologies, Gaithsburg, MD). This was layered at a ratio of 3:1 
onto lymphoprep® density gradient (Axis-Shield, Oslo, Norway) and 
centrifuged at 800g for 20 minutes at 4ºC. PBMC were removed from the 
lymphoprep® and plasma interface. They were then washed in HBSS 
supplemented with 2% foetal bovine serum (FBS; PAA laboratories, 
Pasching, Austria) (2%FBS/HBSS), at 600g for 10 minutes at 4ºC. PBMC 
were washed again in HBSS supplemented with 2%FBS/HBSS at 200g for 10 
minutes at 4ºC. This cell purification protocol has been previously 
described.178, 386 
 
4.2.5 Preparation of CD8 depleted PBMC cells  
CD8+ T cells were removed from total PBMC by positive selection using 
Dynabeads (Dynal, Oslo, Norway; typical removal 98.5%). The PBMCs were 
incubated with CD8 coated Dynabeads® (CD8 beads: 25µl per 107 PBMC) for 
20 minutes at 4ºC under continuous rotation. The sample was then placed on 
a magnet for 2 minutes. The supernatant containing the CD8 depleted cells 
were transferred to a fresh tube and bead bound cells were discarded.  The 
CD8 depleted cells were then washed twice in 2%FBS/HBSS at 200g for 10 
minutes at 4ºC to remove any trace of the Dynabeads®. The typical levels of 
depletion of CD8T cells were >99% (Figure 4.2). Isolated populations were 
washed and resuspended at 1×106/ml in RPMI 1640 (Life Sciences, 
Abingdon, GB) containing 10% heat-inactivated FCS (PAA Laboratories, 
Oxford, GB), 2 mM L-glutamine (Life Technologies) and 50 mg/ml gentamicin 
(Sigma-Aldrich).  
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Figure 4.2 Typical depletion of CD8 T cells isolated by bead-based 
selection  
CD8+ T depleted cells were isolated from PBMCs by bead selection using antibody-
coated Dynal®. Purity was assessed by surface staining using CD4-APC, CD8-PE.  
10,000 live cells were analysed for fluorescence by FACS. Values shown are 
indicative of the percentage of positive cells within the relevant quadrant.  
 
 
 
 
4.2.6 CD8 depleted PBMC cell culture  
Isolated cells were counted using a haemocytometer with dead cells excluded 
by the use of Trypan blue staining. Purified cells were resuspended at a 
concentration of 1x106cells/ml in 10%FCS/RPMI/ L-glutamine/gentamicin. On 
day 0, CD8 depleted PBMC cells were stimulated with the T cell stimulus 
plate-bound anti-CD3 (1mg/ml, clone OKT3; purified in-house) and IL-2 
(50U/ml; Eurocetus, Harefield, UK). Cells were treated with a titration of 
dexamethasone (10-9 to 10-7 M Dex, Sigma-Aldrich, UK) and /or 10-7M 1alpha, 
25-dihydroxyvitaminD3 (also known as calcitriol, the active form of vitamin D3; 
Enzo Life Sciences, USA) on day 0. Cells were then incubated at 
37ºC/5%CO2 for 7 days. Feeding occurred on day 3; half the volume of 
culture medium was removed and replaced with 10%FCS/RPMI with 20U/ml 
IL-2. Removed supernatant was frozen at -20 C. On day 7, cells underwent a 
second cycle of stimulation. The rationale for this restimulation is to account 
for differential cell loss under different culture /drug conditions during the initial 
7-day culture period. Prior to restimulation, cell culture supernatant was frozen 
at -20ºC. Cells were washed twice in 2% FCS/HBSS by centrifugation at 200g 
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for 10minutes at 4ºC. To exclude dead cells from the analysis 0.4mcg 
propidium iodide (PI; Sigma-Aldrich) was added. Prior to restimulation, 
counting was also performed by flow cytometer analysis, using a FACS 
Calibur (BD Biosciences). Cells were then resuspended at 1x106cells/ml in 
10%FCS/RPMI and restimulated with plate-bound anti-CD3 and IL-2 
(50U/ml). On day 9 (48 hrs after restimulation), cell culture supernatant was 
taken and stored at -20ºC to assess cytokines by CBA (chapter 2 section 2.5). 
 
The doses of dexamethasone (10-7M) and 1α,25VitD3 (10-7M) used are based 
on extensive earlier work in the laboratory in adults,162, 171, 178 paediatric 
(Xystrakis and Payne, unpublished data) and cord blood studies (Hornsby, 
Rice and Hawrylowicz, unpublished data). Also, dose titrations with paediatric 
PBMC (n=3 non-asthmatic controls) showed optimal IL-10 secretion with the 
dose of 10-7M 1α,25VitD3 and 10-7M dexamethasone (Figure 4.3). It would 
have been ideal to perform a dose response in all the subjects, but this was 
limited by the small volume of blood permitted by the Ethics committee.  
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Figure 4.3. The effect of various concentrations of 1α,25VitD3 and 
dexamethasone on CD8 depleted PBMC cytokine production.  
 
 
CD8-depleted PBMC from non-asthmatic controls (n=3) were cultured for 7 days 
with polyclonal conventional T cell stimulation (soluble anti-CD3 (1mcg/ml) plus 
neutral conditions (IL-2, 50U/ml) or additionally in the presence of dexamethasone 
(Dex;10-7M and/or 1α,25VitD3 (VitD;10-xM as indicated). At day 7, cells were re-
stimulated for 48 hours with anti-CD3 and IL-2 and supernatants were harvested and 
analysed for IL-10 content by CBA. The optimal IL-10 secretion was noted with the 
1α,25VitD3 dose of 10-7M.  
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4.3 Results 
Demographic data of the children studied are presented in Table 4.1. 
 
  
Table 4.1. Demographic characteristics of subjects✪  
No significant differences between children with MA, STRA, and non-
asthmatic controls in age and sex. As expected, children with STRA had lower 
spirometry, ACT and more exacerbations and were prescribed higher dose of 
inhaled corticosteroids.    
 
 STRA (n=19) MA (n=16) Controls 
(n=13) 
p value 
Age (years) 11 (9-14) 12 (11-13) 10.5 (9-13) 0.2a 
Male  9 (47%) 7 (58%) 8 (61% 0.1 
%predicted 
FEV1  
75 (65-86) 89 (84-96) 95 (90-98) <0.001a 
%predicted FVC  88 (76-96) 102 (96-110) 96 (94-108) <0.001 a 
FEV1 / FVC 
ratio 
73 (68-84) 88 (78-92) 93 (89-97) <0.001a 
Atopic+ (%) 16 (84%)  12 (75%) 3 (23%) <0.001£ 
IgE (IU/ml) 498 (127-650) 690 (280-1240) 12.5 (8-51) <0.001a  
BDR$ (%) 14 (6-17) 4 (3.5-6) (n=4) N/A 0.08& 
ACT^ 12 (8-15)  19 (17-21) N/A <0.001& 
Daily Inhaled 
Corticosteroid 
dose 
(microgram/day) 
1400 (1000- 
2000) 
600 (500-800) N/A <0.001& 
Median 
exacerbations in 
last six months 
requiring oral 
steroids 
3 (2-4) 1 (0-2) N/A <0.001& 
Median serum 
25[OH]D3 
(nmol/L) 
33 (22-42) 44 (31-61) 54 (46-68) <0.001& 
Ethnicity  
White 
Non-white  
 
12 (64%) 
7 (36%) 
 
14 (87%) 
2 (13%) 
 
11 (85%) 
2 (15%) 
0.1£ 
137" "
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; BDR= 
Bronchodilator response; ACT= asthma control test;  
✪ Values are given in Median (interquartile range) for continuous variables or as 
number (%) for binary variables; +One or more positive allergen-specific IgE 
responses; $  Rise in FEV1 post bronchodilator (%); ^ Score out of 25; 
%Beclomethasone equivalent;  aP value calculated by  Kruskal- Wallis test; £P value 
calculated by  Chi-square test; & P value calculated by  Mann Whitney test. 
   
 
4.3.1 Serum cytokine levels  
All the cytokines (IL-1β, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, TNF-α and IFN-γ) 
measured by CBA in serum from STRA, MA and non-asthmatic controls were 
largely undetectable with more than 75% of cytokines below the detection 
limit. The median serum cytokine levels of all the subjects are shown below in 
Table 4.2 and correlation with serum vitamin D levels are shown in Table 4.3  
 
Table 4.2 Comparison of serum cytokines in all groups.  
Serum cytokines were undetectable in more than 90% of controls and 75% of MA & 
STRA   
Serum 
Cytokine 
(N) STRA (N) MA (N) Control 
IL-1β 4/19 u(u-4) 1/16 u(u-2) 0/13 u 
IL-5 1/19 u(u-2) 0/16 u 0/13 u 
IL-6 3/19 u(u-22) 1 u 0/13 u 
IL-8 12/19 3.5(u-
22) 
8/16 9.5(u-
33) 
3/13 u(u-25) 
IL-10 18/19 u(u-5) 10/16 2(u-13) 8/13 2(u-4) 
IL-13 5/19 u(u-3) 0/16 u 0/13 u 
IL-17 7/19 u(u-
137) 
1/16 u(u-52) 0/13 u 
TNF-α 7/19 u(u-59) 6/16 11(u-
87) 
1/13 u(u-26) 
IFN-γ 3/19 u(u-9) 2/16 u(u-2) 0/13 u 
N=detectable cytokines, u=undetectable 
All values median (range) and pg/ml. The numbers were too low to do any reasonable 
statistics.   
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Table 4.3 Relationship between serum vitamin D levels and serum 
cytokines of those asthmatics with detectable cytokines.  
No significant correlation between serum vitamin D levels and serum cytokines.  
 
Serum 
Cytokine 
N with 
detectable 
cytokines in 
asthmatics   
Serum vitamin D 
r p 
IL-8 20 0.04 0.8 
IL-10 28 -0.01 0.9 
IL-17 8 -0.6 0.1 
TNF- 13 -0.2 0.5 
Analysis performed using Spearman correlations.  
    
 
 
4.3.2 CD8 depleted PBMC from asthmatic children demonstrate 
impaired IL-10 secretion. 
The relative capacity of CD8 depleted PBMC from non-asthmatic controls, MA 
and children with STRA to produce cytokines in vitro was first assessed. 
PBMC were depleted of CD8+ T cells, to provide a CD4+ T cell-enriched cell-
culture system. Following polyclonal T cell activation with soluble anti-CD3 
(1mcg/ml), induced IL-10 secretion was significantly lower in MA and STRA 
as compared to non-asthmatic control subjects (p<0.001, Figure 4.4). There 
was also a non-significant trend for increased IL-13 and IL-17A secretion 
(Figure 4.4); these responses  were more heterogeneous in the group.  
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***p<0.001. 
 
Figure 4.4. CD8-depleted PBMC from asthmatics secrete significantly 
less IL-10 than non-asthmatics, and there is a non-significant trend 
towards increased IL-17A and IL-13 production. 
CD8-depleted PBMC from non-asthmatic controls (n=13), MA (n=16) and STRA 
(n=19) were cultured for 7 days with polyclonal conventional T cell stimulation 
(soluble anti-CD3 (1mcg/ml) plus IL-2 (50U/ml). At day 7, cells were re-stimulated 
for 48 hours with anti-CD3 and IL-2 and supernatants were harvested and analysed 
for (a) IL-10 (b) IL-17A and (c) IL-13 content by CBA. For some controls (n=4) IL-
13 in was below the detection limit, hence not the same number of symbols in each 
group.  
Data are presented as individual donor responses and the bars represent the mean. A 
Mann Whitney U test was used to compare differences between groups followed by a 
Bonferroni correction. 
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4.3.3 Dexamethasone inhibits IL-13 secretion, but enhances both IL-10 
and IL-17A production in cultures of  CD8 depleted PBMC 
To investigate in vitro dose response and regulation by corticosteroids of CD8 
depleted PBMC cytokine profiles in paediatric asthma, cells were cultured with 
dexamethasone (10-7M to 10-9M).  This significantly promoted IL-10 secretion 
by CD8 depleted PBMC in all three patient groups studied.  IL-10 induction 
occurred in a dose-dependent manner across the range of dexamethasone 
doses studied (10-7M to 10-9M) but remained markedly less in asthmatics (MA 
and STRA) as compared to non-asthmatic control children (p<0.01, as 
assessed by repeated measures ANOVA) (Figure 4.5).  There was no clear 
difference between children with MA and STRA in IL-10 secretion (Figure 
4.5). Additionally, dexamethasone significantly reduced IL-13 secretion by 
PBMC from children with STRA, which was elevated compared to the other 
groups studied (Figure 4.5).  However, PBMC IL-17A secretion, which was 
also the highest in STRA was not suppressed by dexamethasone treatment, 
but was in fact significantly further enhanced (Figure 4.5) 
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**p<0.01, ***p<0.001, @p=0.1, £p=0.07,$p=0.21,&p=0.19  
 
*p<0.05, **p<0.01 
 
*p<0.05, **p<0.01 
Figure 4.5 Dexamethasone increases IL-10 secretion, and in STRA 
inhibits IL-13 secretion, but significantly enhances IL-17A production by 
PBMCs. 
CD8-depleted PBMC from non-asthmatic controls (n=13), MA (n=16) and STRA 
(n=19) were cultured for 7 days with polyclonal conventional T cell stimulation 
(soluble anti-CD3 (1mcg/ml) and IL-2 (50U/ml), without or with a titration of 
dexamethasone (10-7 to 10-9M). At day 7, cells were re-stimulated for 48 hours with 
anti-CD3 and IL-2 alone and supernatants were harvested and analysed for expression 
of (a) IL-10, and (b) IL-17A and (c) IL-13 by CBA. Data are summarized as mean +/- 
SD. Mann Whitney U test was used to compare differences across the various 
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concentrations of dexamethasone."Repeated measures ANOVA was used to compare 
differences between the groups.""
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4.3.4 Vitamin D potentiates steroid-induced IL-10, but not IL-17A in CD8 
depleted PBMC cultures 
In healthy adults, the active form of vitamin D, 1α,25-dihydroxyvitamin D3 
drives IL-10 secretion by CD4+ T cells in vitro and additionally potentiates 
dexamethasone-induced IL-10.171, 178 Furthermore, in steroid-refractory 
asthmatics, oral vitamin D ingestion restores impaired T cell responsiveness 
to dexamethasone in vitro for IL-10 induction.163 Conversely, vitamin D is 
reported to negatively regulate IL-17A expression, both in human lymphocytes 
in vitro and in a number of experimental autoimmune models.387, 388 The 
effects of vitamin D on dexamethasone-induced IL-10 and IL-17A production 
by PBMC were therefore investigated. In both asthmatic and control 
individuals, inclusion of vitamin D with dexamethasone potentiated IL-10 
secretion, although notably this still remained lower in the MA and STRA 
patients as compared to controls (Figure 4.6A). Vitamin D did not however 
further enhance steroid-induced IL-17A expression in STRA (Figure 4.6B) and 
vitamin D alone without dexamethasone did not significantly alter PBMC 
secretion of IL-10, IL-13 or IL-17A in any group studied (Figure 4.6). However, 
there was a trend towards inhibition of IL-17A by vitamin D alone in controls 
(p=0.06) and MA (p=0.08) but not in STRA (p=0.7). Because of limited sample 
size it was not possible to assess multiple concentrations of dexamethasone 
and vitamin D.  
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(A) 
 
(B) 
 
(C) 
 
*p<0.05, **p<0.01, ***p<0.001 
Figure 4.6 Vitamin D enhances dexamethasone-induced IL-10 secretion 
by asthmatic PBMC (A), but does not alter IL-17A (B) or IL-13 secretion 
(C). 
CD8-depleted PBMC were cultured as described in figure 4.5 with or without 
dexamethasone, 1,25VitD3 or a combination of both (at 10-7M) and supernatants 
were harvested and analysed for expression of (a) IL-10, (b) IL-17A and (c) IL-13 by 
CBA. Data are summarized as mean +/- SD. Mann Whitney U test was used to 
compare differences across the various treatments. Repeated measures ANOVA was 
used to compare differences between the groups 
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4.3.5 Effect of dexamethasone and Vitamin D on CD8 depleted PBMC 
cytokine profiles of STRA - related to clinical steroid 
responsiveness 
Having demonstrated the capacity for vitamin D to enhance steroid-induced 
IL-10 secretion in STRA by paediatric PBMC in vitro. STRA children enrolled 
in the study were further sub-classified according to their clinical response to 
a single dose of an intramuscular steroid (triamcinolone).134 There is no 
accepted definition of steroid responsiveness in children; neither the dose, 
route of administration or duration of steroid therapy is standardized, nor the 
criteria for positive response. In this study, single dose triamcinolone was 
chosen to avoid the problems of adherence, maximizing the chance of 
showing responsiveness and minimizing side effects. This is not an evidence 
based protocol but is the standard clinical protocol at RBH to assess steroid 
responsiveness (see chapter 1, section1.2.1).134 The demographic data of the 
children are presented in table 4.4 Six subjects were classified as complete 
responder (SS), 7 as partial responders (PR) and six as non-responder (SR) 
as suggested by Bush et al.134 There were no significant differences in lung 
function, ACT, inflammation in any compartment at baseline between the 
three groups. As there are very small numbers in each group, data should be 
interpreted with caution.       
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Table 4.4 Demographic of children with complete, partial and non-
response to intramuscular steroid (triamcinolone).  
 Non-
response  
(n=6) 
Partial 
response  
(n=7) 
Complete 
response  
(n=6) 
 
Age 12 (11,14) 10 (8.7,14) 13.5 (9,14) NS 
Atopy 5 6 5 NS 
FeNO50  58 (39, 124) 52 (16, 86) 48 (18, 79) NS 
ACT 11 (6.7,11.5) 15 (13, 17) 12 (7.5, 15) NS 
FEV1 % 72 (53, 84) 80 (74, 75) 75 (64, 87) NS 
FVC% 86 (63, 93) 96 (80, 101) 91 (85, 101) NS 
ICS dose% 1600 (1475, 
2000) 
1400 (1000, 
2400) 
1500 (1400, 
2000) 
NS 
Exacerbations 3.5 (1.7,4) 3 (2, 4.5) 3.5 (2.7, 4.7) NS 
Serum 
25[OH]D3  
23 (16.5, 35) 38 (15, 43) 31 (24, 44) NS 
IgE 400 (129, 
1389) 
458 (122, 
640) 
276 (44, 
2179) 
NS 
Blood 
eosinophils 
0.8 (0.2, 1.1) 0.8 (0.4, 1) 0.5 (0.07, 
1.6) 
NS 
Sputum 
eosinophils 
3 (2.5, 10) 3.6 (0.6, 8) 2.8 (0.8, 3) NS 
BAL 
eosinophils 
2.1 (0.7, 3.2) 3.5 (0.7, 6.4) 2 (0, 5) NS 
Analysis was performed using Kruskal-Wallis with correction for multiple groups. 
Data are number tested or Median (interquartile range) (IQR), FEV1 = forced 
expiratory volume in 1 second; FVC = forced vital capacity; BDR= Bronchodilator 
response; ACT= asthma control test; FeNO50 fractional exhaled nitric oxide at 50 
ml/sec; Exacerbations in last 6 months needing oral steroid 
% Beclomethasone equivalent; NS (non-significant) =P>0.05 
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CD8-depleted PBMC from complete responders (SS, n=6), partial responders 
(PR, n=7) and non-responders (SR, n=6) were cultured with polyclonal 
conventional T cell stimulation. (Figure 4.7) Stratification of in vitro responses 
in this manner revealed that PBMC from the complete responder (SS) group 
had higher IL-10 secretion as compared to the partial (PR) (p=0.03) or non-
responder group (p=0.01) (SR).  Dexamethasone induced IL-10 in all three 
groups, however it only achieved significance in the complete responder (SS) 
group (Figure 4.7A). The addition of vitamin D with dexamethasone also 
potentiated IL-10 secretion, however it only achieved significance in the 
complete responder (SS) group (Figure 4.7A). In contrast, PBMC from non-
responders (SR) had higher IL-17A secretion as compared to non-responders 
(SR) (p=0.008). There was non-significant trend in dexamethasone induced 
IL-17A secretion in complete responders (p=0.07) and IL-17A was not 
suppressed by dexamethasone in the partial responder (PR) (p=0.1) or non-
responder groups (SR) (p=0.3) (Figure 4.7B). IL-13 secretion was highest in 
non-responders (SR) as compared to partial (PR) or complete responder (SS) 
groups (p=0.03). Dexamethasone alone and in combination with vitamin D 
suppressed IL-13 secretion in the non-responder group (SR) but not in partial 
(PR) or complete responder (SS) group (Figure 4.7B).    
 
In summary on further stratification of children with STRA, PBMC from steroid 
non-responders (SR) produced the greatest amounts of both IL-13 and IL-17A 
in vitro, but whilst IL-13 could be suppressed by dexamethasone, IL-17A was 
not (Figure 4.7B&C). Children with a complete clinical response (SS) also 
demonstrated the best response in vitro in terms of IL-10 induction (Figure 
4.7A). IL-10 potentiation by vitamin D was highest in SS STRA, and apparent 
in SR and PR as well. The vitamin D did not profoundly alter IL-13 or IL-17A 
profiles in any subgroup (Figure 4.7B&C).  
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(A)        
 
(B) 
 
 
(C) 
 
*p<0.05, **p<0.01, ***p<0.001 
Figure 4.7 Effect of dexamethasone and 1α,25VitD3 on PBMC cytokine 
profiles of STRA asthmatics delineated by steroid-responsiveness.  
CD8 depleted PBMC from complete responder (SS, n=6), partial responders (PR, 
n=7) and non-responder (SR, n=6) STRA were cultured for 7 days with polyclonal 
conventional T cell stimulation (soluble anti-CD3 (1mcg/ml), IL-2 (50U/ml). 
Additionally they were treated with or without dexamethasone, 1α,25VitD3 or a 
combination of both (both at 10-7M).  At day 7, cells were re-stimulated for 48 hours 
with anti-CD3 and IL-2 alone and supernatants were harvested and analysed for 
expression of (a) IL-10, (b) IL-17A and (c) IL-13 by CBA.  
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CD8 depleted PBMC from SR children produced the greatest amounts of both IL-13 
(C) and IL-17A in vitro (B), but whilst IL-13 could be suppressed by dexamethasone 
(C), IL-17A could not (B). SS individuals demonstrated the best response in terms of 
IL-10 induction (A). IL-10 potentiation by 1α,25VitD3 was highest in SS STRA (A) 
and 1α,25VitD3 did not profoundly alter IL-13 (C) or IL-17A (B) profiles in any 
subgroup. 
Data are summarized as mean +/- SD. *p<0.05, **p<0.01, ***p<0.001 as assessed by 
Mann Whitney U test was used to compare differences. 
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Further stratification of IL-10 secretion according to all 4 individual responses 
(symptom, lung function, FeNO50 and sputum eosinophils) after intramuscular 
steroid (triamcinolone) is described next. PBMC of STRA children who had a 
positive (SS) and negative response (SR) to lung function (normalization or 
improvement of more than 15% in FEV1) (Figure 4.8A) showed induction of 
IL-10 secretion with dexamethasone alone and in combination with 
dexamethasone and 1α,25VitD3. A similar trend was noted with symptom 
response (normalisation or improvement by ≥ 50% in ACT) (Figure 4.8B), 
FeNO50 response (normalisation of FeNO50 <24ppb) (Figure 4.8C) and 
sputum eosinophil response (normalization of sputum eosinophil to <2.5%) 
(Figure 4.8D). This correlation between clinical steroid response and IL-10 
secretion revealed no significant difference between the two groups, however 
a trend towards higher secretion in non-responders (SR) as compared to 
responders (SS) was apparent with symptoms and inflammatory response 
(Figure 4.8). However, as stated above, the numbers are small and the results 
must be considered preliminary. 
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*p<0.05, **p<0.01, ***p<0.001 
Figure 4.8 Similar PBMC IL-10 secretion following dexamethasone and 
1α,25VitD3 from SR and SS STRA.  
Steroid responsiveness was assessed after a trial of intra-muscular triamcinolone 
injection in four ways, (A) Lung function response (normalisation or improvement of 
≥15% in FEV1) - responder (SS, n=7), and non-responder (SR, n=12) STRA (B) 
Symptom response (normalisation or improvement by ≥ 50% in ACT) - responder 
(SS, n=7), and non-responder (SR, n=12) STRA (C) FeNO50 response (normalisation 
of FeNO50 <24ppb) - responder (SS, n=10), and non-responder (SR, n=9) STRA (D) 
Sputum eosinophil response (normalisation of sputum eosinophil % <2.5%) - 
responder (SS, n=14), and non-responder (SR, n=5) STRA. Data are summarized as 
mean +/- SD.   
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4.3.6 Relationship between serum vitamin D levels and steroid 
responsiveness 
The relationship between serum vitamin D levels and markers of asthma 
severity are described in chapter 3.  This section compares serum vitamin D 
levels in children with STRA to individual clinical response following 
intramuscular steroid trial. Serum 25[OH]D3 levels were significantly lower in 
SR as compared to SS children when steroid responsiveness was assessed 
using symptom response (Figure 4.9b). However, no difference was noted 
when steroid responsiveness was assessed using lung function response, 
FeNO50 response or sputum eosinophil response (Figure 4.9a,c,d)  
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*p<0.05 
Figure 4.9 Relationship between serum vitamin D (25(OH)D3) and steroid 
responsiveness in children with STRA stratification  
Serum vitamin D levels were higher in responder (SS) STRA as compared to non-
responder (SR) STRA, when steroid responsiveness was assessed with symptom 
response (normalisation or improvement by ≥ 50% in ACT) after a trial of intra-
muscular corticosteroid (triamcinolone) injection (b).  No difference in serum vitamin 
D levels in SR and SS STRA, when steroid responsiveness was assessed with (a) 
Lung function response (normalisation or improvement of ≥15% in FEV1) (c) 
FeNO50 response (normalisation of FeNO50 <24ppb) (d) Sputum eosinophil response 
(normalisation of sputum eosinophil % <2.5%) Data are summarised as median +/- 
interquartile range. A Mann Whitney U test was used to compare differences between 
groups 
 
 
This section compares serum vitamin D levels in children with STRA, to 
combined (all three domains – symptoms, lung function and inflammation) 
clinical response following intramuscular steroid injection. In this thesis, non-
response (SR) was classified as no improvement in any of three domains; 
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partial response (partial responders, PR) was improvement in one or two 
domains; and complete response (SS) was normalisation in all three domains 
(see chapter 1, section 1.2.1)134 There was a non-significant trend towards 
lower serum vitamin D levels in non-responders, median 23 nmol/L (16.5, 35) 
as compared to complete responders, median 31 nmol/L (24, 44) (p=0.4) 
(Figure 4.10 ). 
 
"
Figure 4.10 Serum vitamin D levels and response to a steroid trial in 
children with STRA.  
No significant differences in serum vitamin D levels between the three groups. 
However, a trend, towards lower serum vitamin D levels in non-responder (SR) as 
compared to responder (SR) and partial responder (PR), when steroid responsiveness 
was assessed in children with STRA using three domains: lung function response 
(normalisation or improvement of ≥15% in FEV1), symptom response (normalisation 
or improvement by ≥ 50% in ACT) and inflammatory response (if paired sputum 
available - normalisation of sputum eosinophil % <2.5% or if paired sputum not 
available normalisation of FeNO50 <24ppb). Data are summarised as median +/- 
interquartile range. A Mann Whitney U test was used to compare differences between 
groups 
 ""
4.4 Discussion  
4.4.1 Principle findings 
The main findings are summarised in Text box 4.1.  
 
SS PR SR
0
10
20
30
40
50
Se
ru
m
 2
5[
O
H
]D
3  
le
ve
ls
 in
 n
m
ol
/L
155" "
Text box 4.1 Main findings in children with STRA 
• Serum cytokines were largely undetectable and no correlation between serum 
vitamin D levels and serum cytokines in those with detectable cytokines. 
• IL-10 induction occurred in a dose-dependent manner across the range of 
dexamethasone doses studied (10-7M to 10-9M). IL-10 secretion was 
significantly lower in MA and STRA as compared to non-asthmatic control 
subjects in CD8 depleted PBMC cell cultures. There was no clear difference 
between children with MA and STRA in IL-10 secretion.  
• Dexamethasone significantly reduced IL-13 secretion by PBMC from children 
with STRA, which was elevated compared to the other groups studied. 
However, PBMC IL-17A secretion, which was also the highest in STRA was 
not suppressed by dexamethasone treatment, but was in fact significantly 
further enhanced. 
• 1α,25VitD3 alone (without dexamethasone) did not significantly alter PBMC 
secretion of IL-10, IL-13 or IL-17A in any group studied. Vitamin D treatment 
showed a non-significant trend for inhibition of IL-17A in the controls 
(p=0.06) and MA (p=0.08) but not in the STRA (p=0.7)   
• In both asthmatic and control individuals, the addition of 1α,25VitD3 to 
dexamethasone potentiated IL-10 secretion, although notably this still 
remained lower in the MA and STRA patients as compared to controls. 
1α,25VitD3 did not however further enhance steroid-induced IL-17A 
expression in STRA.  
• On further stratification of children with STRA, PBMC from non-responder 
group (SR) produced the greatest amounts of both IL-13 and IL-17A in vitro, 
but whilst IL-13 could be suppressed by dexamethasone, IL-17A could not. 
Children with complete response (SS) demonstrated the best response in terms 
of IL-10 induction.. 
• Serum 25[OH]D3 levels were significantly lower in non-responder group (SR) 
children with STRA than those with complete response (SS), when steroid 
responsiveness was assessed using symptom response, but not in any other 
domain.  
The most striking peripheral immunological parameter noted was defective IL-
10 protein secretion in PBMC culture from asthmatics. Dexamethasone 
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significantly promoted IL-10 secretion from cultures of PBMCs in a dose 
dependent manner. Importantly, inclusion of vitamin D to these cultures 
enhanced IL-10 responses to dexamethasone. These findings support a 
potential role for IL-10 in regulating peripheral immune responses in children 
with STRA and build on independent data from both human studies and 
animal experimental models. There was a non-significant trend for increased 
IL-13 and IL-17A secretion from STRA PBMC cultures (Figure 4.4), although 
these responses were heterogeneous. Dexamethasone significantly reduced 
IL-13 secretion from children with STRA. Interestingly, IL-17A secretion was 
not suppressed by dexamethasone treatment but was further enhanced.  
 
Looking at the peripheral culture responses in the asthmatics, there was no 
significant difference between MA & STRA in IL-10, IL-13 or IL-17A secretion. 
There was a non-significant trend towards higher secretion of IL-17A and IL-
13 in STRA as compared to MA. There was no difference in dexamethasone 
induced IL-10 secretion alone or in combination with vitamin D between MA & 
STRA. Dexamethasone significantly reduced IL-13 secretion from children 
with STRA but not MA. On the other hand IL-17A secretion was enhanced by 
dexamethasone treatment in STRA but not in MA. There was no statistically 
significant difference in IL-17A synthesis in MA and STRA cultures with 
vitamin D treatment alone but a trend towards inhibition of IL-17A in MA but 
not in STRA was seen. The STRA children were then further delineated 
according to clinical steroid responsiveness, as assessed by their response to 
intramuscular triamcinolone. Although, there are very small numbers in each 
group, an interesting trend was noted while for the first time comparing clinical 
findings with in vitro work.  PBMC from complete responders produced the 
greatest amounts of IL-10 in vitro. Dexamethasone induced IL-10 secretion 
from PBMC from non-responders was less than from complete responders. 
PBMC from non-responders produced the greatest amounts of both IL-13 and 
IL-17A in vitro, but whilst IL-13 could be suppressed by dexamethasone, IL-
17A could not. Inclusion of vitamin D in peripheral culture significantly 
enhanced IL-10 responses to dexamethasone. IL-10 potentiation by vitamin D 
treatment was highest in complete responders but apparent in non-responder 
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(SR) and PR as well. However, vitamin D treatment did not profoundly alter 
IL-13 or IL-17A profiles in any subgroup.  
 
4.4.2 Strengths and weaknesses 
This is the first in vitro study to assess peripheral IL-10 secretion and 
responses to vitamin D in children with STRA and compare the findings with 
clinical steroid responsiveness. The strength of the present study is that it 
assesses a clearly defined and characterized population of children with 
STRA. The requirement to withdraw only small volumes (1ml/kg) of peripheral 
blood, after the samples for clinical purposes had been taken, precluded 
thorough functional and mechanistic experiments. For example in vitro 
detailed dose response curves, confirmation of the cellular source of IL-10 
and the regulatory activity of IL-10-secreting cells, which although reported in 
adult studies,377, 383 would be of interest in this paediatric cohort. Correlation of 
serum vitamin D levels with peripheral blood CD4+ IL-10 and Treg FoxP3 
cells by flow cytometry is also desirable. In addition, more patients are needed 
to delineate any associations between clinical steroid responsiveness and the 
in vitro IL-10 studies. In general, since many comparisons have been made, 
those in particular of borderline significance must be considered preliminary 
and hypothesis-generating, rather than definitive. 
 
4.4.3 Strengths and weaknesses in relation to other studies 
Lim et al 379 investigated whether the difference in IL-10 production between 
asthmatic and healthy controls was due to a difference in the distribution of 
the IL-10 producing haplotypes (GCC and ATA). The GCC haplotype has 
been associated with higher and the ATA halotype with lower IL-10 production 
in PBMC. They used sequence-specific oligonucleotide probing to screen for 
the haplotypes in 241 controls, 82 adults with mild asthma, and 113 adults 
with severe asthma. The distribution of haplotypes in those with mild 
asthmatics and controls did not differ. But, fewer severe asthmatic had the 
high IL10-producing haplotype (GCC) and more had the putative low IL-10 
producing haplotype (ATA), suggesting the low IL10-producing haplotype is 
more likely to be associated with severe asthma in adults.379 IL-10 producing 
haplotypes were not assessed in this chapter but reduced peripheral IL-10 
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expression noted in asthmatics as compared to controls, was consistent with 
the adult study.379  
 
Both corticosteroids and vitamin D have been proposed as therapeutic 
candidates to drive IL-10 induction in asthma,92 however in adult asthma, 
patients who fail to demonstrate a clinical response to steroid treatment also 
demonstrate an impaired IL-10 response to dexamethasone in vitro.162 In the 
present chapter, it has been shown that dexamethasone induces IL-10 
secretion in PBMC cultures from paediatric asthmatics and controls. However, 
this is significantly reduced in STRA and MA compared to non-asthmatic 
controls. Interestingly, significant dexamethasone-induced IL-10 secretion 
was observed in our children with STRA, which is in contrast to steroid-
refractory adults where no significant induction was observed. 
Dexamethasone-induced IL-10 in CD8 depleted PBMC from non-responder 
STRA children was less than that from complete responder STRA children. 
This was similar to the observations made in steroid-refractory adult 
asthmatics. It was not possible to perform a direct comparison between this 
paediatric study and adult study163"for various reasons including differences in 
study populations, no standard for comparison between assay, different timing 
and culture conditions. However, despite these differences, the fact that many 
results were similar strengthens the likely significance of the findings. 
 
In adult asthmatics it has been demonstrated that in vitro addition of 
1α,25VitD3 restored T cell IL-10 responses to dexamethasone in culture.163 
Also, oral treatment with the active form of vitamin D (0.5 mcg of calcitriol 
daily for 7 days) restored IL-10 responses to dexamethasone.163 Similarly, in 
this chapter non-asthmatic control children and in MA and STRA, inclusion of 
vitamin D in culture significantly enhanced IL-10 responses to 
dexamethasone. However in contrast to the adult studies, IL-10 production 
achieved with vitamin D from the asthmatics in this cohort remains less than 
that seen in cultures of cells from non-asthmatic controls and the reason for 
this difference is currently unclear. Other factors (e.g. genetic) for defective IL-
10 may potentially contribute in children, or perhaps duration, route or dose of 
159" "
vitamin D exposure (in vivo versus in vitro) may be important. However, 
definitive data from interventional studies is needed to confirm the benefit of 
supplementation with vitamin D, alone or together with inhaled corticosteroids, 
as a therapeutic approach to augment IL-10 in paediatric asthma.  
 
Vitamin D alone did not drive significant IL-10 secretion from CD8 depleted 
PBMC cultures in the present study, however, in adult CD4+ T cell cultures 
vitamin D increased IL-10 secretion.163 This observation made in steroid-
refractory adult asthmatics has not been extended into our well-characterised 
children with STRA. However, the sub-optimal response may be secondary to 
a sub-optimal dose of vitamin D in children, it could be postulated that children 
are less sensitive but the plateau being the same (right shift of the dose-
response curve). Importantly, several differences in culture conditions and 
systems may have accounted for this difference.  
 
Conversely, IL-17A secretion in STRA peripheral cultures could not be 
suppressed by dexamethasone treatment in vitro but in fact was significantly 
enhanced. This effect was not observed in MA and non-asthmatic controls.  
This is interesting given the successful use of steroids to control a large 
proportion of steroid-responsive asthmatic disease and it could be postulated 
that IL-17A is protective in children with STRA but further studies are needed 
to clarify this. Moreover, it does confirm, for the first time in humans, findings 
from an earlier study in a mouse model of asthma, where disease induced by 
adoptively transferred Th17 cells could not be abrogated by dexamethasone 
treatment, despite a clear benefit in a parallel Th2-adoptive transfer system. 
389 It may also provide some insight into observations made in adults that “Th2 
low” asthma does not respond to high doses of steroid treatment, though 
importantly Th17 activity was not described in this instance.40 The implication 
of these data is that in addition to a defective anti-inflammatory IL-10 
response, the clinical picture characterised as steroid-resistant asthma may 
actually reflect an aberrant inflammatory IL-17A response to escalating doses 
of inhaled steroids in these patients. This is, in part, supported by data from 
adult asthmatics indicating that inhaled steroid dose correlates with IL-17A 
production by PBMC in vitro.35 However, it could be postulated that children 
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with bad asthma will be on high doses of steroids to control the disease and 
bad asthma leads to more IL-17A as an attempted compensatory mechanism. 
The exact role of IL-17A in paediatric asthma is yet to be fully defined, with 
data arising from murine models indicating that IL-17A from gamma-delta T 
cells is protective in the resolution of acute airway inflammation.67 Importantly, 
the CD8-depleted PBMC cell culture employed here does contain gamma-
delta T cells, and they cannot be ruled out as a source of steroid-induced IL-
17A. There are thus two totally opposite hypotheses about the role of IL-17A, 
and from this work it remains difficult to elucidate whether IL-17A was 
detrimental to disease or had a protective role. Thus the role of IL-17A in the 
human airway requires further investigation. Notably, inclusion of vitamin D in 
dexamethasone-treated PBMC cultures did not further modulate IL-17A or IL-
13 expression, whilst it did augment IL-10 expression. Vitamin D treatment 
alone without dexamethasone did not significantly alter PBMC secretion of IL-
17A in any group studied. However, vitamin D treatment showed a trend 
towards inhibition of IL-17A in the controls (p=0.06) and MA (p=0.08) but not 
in STRA (p=0.7). Previously published data show that vitamin D potently 
inhibits Th17 cells and IL-17A production. Earlier data form our laboratory 
(Nanzer et al35 and unpublished data) demonstrate that dexamethasone 
induces IL-17A synthesis by the CD4+ T cell compartment and that this 
response is inhibited by vitamin D. It would therefore be important to establish 
whether the steroid induced IL-17A seen in the paediatric studies derives from 
the CD4 T cells, or some other cellular source e.g. gamma-delta T cells, 
neutrophils or other cells that might potentially be less sensitive to vitamin D 
mediated inhibition.  
 
4.4.4 Meaning of the results 
Having established reduced anti-inflammatory IL-10 protein synthesis by 
peripheral immune cells from children with STRA, and importantly that vitamin 
D potentiates steroid-induced IL-10 secretion, it is logical to suggest vitamin D 
plays an important role in children with STRA by improving the efficacy of 
inhaled and oral steroid therapy. The lack of functional and mechanistic 
experiments limits the ability to propose a unifying hypothesis, nevertheless, 
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supports for the need for interventional studies in this important patient cohort 
on high dose steroid therapy.  
 
4.4.5 Summary 
In summary, paediatric asthma is characterized immunologically by defective 
IL-10 protein expression by peripheral immune cells, amongst other 
abnormalities. Whilst dexamethasone does induce IL-10 expression by 
peripheral immune cells in vitro, this is impaired in STRA, where it also 
significantly augments IL-17A secretion. Inclusion of vitamin D in culture 
enhances dexamethasone-induced IL-10, but not IL-17A and may therefore 
improve steroid efficacy or allow for reduced steroid doses.  
 
Reverting back to the original hypothesis, the work of this chapter has proven 
that in vitro peripheral blood CD8-depleted PBMCs, from children with STRA 
exhibited a reduction in glucocorticoid-induced IL-10 synthesis in cell culture, 
and this is restored by vitamin D.  
 
This chapter reports immunological data on PBMCs, and the relationship with 
vitamin D, the clinical significance of which is difficult to assess. The next 
chapter describes the relationship of airway (BAL) cells to the vitamin D axis, 
thus bringing the immunological work closer to the target organ of interest, 
namely the airway. 
 
 
.
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Chapter 5  The effects of vitamin D on IL-10 secretion from BAL cells 
 
5.1 Introduction 
In the previous chapter, the cytokine response of PBMC cultures from STRA, 
MA and non-asthmatic controls to glucocorticoids and vitamin D was 
described. The most striking findings were significantly reduced IL-10 by 
peripheral blood cells from asthmatics, and their regulation by 
dexamethasone and vitamin D and in this chapter these observations are 
further investigated using cells derived from the target organ (BAL). In this 
chapter, the relationship between serum vitamin D levels and BAL cells is also 
described. Some of the findings have been reported in the European Journal 
of Immunology273 and others resubmitted to Thorax after revision. 
 
Two important mechanisms for maintenance of peripheral tolerance are the 
anti-inflammatory cytokine IL-10 and regulatory T cells, one prominent 
population being CD4+Foxp3+ Treg.68, 179 The role of IL-10 in maintaining 
immune tolerance in the airways is supported by animal studies.68, 92, 390 In 
models of allergic airways disease a reduced cellular infiltration and 
inflammation (protective effect) is noted after direct IL-10 instillation into the 
airways, or airway-targeted IL-10 gene transfer.391, 392 Specifically, IL-10 dose-
dependently inhibited both neutrophilia and eosinophilia in the BAL fluid and 
in the histologic evaluation of the lung tissue corroborated the findings in the 
BAL.   
 
Studies in adult patients have shown that IL-10 mRNA and protein in the BAL 
and alveolar macrophages of mild asthmatics (n=12) is reduced when 
compared with healthy controls.393 Also, there is an inverse association 
between BAL IL-10 levels and the incidence and GCC and ATA haplotypes 
associated with low IL-10 production and severity of asthma in adults.378, 379 
Importantly, adult peripheral blood culture studies have shown that vitamin D 
restored the defect in steroid-induced IL-10 synthesis in steroid resistant 
asthmatics.163 However, so far all data is from peripheral blood and very little 
is known about the in vitro response of BAL cells to vitamin D and 
corticosteroids in children with STRA.  
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To assess in vitro responses of BAL cells to glucocorticoid and vitamin D in 
culture  
 
Some of the findings have been reported in the European Journal of 
Immunology 273 and Thorax. 385 
 
  
5.2 Methods 
5.2.1 Subjects  
Children aged 5-16 years with STRA (n=16), MA (n=5) and non-asthmatic 
controls (n=10) were recruited prospectively from the Royal Brompton 
Hospital, London. Non-asthmatic controls (n=10) comprised either children 
with no lower airway disease whose parents had consented for a flexible 
bronchoscopy, BAL and blood test during an elective surgical procedure 
(cardiac catheterization n=2, persistent ductus arteriosus repair n=1, 
electrophysiology study n=1) or children undergoing a clinically indicated 
bronchoscopy for upper airway symptoms (recurrent episodes of shortness of 
breath n=1, barking cough n=2, croup/stridor n=2, haemoptysis n=1) at RBH. 
The indications for flexible bronchoscopy in non-asthmatic controls are 
described in table 5.1. 
  
5.1.1 Hypothesis 
In this chapter the hypothesis tested is that BAL cells from children with STRA 
exhibit a reduction in glucocorticoid-induced IL-10 synthesis in cell culture, 
and this is restored by vitamin D.  
 
5.1.2 Aims 
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 Table 5.1 Clinical Indications of flexible bronchoscopy in non-asthmatic 
controls 
S.No Sex Atopic 
status 
Indication Findings at 
Fibreoptic 
bronchoscopy 
1 Male Nonatopic  Cardiac 
catheterization 
Normal 
2 Male Atopic Recurrent 
episodes of 
shortness of 
breath 
Laryngomalacia, 
tracheomalacia 
3 Female Nonatopic Persistent ductus 
arteriosus repair 
Normal 
4 Male Nonatopic Cardiac 
catheterization 
Normal 
5 Female Nonatopic Electrophysiology 
study/change of 
pacemaker 
Normal 
6 Male Atopic Recurrent croup 
and barking 
cough 
Tracheomalacia 
7 Female Nonatopic Hemoptysis No cause found, 
normal 
8 Male Nonatopic Noisy breathing Pharyngomalacia,  
9 Female Atopic Stidor Enlarged tonsils 
and adenoids 
10 Male Nonatopic Recurrent croup No cause found, 
normal 
 
 
 
5.2.2 Isolation of cells from BAL fluid  
BAL was performed as described in Methods (Chapter 2 Section 3), and 
whole BAL fluid was transferred immediately (<1hr) to the laboratory. BAL 
fluid was filtered using a 100µm pore nylon mesh filter, held at a 45-degree 
angle over a 75mm petri dish (such that an edge of the strainer was touching 
the petri dish). The resultant filtered BAL fluid was run to the bottom of the 
mesh filter and into the Petri dish. The mesh filter was discarded and filtered 
BAL fluid was transferred into a 15ml falcon tube and centrifuged at 200g for 
10 minutes at 4 0C. BAL supernatant was removed and stored at -800C.  Cell 
pellets were resuspended in 1ml FACS Flow containing 1% Mouse Serum to 
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recover total BAL cells. A 50ul of cell suspension was taken to count cells on 
a haemocytometer and cell concentration was adjusted to 1x106/ml. 
 
5.2.3 BAL cytology  
Quantification of inflammatory cells in BAL was performed by the 
histopathology department at the RBH as described in chapter 2 section 2.3.1 
 
5.2.4 BAL cell culture 
Isolated cells were counted using a haemocytometer with dead cells excluded 
by the use of Trypan blue (Sigma Aldrich, Dorset, UK) staining. BAL cells 
were then suspended at 1 x 106/ml in 10% FCS/RPMI and cultured in a 96 
well plate (250,000 cells per well). BAL cells were incubated at 37ºC/5%CO2 
and were either left unstimulated or were stimulated with lipopolysaccharide 
(LPS, 50ng/ml; R&D Systems) alone and in combination with 1 x10-7M 
dexamethasone (Sigma) and /or 1 x 10-7M 1 alpha,25-dihydroxyvitaminD3 
(Enzo Life Sciences, USA). On day 3, cell culture supernatant was frozen at -
80ºC and cell pellets were preserved by snap freezing in liquid nitrogen and 
stored in -80ºC for future analysis. 
 
5.2.5 Cytokine analysis by CBA  
Cytokines were analysed using the CBA kit (CBA, Human Inflammation kit, 
BD Biosciences, Pharmingen, San Diego) as described in Chapter 2 Section 
2.5. This is a flow cytometry based multiplex array application. 
 
5.2.6 FoxP3 intranuclear analysis by flow cytometry 
FoxP3 staining was performed with a PE conjugated FoxP3 antibody and the 
FoxP3 staining buffer set, (Ebiosciences, San Diego, USA) according to 
manufacturer’s instructions as described in chapter 2 section 2.6. Calculations 
were performed with Cell Quest software (Becton Dickinson). 
 
5.3 Results 
Demographic data of the children studied are presented in Table 5.2. "
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Table 5.2. Demographic characteristics of subjects✪ No significant 
differences between children with MA, STRA, and non-asthmatic controls in 
age and sex. Children with STRA had lower spirometry and ACT and more 
exacerbations and were prescribed higher dose of inhaled corticosteroids.    
 
 STRA(n=16) MA(n=5) Controls(n=10) p value 
Age (years) 12 (10-14) 11 (8-14) 9 (6.7-12) NSa 
Male  
 
9 (56%) 2 (40%) 6 (60%) NS£ 
%predicted FEV1  76 (58-89) 88 (78-102) 92 (88-95) <0.05a 
%predicted FVC  
 
89 (76-103) 98 (89-111) 96 (93-102) <0.05a 
Atopic+ (%) 13 (81%)  3 (60%) 2 (20%) <0.05£ 
IgE (IU/ml) 196 (67-587) 25 (8-1176) 14 (7.5-84) <0.05a  
ACT^ 11.5 (7.2-15)  18 (17-23) N/A <0.05& 
Daily ICS dose 
(microgram/day) 
1450 (1000- 
2000) 
500 (400-700) N/A <0.05& 
Exacerbations§  3 (2-4) 2 (0.5-2.5) N/A <0.05& 
BAL cytology 
Macrophages 
Lymphocytes 
Eosinophils 
Neutrophils 
  
84% (64-94) 
8.5%(3-14) 
3.5%(0-18) 
4%(0.5-16) 
 
88%(68-92) 
4%(1.8-8.2) 
1.5%(0.7-6) 
3.2%(2.2-16) 
 
90%(76-94) 
5.6%(2.5-12) 
1.2%(0-6.2) 
2.8%(1-12) 
NS 
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; ACT= 
asthma control test; ICS=inhaled corticosteroid  
✪ Values are given in Median (interquartile range) for continuous variables or as 
number (%) for binary variables.  
+One or more positive allergen-specific IgE responses 
^ Score out of 25 
% Beclomethasone equivalent  
§Median exacerbations in last six months requiring oral steroids 
 
aP value calculated by  Kruskal- Wallis test.  
£P value calculated by  Chi-square test. &"P"value"calculated"by""Mann"Whitney"test."
 
5.3.1 BAL fluid cytokines  
Levels of BAL IL-10 were significantly lower in both MA and STRA as 
compared with non-asthmatic controls (Figure 5.1A).  Other cytokines were 
also measured, including IL-17A, IL-13, IL-5, IL-6 and IL-8 (Figure 5.1). BAL 
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IL-1bL-1ls ofTNF-α and IFN-γ were undetectable in the majority of children 
(Table 5.2). BAL IL-17A levels were elevated in two asthmatics compared to 
controls, obviously this did not reach statistical significance (Figure 
5.1B).There was no statistically significant difference between the three 
groups studied in levels of IL-6 and IL-8 (Figure 5.1E&F). The Th2 cytokines 
IL-5 and IL-13 and IFN-γ were largely undetectable (Figure 5.1 C & D, and 
Table 5.3). Stratification of individuals into two groups according to the 
dichotomous BAL IL-17A distribution identified that those with higher BAL IL-
17A (>10pg/ml) demonstrated a non-significant trend for worse lung function 
(% predicted FEV1, 71% versus 79%, p=0.09) and use of higher doses of 
inhaled corticosteroids (ICS dose 1800 mcg/day versus 1300 mcg/day, 
p=0.09). 
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*p<0.05, ***p<0.001 
Figure 5.1. Reduced IL-10 concentrations in the bronchoalveolar lavage 
in STRA.  
There was no significant difference in other cytokines measured in the BAL fluid.  
 
BAL cytokine levels were measured directly ex vivo, with no further in vitro 
manipulation, in all of the three groups as delineated in Table 5.1. Cytokine levels 
were measured by high-sensitivity cytometric bead array (CBA); data are presented as 
individual results and the bar represents the median. A Mann Whitney U test was used 
to compare differences between groups. 
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Table 5.3 Undetectable cytokines in the BAL fluids. IL-1β, IL-9, TNF-α and 
IFN-γ were undetectable in all the three groups  
BAL 
cytokines 
(pg/ml) 
STRA  
(n=16) 
MA        
(n=5) 
Controls 
(n=10) 
 
IL-1β u (u-116) u (u-69) u (u-41) NS 
IL-9 u (u-71) u (u-88) u (u-75) NS 
TNF-α  u (u-18) u (u-15) u (u-30) NS 
IFN-γ u (u-19) u (u-17) u (u-10) NS 
BAL cytokine levels were measured directly ex vivo, with no further in vitro 
manipulation in all the three groups. Cytokine levels were measured by high-
sensitivity CBA; data are presented as median. A Mann Whitney U test was used to 
compare differences between groups. 
U-undetectable  
 
 
5.3.2 FoxP3 intranuclear staining   
Tregs are important in maintaining immune homeostasis in pulmonary health 
and may exhibit impaired function in asthma68, 80, 81 (discussed in chapter 1 
section 1.1.5). Having noted significantly low IL-10 protein levels in the BAL of 
children with STRA as compared to controls, the frequency of CD4+Foxp3+ 
cells in BAL cells was assessed next in this chapter. 
 
There was no difference in the frequency of CD4+FoxP3+ cells in the BAL of 
STRA (n=11) and non-asthmatic subjects (n=5) measured by Flow cytometry 
(Figure 5.2).  Flow cytometry density plots to demonstrate the gating strategy 
employed to analyse the frequency of CD4+FoxP3+ cells (Treg cells) in BAL 
are shown in Figure 5.2A. BAL lymphocytes were identified according to 
forward and side scatter and then cells were next gated on the basis of 
positive expression of CD3 and CD4 (R2).   
 
Unfortunately, because of very limited BAL volumes available for experiments, 
it was only possible to perform FoxP3 intranuclear staining in 11 children with 
STRA and 5 non-asthmatic controls. The difference in FoxP3 may have been 
significant if more subjects could have been included (Figure 5.2).  
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(A) 
 
(B) 
 
Figure 5.2 Frequency of regulatory T cells (CD4+FoxP3+ cells) in 
bronchoalveolar lavage (BAL) cells of STRA (n=11) and controls (n=5).  
(A) Flow cytometry density plots to demonstrate the gating strategy employed to 
analyse the frequency of Treg in BAL cells. BAL lymphocytes were identified 
according to forward and side scatter. Cells were next gated on the basis of positive 
expression of CD3 and CD4 (R2). Values represent the % of gated cells. Quadrant 
markers were set according to the isotype control, as shown. (B) There was no 
difference in the frequency of CD4+FoxP3+ cells in the BAL cells of STRA (n=11) 
and non-asthmatic controls (n=5). This may be the reflection of small numbers and/or 
the inevitable lack of true healthy controls. Because of very limited BAL volume 
available for experiments, it was not possible to perform FoxP3 intranuclear staining 
in all the subjects.   
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5.3.3 The effect of vitamin D and dexamethasone on BAL cell cultures  
In addition to studying peripheral immune cell responses (described in chapter 
4), the cytokine secretion profiles of airway-resident populations were 
addressed by culture of total BAL cells in children with STRA (n=9) and non-
asthmatic controls (n=4). This experiment was only possible in a small sub-
group of children with STRA and controls because of limited volume of BAL 
available. Median BAL cells in STRA comprised of a large proportion of 
alveolar macrophages (84%), lymphocytes (8.5%), neutrophils (4%) and 
eosinophils (3.5%) (Table 5.1).  
 
Whole BAL cells were suspended and either left unstimulated or were 
stimulated with LPS (50ng/ml) alone and in combination with 1 x10-7M 
dexamethasone and /or 1 x 10-7M 1 alpha,25-dihydroxyvitaminD3. They were 
incubated at 37ºC/5%CO2 for 72 hours. Cytokines analyzed by CBA from cell 
culture supernatant revealed IL-10 secretion from STRA BAL cells was 
significantly lower as compared to non-asthmatic controls (p<0.01, assessed 
by 2 way Repeated measures ANOVA,) (Figure 5.3A). There was a trend (p-
0.07) toward reduced IL-17A secretion with 1alpha, 25-dihydroxyvitamin D3 
alone (Figure 5.3B), and dexamethasone in combination with 1alpha, 25-
dihydroxyvitamin D3 increased IL-10 secretion, although not to a significant 
degree (p-0.09 in controls and p-0.1 in STRA)(Figure 5.3A). There was a 
trend towards reduced IL-13 secretion with dexamethasone alone (Figure 
5.3C) but not to a significant degree (p=0.1). In fact, IL-13 secretion was very 
low in both the groups. ""
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Figure 5.3 The effect of vitamin D and dexamethasone on cytokine 
secretion profiles of total BAL cell cultures, stimulated with LPS, from 
non-asthmatic controls (n=4) and STRA (n=9).  
BAL cell culture with lipopolysaccharide stimulation (LPS) (50ng/ml) revealed no 
statistically change in IL-10 secretion with vitamin D or dexamethasone treatment 
(A). However, IL-10 secretion from STRA BAL cells was significantly lower as 
compared to non-asthmatic controls (p<0.01, assessed by repeated measures 
ANOVA).  There was a non-significant trend in cultures containing dexamethasone in 
combination with 1alpha, 25-dihydroxyvitamin D3 towards increased IL-10 secretion, 
although not to a significant degree (p-0.09 in controls and p-0.1 in STRA). BAL cell 
culture revealed no statistically significant change in IL-17A (B) and IL-13 (C) 
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secretion. However, trend toward reduced IL-17A secretion with 1alpha, 25-
dihydroxyvitamin D3 alone in STRA (B), although not to a significant degree (p-
0.07). IL-13 secretion was very low in both control and STRA (C)  
 
BAL cells were cultured with LPS (50ng/ml) alone and in combination with 10-7M 
dexamethasone (D; 10-7 M) and/or 1alpha, 25-dihydroxyvitamin D3 for 72 hours. 
Supernatants were harvested and analysed for expression of IL-10, IL-13 and IL-17A 
by cytometric bead assay.   
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5.3.4 Serum vitamin D status correlates with BAL IL-10 and CD4+FoxP3 
cells. 
Having demonstrated that vitamin D enhances dexamethasone-induced IL-10 
secretion by paediatric PBMC in vitro (described in chapter 4), and that 
reduced levels of IL-10 were detected in the BAL of asthmatic (MA and STRA) 
as compared to non-asthmatic controls (Figure 5.1), the next investigation 
was to address whether a correlation existed between systemic (serum) 
vitamin D status and BAL IL-10 concentrations in vivo. There is evidence that 
serum vitamin D levels in both adults and children are frequently deficient or 
insufficient in moderate to severe asthma (chapter 1 section 1.4.6) and also I 
have shown that BAL IL-10 levels correlated with the clinical severity of 
asthma (Figure 5.1A).  
 
Serum vitamin D (25(OH)D3) was measured in samples taken at the time of 
bronchoscopy and compared with BAL fluid IL-10. When samples from all 
groups (STRA, MA and non-asthmatic controls) were combined, this revealed 
a significant correlation between BAL IL-10 and serum 25(OH)D3  status 
(Spearman r=0.60, p<0.001, Figure 5.4A). However, correlation analyses within 
each patient group are important to consider but were limited by low numbers of 
children in whom bronchoscopy was clinically indicated, and should not be over-
interpreted. However, they may indicate that in asthmatics the association 
between serum 25(OH)D3 levels and airway (BAL) IL-10 is more important than 
in non-asthmatic controls (controls, n=10, Spearman r=0.17, p=0.63; MA n=5 
Spearman r=0.90, p=0.08; STRA Spearman r=0.41, p=0.12) (Figure 5.4B). There 
was no association between serum 25(OH)D3 levels and BAL IL-13 (Spearman 
r=-0.18, p = 0.30) or IL-17A (Spearman r=0.28, p=0.24), which supports the 
earlier in vitro peripheral culture observations (Figure 4.4).  
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(A) 
 
(B) 
 
Figure 5.4 Relationship between BAL IL-10 levels and serum vitamin D 
levels.  
BAL fluid IL-10 directly correlates with serum vitamin D status when samples from 
all three groups were combined (Spearman r=0.63, p<0.001) (B) However, this in not 
significant when each individual group is correlated. (STRA Spearman r=0.41, p=0.12; 
MA n=5 Spearman r=0.90, p=0.08; controls, n=10, Spearman r=0.17 p=0.63) 
 
Cytokine levels in BAL fluid were measured by CBA directly ex vivo, with no further 
in vitro manipulation in paediatric non-asthmatic controls (n=10), MA (n=5) and 
STRA (n=16). These levels were correlated with matched serum 25(OH)D3 
concentration. A Spearman rank test was used to assess correlation.  
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Having demonstrated that serum vitamin D levels are positively associated 
with BAL IL-10 levels (figure 5.4) and vitamin D in vitro enhances steroid-
induced IL-10 expression by CD8 depleted PBMC cells (chapter 4) in culture, 
I next determined whether serum vitamin D status influences Foxp3 
expression in whole BAL cells. A statistically significant correlation between 
serum vitamin D status, and the frequency of CD4+Foxp3+ T cells in the BAL 
was observed (r=0.7, p = 0.01), suggesting an association between vitamin D 
levels with Foxp3+ Treg (Figure 5.5). 
 
 
 
Figure 5.5 Relationship between BAL CD4+ FoxP3+ cells and serum 
vitamin D levels.  
Positive correlation between serum 25-hydroxyvitamin D3 levels and the percentage 
of CD4+ FoxP3+ cells in BAL of pediatric asthma patients.   
 
BAL Treg (% of CD4+ cells expressing FoxP3) expression was determined by flow 
cytometry (as shown in Figure 5.2) in the STRA children. Serum was collected from 
the same patients and the concentration of the circulating form of vitamin D3, 25-
hydroxyvitamin D3, was determined.  
p<0.05 as determined by the Spearman rank correlation test. 
177" "
 
5.3.5 Relationship between airway inflammation and BAL IL-10 in 
children with STRA.   
Having demonstrated reduced IL-10 concentration in BAL supernatant and 
cell cultures in the children with STRA as compared to the controls and also 
positive associations between serum vitamin D levels and BAL IL-10 protein 
levels and CD4+Foxp3+ T cells, correlation between BAL IL-10 levels, LPS 
induced IL-10 secretion and dexamethasone induced IL-10 secretion and 
airway inflammation was examined next.    
 
Airway inflammation was assessed in sputum and BAL (lumen compartment) 
and submucosa (airway wall) (described in chapter 2) and correlated with BAL 
supernatant IL-10 concentration measured directly ex vivo, with no further in 
vitro manipulation and LPS induced IL-10 secretion and dexamethasone 
induced IL-10 secretion in the BAL cultures. As discussed earlier, because of 
limited volume of BAL available, it was only possible to do BAL cell culture in 
a small sub-group of children with STRA (n=9).  
 
 In children with STRA, no association was noted between inflammatory cells 
quantified (eosinophils or neutrophils cells) and IL-10 secretion (basal or 
dexamethasone induced) (Table 5.4). This remained true for both luminal 
inflammation (sputum and BAL) and tissue inflammation (EB). However, this 
may be related to small sample size (n=9) and also any possible confounding 
effects of steroid therapy on any relationship.  " "
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Table 5.4 No association between airway inflammation and BAL IL-10, 
dexamethasone induced IL-10 secretion in BAL cell culture and % BAL 
CD4+FoxP3 cells in children with STRA.  
 BAL IL-10 LPS induced IL-
10 secretion in 
BAL cell culture   
Dexamethasone 
(1x10-7M) 
induced IL-10 
secretion in BAL 
cell culture 
Airway 
inflammation 
r p r p r 
 
p 
% Sputum 
eosinophil  
0.42 
 
0.6 -0.13 0.4 0.57 0.4 
% Sputum 
neutrophil 
0.74 
 
0.7 -0.36 0.25 0.10 0.64 
% BAL     
eosinophil  
0.18 
 
0.5 -0.31 0.7 0.64 0.3 
% BAL  
neutrophil 
0.32 
 
0.4 -0.18 0.35 0.45 0.34 
Submucosal 
eosinophils (/mm2) 
0.25 0.2 -0.30 0.56 0.2 0.21 
Submucosal 
neutrophils (/mm2) 
0.10 0.4 -0.42 0.35 0.18 0.14 
BAL, bronchoalveolar lavage; IL, interleukin;  
Analysis performed using Spearman correlations. 
 
5.4 Discussion  
5.4.1 Principle findings 
The main findings are summarised in Text box 5.1.The aim of this chapter 
was to investigate cytokine expression profiles in the BAL of children with 
STRA.  The most striking immunological observation was of reduced IL-10 
protein expression in the BAL of children with STRA in comparison to non-
asthmatic controls. Furthermore, the levels of this anti-inflammatory cytokine, 
but not with the other cytokines measured in BAL showed a positive 
correlation with serum vitamin D levels. Moreover, in vitro IL-10 secretion by 
total BAL cells cultured with LPS was significantly lower in STRA as 
compared to non-asthmatic controls (p<0.001) These findings suggest a 
central role for IL-10 in regulating airway immune responses, and provide 
additional support for  
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Text box 5.1 Main findings in airway studies in children with STRA 
• Levels of BAL IL-10 protein were significantly lower in both MA and STRA 
as compared with non-asthmatic controls. There was no statistically significant 
difference between the three groups studied in levels of other cytokines measured. A 
preliminary observation which requires further study was that BAL IL-17A levels 
were elevated in some asthmatics compared to controls and had a clear dichotomous 
distribution.     
• There was no difference in the frequency of CD4+FoxP3+ cells in the BAL of 
STRA (n=11) versus non-asthmatic subjects (n=5) measured by Flow cytometry  
• IL-10 secretion from STRA BAL cells in culture was significantly lower as 
compared to non-asthmatic controls (p<0.01). There was a trend towards reduced IL-
13 secretion with dexamethasone treatment alone (Figure 5.3C) but not to a 
significant degree. There was also a trend (p-0.07) toward reduced IL-17A secretion 
with vitamin D treatment.  
• There was a significant positive correlation between systemic (serum) vitamin 
D and BAL IL-10 status but not with BAL IL-13 and IL-17A 
• There was a positive correlation between serum 25-hydroxyvitamin D3 levels 
and the percentage of CD4+ FoxP3+ cells in BAL of paediatric STRA patients.   
• In children with STRA, no association was noted between inflammatory cells 
quantified (eosinophils or neutrophils cells) and IL-10 secretion (basal or 
dexamethasone induced) (Table 5.3).  
 
 
interventional studies. The other important mechanism for maintenance of 
peripheral tolerance is Tregs and in this chapter circulating levels of serum 
vitamin D directly correlated with CD4+FoxP3+ cells in airway lavage. 
 
5.4.2 Strengths and weaknesses 
This is the first study to assess the relationship between BAL cells and serum 
vitamin D in children with STRA. The availability of a limited amount of BAL 
fluid, after the samples for clinical purposes had been taken, precluded 
thorough functional and mechanistic experiments, for example in vitro 
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confirmation of the regulatory activity of IL-10-secreting cells and source of IL-
10 in BAL. More patients are needed to delineate any associations between 
the groups. Additionally the recruitment of controls and MA for 
bronchoscopies is difficult.  All bronchoscopies performed on children at our 
centre are performed under general anaesthesia; it is therefore unethical for 
children to have these performed solely for research purposes.  Children 
having clinically indicated bronchoscopies have respiratory conditions and 
therefore very rarely are completely healthy controls, albeit they are non-
asthmatic. 
 
IL-10 is an important immunomodulatory cytokine and the augmentation or 
restoration of levels in the asthmatic airway may have important therapeutic 
potential. Interestingly, in children with STRA we did not find an association 
between inflammatory cells quantified (eosinophils or neutrophils cells) and 
IL-10 secretion (basal or dexamethasone induced). This may be related to 
small n numbers or effects of steroid treatment of the children perturbing the 
relationship. Also, it was not possible to elucidate an effect of ICS treatment 
on the positive correlation between serum vitamin D and BAL IL-10 and 
CD4+FoxP3 cells noted in this chapter.  
 
5.4.3 Strengths and weaknesses in relation to other studies 
Defective IL-10 expression in asthmatics (MA and STRA) is consistent with 
the defective IL-10 expression observed in adult asthma.162, 163, 379, 394 A 
substantial reduction in IL-10 mRNA and protein was reported in the BAL of 
adult patients with asthma as compared to control healthy subjects.393 IL-10 
gene promoter polymorphisms resulting in reduced IL-10 expression are 
associated with more severe disease in adult asthmatics.379 Airway (sputum) 
IL-10 levels were reduced in mild-moderate adult asthmatics as compared to 
controls.394 Mild asthmatics were not included in our study but children with 
moderate asthma had lower BAL IL-10 as compared to the non-asthmatic 
controls. Sputum cytokines were not quantified in this study but looking at the 
BAL, similar results were noted.   
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Both corticosteroids and vitamin D have been proposed as therapeutic 
candidates to drive IL-10 induction in asthma,92 however in adult asthma, 
patients who fail to demonstrate a clinical response to steroid treatment also 
demonstrate an impaired peripheral IL-10 response to dexamethasone in 
vitro.162 Whilst dexamethasone and vitamin D did not drive significant IL-10 
expression by total BAL cells in the present study, as a group children with 
STRA had significantly lower IL-10 secretion compared to the controls. Small 
numbers, different cell type (BAL had predominant macrophages), or perhaps 
duration or route or dose of vitamin D and steroid exposure may be important 
and further studies are required to address these issues.  
 
Here it has been clearly demonstrated that serum vitamin D directly correlates 
with IL-10 levels in BAL and this may be evidence that in vivo vitamin D acts 
as a cofactor for IL-10 expression. It would have been interesting to correlate 
BAL IL-10 levels with BAL vitamin D levels. However, reliable and readily 
accessible assays for the measurement of vitamin D levels in the BAL are not 
yet available and I was therefore unable to assess this (discussed further in 
chapter 7 section 7.4). However, definitive data from interventional studies is 
needed to confirm the benefit of supplementation or treatment with vitamin D, 
alone or together with corticosteroids, as a therapeutic approach to augment 
airway IL-10 in paediatric asthma.  
 
The Th2-associated cytokines in the BAL, for example IL-5 and IL-13 were 
largely undetectable.  Although not in agreement with early findings in adult 
asthmatics this is consistent with observations made in similarly-characterised 
paediatric asthmatics, where Th2 cytokines were not prevalent and could only 
be detected in a small subgroup of individuals,44, 119 and is in agreement with 
more recent findings in adults that some asthma is not characterised by Th2 
activity.39, 40 
 
The exact role of IL-17A in asthma is also yet to be fully defined and from this 
chapter it was difficult to elucidate whether IL-17A caused disease or had a 
protective role in children with STRA. The implication of these data is that in 
addition to a defective anti-inflammatory IL-10 response, the clinical picture 
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characterised as steroid-resistant asthma may indeed actually reflect an 
aberrant inflammatory IL-17A response to escalating doses of inhaled steroids 
in these patients.  This is, in part, supported by the observation made here 
that those with higher BAL IL-17A levels (>10pg/ml) tended to be receiving 
higher doses of inhaled corticosteroids – though this did not achieve 
significance given the sample size (p=0.09), and is additionally supported by 
data from adult asthmatics indicating that inhaled steroid dose correlates with 
IL-17A production by PBMC in vitro.35 However, as discussed in chapter 4, 
section 4.4.3) IL-17A could have a protective role and that children are 
prescribed high doses of steroids if they have severe disease and severe 
asthma could lead to more IL-17A as an attempted compensatory 
mechanism. A protective role of IL-17A is supported by data from murine 
models. It is important to emphasize that results of this study are hypothesis 
generating and need to be tested further in children with STRA.  
 
An independent study in BAL and peripheral blood in children demonstrated 
reduced Foxp3 mRNA in the BAL cells (but not peripheral blood) in the 
moderate to severe asthmatic subjects in comparison to children with cough 
but not asthma.79 It also demonstrated that in the asthmatic children BAL, but 
not blood, CD4+ CD25high T cells were decreased in number; however, this 
was restored following inhalation of corticosteroids.79 In this study, there was 
no difference in BAL CD4+FoxP3 cells between STRA and non-asthmatic 
controls. However, a number of differences exist between these two studies 
that may account for this, including sample size, the patient cohorts studied, 
and the antigenic markers used to define Treg.  
 
5.4.4 Meaning of the results 
Having established reduced anti-inflammatory IL-10 protein in children with 
STRA by peripheral immune cells (discussed in chapter 4) and BAL IL-10 
levels and importantly, a link between serum vitamin D levels and BAL IL-10 
and Treg cells (FoxP3), it is logical to suggest vitamin D plays a critical role in 
children with STRA and may improve steroid efficacy. However, it was not 
possible to confirm if IL-10 and Tregs are both associated cofactors 
modulated by vitamin D and the lack of functional and mechanistic 
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experiments limits the ability to propose unifying hypothesis. Nevertheless, 
these data support the need for interventional studies in this important patient 
cohort.  
 
5.4.5 Summary. 
In summary, paediatric STRA is (in part) characterized immunologically by 
defective IL-10 protein expression in BAL cells, and systemic vitamin D status 
(as measured by serum 25(OH)D3 levels) positively correlates with BAL IL-10 
and CD4+FoxP3 cells. Both of these parameters are believed to represent 
important tolerogenic mechanisms to control inappropriate inflammation both 
peripherally and in the airways.  "
Reverting back to the original hypothesis, it was not possible to prove that in 
vitro addition of vitamin D to BAL cells improves steroid responsiveness in 
children with STRA.  This may relate to the small numbers and limited sample 
size. In this chapter BAL cells from children with STRA did not exhibit a 
reduction in glucocorticoid-induced IL-10 synthesis in cell culture, and was not 
restored by vitamin D. However, this chapter does reinforce the importance of 
studying the vitamin D axis and immunology locally rather than just relying on 
peripheral blood.  
 
The vitamin D axis not only includes vitamin D but also incorporates VDBP 
and the vitamin D receptor. The next chapter takes forward these 
observations by describing the expression of VDBP in children with STRA, 
with the aim of gathering further data on potential mechanisms whereby 
Vitamin D may influence the airway immunological milieu.  
 
184" "
 
Chapter 6. Relationship between Vitamin D binding protein and asthma 
severity in children "
6.1 Introduction 
In the previous chapters it has been shown that serum vitamin D levels are 
associated with asthma severity, asthma control, exacerbations, function 
(FEV1, FVC and BDR) and remodelling (ASM mass). Also, in the previous 
chapters vitamin D and dexamethasone were shown to regulate the synthesis 
of the anti-inflammatory cytokine IL-10 and pro-inflammatory cytokines (e.g. 
IL-13, IL-17A) in PBMC and BAL cell cultures. These data were complimented 
by evidence for a positive correlation between BAL IL-10 concentration and 
the frequency of CD4+Foxp3+ T cells with the systemic (serum) vitamin D 
status of the host. However, the vitamin D axis not only includes vitamin D but 
also incorporates VDBP (Figure 1.8), the vitamin D receptor and the various 
enzymes involved in the generation of active vitamin D, 1α,25VitD3, as well 
as its inactivation. 
 
IL-10 protein concentration in BAL cells culture from children with MA & STRA 
was also reduced as compared to controls and importantly BAL IL-10 
correlated with serum vitamin D levels. Also, serum vitamin D was positively 
associated with CD4+ FoxP3 cells. Moreover, in vitro IL-10 secretion by total 
BAL cells cultured with LPS was significantly lower in STRA as compared to 
non-asthmatic controls, however small numbers made statistical comparison 
difficult in the BAL cultures."" 
 
The vitamin D axis incorporates VDBP and the vitamin D receptor. VDBP is a 
glycosylated α-globulin, with 458 amino acids folded into a disulfide-bonded, 
triple-domain structure (chapter 1, figure 1.8).298 Most of the vitamin D in the 
circulation, both 25(OH)D3 and 1α,25VitD3, is bound to VDBP with high 
affinity. Vitamin D is taken up into cells by diffusion of unbound vitamin D 
across cell membranes and by endocytosis of that bound to VDBP.299 
Circulating vitamin D is also bound to albumin. Since the affinity of albumin for 
vitamin D is lower than that of VDBP300 the vast majority is bound to VDBP. 
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The relationship of VDBP and vitamin D concentrations is not yet clear. Low 
vitamin D concentrations were reported in the VDBP knockout mouse model, 
but did not appear to influence levels of vitamin D that are free to enter cells 
and tissues.301 
 
As discussed in chapter 1 section 1.4.9, VDBP is a multifunctional protein. Its 
major functions include binding, solubilization and serum transport of vitamin 
D. VDBP circulates in the plasma at concentrations 20-fold higher than the 
total amount of vitamin D metabolites. The purpose of this large molar excess, 
which is unusual among the carrier proteins of other hormones and vitamins, 
might relate to the immunomodulatory functions of VDBP.395 302, 303 299, 302, 304 
VDBP is expressed in the plasma membrane of neutrophils,305, 306 contributes 
to macrophage activation,303 augments monocyte and neutrophil chemotaxis 
to C5-derived peptides307, 308 and acts as a scavenger protein to clear 
extracellular G-actin released from necrotic cells.309, 310 The anti-inflammatory 
role of VDBP, together with the relationship with serum vitamin D, may 
therefore be important in children with asthma. It could he hypothesised that 
airway inflammation may affect BAL VDBP levels by influencing BAL vitamin 
D levels.  VDBP is present in many body fluids, including serum, BAL, 
peritoneal fluid 396 and cerebrospinal fluid,397 and is also found on the surface 
of many cell types including human neutrophils.306 This also implies 
widespread functionality of the protein, consistent with its effects on the innate 
immunity.  The functions of VDBP are summarised in table 6.1 
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Table 6.1 The functions of VDBP. Reproduced and modified from ‘The 
vitamin D axis in the lung: a key role for vitamin D-binding protein’ Chishimba 
et al299 
 
Function Significance to lung  Mechanism 
Vitamin D 
transportation 
299, 300 
 
Potential influence of 
levels of vitamin D on 
host defence and 
regulation of cell 
proliferation 
Delivery of vitamin D to lung 
parenchyma and to alveolar 
macrophages 
Actin binding 
398 
Prevents systemic 
vascular occlusion 
following cellular 
damage. Potential 
relevance lung injury 
and sepsis 
Prevents formation of F-actin 
networks in the systemic 
circulation. 
The ability of VDBP to bind actin 
blocks the formation of F-actin 
networks that might otherwise 
occlude the vasculature 
following cellular damage. 
Neutrophil 
chemotaxis 307, 
308, 399 
Neutrophil recruitment is 
a key part of host 
defence. Neutrophilic 
inflammation is a 
recognised part of adult 
asthma pathogenesis. 
Enhances chemotactic effect of 
complement-derived peptides.  
DiMartino et al305 demonstrated 
VDBP-binding sites are 
upregulated on activated 
neutrophils,305 suggesting that 
changes in local VDBP 
circulating concentration might 
occur in inflammatory conditions 
like asthma. 
VDBP enhances the 
chemotactic effect of 
complement-derived peptides 
(C5a).399 
Macrophage 
activation 303 
Macrophage activity is a 
key part of host defence 
VDBP is converted to 
macrophage-activating factor by 
enzymes derived from 
lymphocytes 
 
Metcalf et al303 suggested that 
VDBP is converted to 
macrophage-activating factor by 
the action of either β-
galactosidase from B 
lymphocytes or sialidase from T 
lymphocytes on carbohydrate 
side chains of the protein.303 
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Wood and her colleagues304 recently noted that circulating VDBP levels 
inversely correlate with FEV1 in an adult cohort with COPD, and that sputum 
VDBP contributes to macrophage activation.304 VDBP is also found in the BAL 
fluid in mouse models of allergic airways disease,400 but there have been no 
paediatric reports comparing VDBP levels of healthy human subjects and 
those with asthma. Despite the wealth of serum vitamin D studies, there has 
been relatively little work concerning the role of VDBP in children with asthma.  
 
6.1.1 Hypothesis 
In this chapter the hypothesis tested is that children with STRA have higher 
serum and BAL VDBP levels compared to MA and non-asthmatic controls, 
and serum and BAL VDBP levels are associated with worse asthma control 
including lung function, symptoms and steroid usage  
 
6.1.2 Aims 
i. To compare serum and BAL VDBP levels in children with STRA, MA 
and non-asthmatic controls. 
ii. To describe the relationship between serum and BAL VDBP and 
clinical parameters of asthma control including lung function, symptoms 
and steroid use. 
 
Some of these finding have already been published.6 
 
6.2 Methods 
6.2.1 Subjects  
Fifteen children with STRA, 7 with MA and 6 non-asthmatic controls were 
recruited prospectively from the Royal Brompton Hospital, London. STRA was 
defined as previously in chapter 1134 and Children with MA were well 
controlled on lower dose (<800mcg/day) ICS also as previously defined in 
chapter 2. Six non-asthmatic controls comprised either children with no 
respiratory disease whose parents had consented for blood tests during an 
elective surgical procedure (n=2) or children undergoing a clinically indicated 
bronchoscopy for upper airway symptoms (n=4). 
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6.2.2 Measurement of Serum 25-hydroxyvitamin D levels 
Serum 25-hydroxyvitamin D was measured using a 2 dimensional high 
performance liquid chromatography system - tandem mass spectrometry (2D 
LC-MS-MS) as previously described in chapter 2.  
 
6.2.3 Measurement of VDBP levels in the serum and BAL and culture 
supernatants 
VDBP in BAL, serum and cell culture supernatant was measured by Enzyme-
linked immunosorbent assay (ELISA) according to the manufacturer’s manual 
(Immunodiagnostik, Bensheim, Germany).304 The wells of the microliter plate 
were coated with polyclonal anti-VDBP antibodies. In a first incubation step, 
the VDBP in the samples is bound to the coated polyclonal rabbit antibodies 
and in a second incubation step, a polyclonal peroxidase-labeled rabbit-anti-
VDBP antibody is added. It is then incubated with the substrate, 
tetramethylbenzidine. An acidic stopping solution is then added, which 
converts colour to yellow. The intensity of the yellow colour is directly 
proportional to the VDBP concentration in the sample and absorption is 
determined immediately with an ELISA reader at 450 nm against 620 nm as 
reference. Lower limit of detection of VDBP is 1.2 ng/ml and the upper limit is 
600 ng/ml.  
 
Test steps  
1. The pre-coated microtiter plate (PLATE) is washed five times with 250 
microlitres diluted wash buffer. After the final washing step, the inverted 
PLATE is firmly tapped on absorbent paper to remove excess solution.  
2. Tests were always carried out in duplicate 
3. One hundred microliters of Standard, Controls and the pre-diluted samples 
are then added into the respective well.  
4. PLATE is then incubated for 1 hour shaking on a horizontal mixer at room 
temperature and then the contents of the PLATE are decanted and the wells 
are washed five times with 250 microlitres diluted wash buffer. 
5. One hundred microliters of diluted conjugate, Peroxidase-labelled antibody 
is then added into the wells and incubated for 1 hour shaking on a horizontal 
189" "
mixer at room temperature. The contents of the PLATE are decanted and the 
wells are washed five times with 250 microlitres diluted wash buffer. 
6. One hundred microliters of diluted conjugate, Peroxidase-labelled antibody 
is then added to all the wells and incubated 
7. One hundred microliters of substrate, Tetramethylbenzidine is then added to 
all the wells and incubated for 10-20 minutes at room temperature.  
8. Reaction is stopped with stop solution (acidic) and absorption is determined 
immediately with an ELISA reader at 450 nm against 620 nm as reference.  
 
6.2.4 BAL cell cultures 
BAL cells (1 x 106/ml in RPMI/10% foetal calf serum), were cultured in 96 well 
plates for 72 hours at 37°C/5%CO2, in the presence of lipopolysaccharide 
(LPS, 50ng/ml, Sigma-Aldrich) with or without dexamethasone (10-7M, Sigma-
Aldrich) as previously described in chapter 2 for 72 hours. Supernatants were 
harvested and analysed for expression of VDBP.  
 
The dose of dexamethasone (10-7M) is based on PBMC culture results 
(chapter 4) and extensive earlier PBMC work in the laboratory in adults,162, 171, 
178 and children. It would have been ideal to perform a dose response in all 
the subjects but was limited by the small volume of BAL. 
 
6.3 Results  
6.3.1 Subjects 
Demographic data of the children studied are presented in Table 6.2. There 
was no significant difference between children with MA, STRA, and non-
asthmatic controls in age and sex. Children with STRA had lower FEV1, FVC 
and asthma control scores, and by definition were prescribed a higher dose of 
ICS.  
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Table 6.2. Demographic characteristics of subjects✪  
 
STRA 
(n=15) 
MA 
(n=7) 
Controls 
(n=6) 
P value 
Age  
(years) 
11(9-13.7) 11 (10-13) 13 (6.7,14.2) 0.9a 
Male  
 
 7 (47%) 5 (71%) 3 (50%) 0.5£ 
FEV1  
(%predicted) 
76 (63, 85) 95 (84, 95) 93 (89, 95) 0.01a 
FVC 
(%predicted) 
 
86 (75, 95) 103 (86,110) 94 (93,103) 0.03 a 
ACT^ 11.5 (7.3, 15)  18 (15, 23) - <0.001& 
Daily Inhaled 
Corticosteroid 
dose % 
(microgram/day) 
1300 (1000- 
1900) 
600 (400-800) - <0.001& 
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; ACT= 
asthma control test;  
 
✪ Values are given in Median (interquartile range) for continuous variables or as 
number (%) for binary variables.  
^ Score out of 25 
% Beclomethasone equivalent  
  aP value calculated by  Kruskal- Wallis test. 
£P value calculated by  Chi-square test.  
& P value calculated by  Mann Whitney test. 
 
 
6.3.2 VDBP levels in asthmatics and control 
VDBP levels were measured by ELISA (section 6.2.3) in serum and BAL of 
children with STRA, MA and non-asthmatic controls.  Children with STRA had 
significantly higher levels of VDBP in BAL, but not serum as compared to MA 
(p<0.05) and control individuals (p<0.01) (Figure 6.1). Interestingly, there was 
no correlation between BAL VDBP and serum VDBP (Spearman r =-0.19, 
p=0.3).  (Figure 6.2) 
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*p<0.05, **p<0.01, 
Figure 6.1 BAL and Serum VDBP in STRA, MA and controls.  
(A) BAL VDBP levels were higher in STRA than MA (p<0.05) and controls 
(p<0.01), (B) however, no difference in serum VDBP existed between the three 
groups (p=0.8).   
Kruskal-Wallis test was used to assess significance   
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Figure 6.2 Serum and BAL VDBP. No correlation between VDBP in BAL and 
serum VDBP (r=-0.199, p=0.3).  
Correlation was determined by the Spearman rank correlation coefficient. 
 
 
6.3.3 VDBP levels and markers of asthma control 
There was a negative association between concentration of VDBP in BAL, but 
not serum, with asthma control (assessed by ACT; BAL VDBP Spearman r =-
0.5, p=0.01; serum VDBP Spearman r=0.2, p=0.3) as well as spirometry 
(%FEV1 (BAL VDBP Spearman r =-0.4, p=0.01; serum VDBP Spearman r=-
0.3, p=0.2)) and a positive association with inhaled corticosteroid usage (BAL 
VDBP Spearman r =0.6, p=0.002; serum VDBP Spearman r=-0.3, p=0.2). 
(Figure 6.3) 
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Figure 6.3 Relationship between BAL and serum VDBP and asthma 
control, FEV1 and ICS usage.  
 
 (A) Negative association between BAL VDBP levels and asthma control  (assessed 
by ACT, r =-0.5, p=0.01). (B). Inverse association between BAL VDBP and % 
predicted FEV1 (r=-0.4, p=0.01). (C) Positive association between BAL VDBP levels 
and inhaled corticosteroid (ICS) usage (r = 0.6, p=0.002). (D-F). No association 
between serum VDBP and asthma control (r=0.2, p=0.3), FEV1 (r-0.3, p=0.2) and 
ICS usage (r=-0.3, p=0.2).  
 
 
6.3.4 VDBP levels and serum vitamin D levels 
There was no association between circulating vitamin D level and either BAL 
or serum VDBP concentration (BAL VDBP Spearman r =-0.3, p=0.1; serum 
VDBP Spearman r=0.1, p=0.6) (Figure 6.4). In these patients, serum 25-
hydroxyvitamin D levels were inversely correlated with prescribed dose of ICS 
(r=-0.43, p=0.03) and positively associated with asthma control (measured by 
194" "
ACT, r=0.62, p<0.01). However, serum 25-hydroxyvitamin D levels were not 
associated with spirometry (% FEV1) (r=0.27, p=0.16). The relationship 
between serum vitamin D levels and markers of asthma severity is discussed 
in chapter 3 
 
 
Figure 6.4. Serum vitamin D and VDBP in the serum and BAL.  
No association between serum 25-hydroxyvitamin D levels (25 [OH] D3) and BAL 
vitamin D binding protein (VDBP) (r=-0.3, p=0.1) and serum VDBP (r=0.1, p=0.6).  
Correlation was determined by the Spearman rank correlation coefficient. 
 
6.3.5 Effect of dexamethasone on VDBP production 
As expected, children with STRA were on higher doses of inhaled 
corticosteroids than MA (Table 6.2) and non-asthmatic controls received no 
corticosteroids. Dexamethasone has previously been reported to increase 
VDBP gene transcription approximately two-fold in a cultured human 
hepatoma cell line;401 and to increase airway VDBP protein levels in a mouse 
asthma model.400 Therefore, the effect of dexamethasone on VDBP was 
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investigated.   
 
The total BAL cells were cultured and stimulated with LPS, with or without 
additional dexamethasone for 72 hours (n=7). The cell culture supernatant 
was harvested and analysed for VDBP levels by ELISA.  
 
In vitro, the corticosteroid dexamethasone did not promote VDBP synthesis by 
total BAL cells (paired t test p = 0.8) (Figure 6.5). Because of limited sample 
size it was only possible to measure VDBP in the supernatant of BAL cultures 
from 7 STRA children.  
 
 
196" "
 
 
Figure 6.5 The effect of dexamethasone on bronchoalveolar lavage 
(BAL) cells of children with STRA (n=7).  
No difference in VDBP production (p=0.8 as assessed by Mann Whitney test).  "
BAL cells were cultured in 96-well plate (250,000 cells per well) and exposed to 
lipopolysaccharide (LPS, 50ng/ml) alone and in combination with 10-7M 
dexamethasone (D; 10-7 M) for 72 hours. Supernatants were harvested and analysed 
for expression of VDBP.  
 
6.3.6 Relationship between BAL VDBP levels and airway inflammation 
and remodelling   
It is logical to try to determine whether inflammation in each compartment is 
correlated with BAL VDBP. Therefore, analysis was performed to investigate 
the relationship between the BAL VDBP and markers of airway inflammation, 
both luminal (represented by sputum and BAL) and mucosal (represented by 
EB). There was no association between BAL VDBP and luminal inflammation 
(BAL neutrophils r=0.048, p=0.8; BAL eosinophils r=0.15, p=0.5; BAL 
macrophages r=-0.01, p=0.9) or tissue inflammation (submucosal neutrophils 
r=0.08, p=0.7; submucosal eosinophils r=-0.3, p=0.2) (Table 6.3)  
 
In this thesis, serum vitamin D is positively associated with ASM but not with 
RBM thickness or epithelial shedding. The association between serum vitamin 
D and airway remodelling (ASM mass) in children with STRA is supported by 
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in vitro and animal work (discussed in chapter 1 section 1.4.10). As BAL 
(local) VDBP, but not systemic (serum) VDBP is raised in children with STRA 
and is associated with disease severity (addressed earlier in this chapter), 
analysis was performed to investigate the relationship between the BAL 
VDBP and markers of airway remodelling in EB of children with STRA 
(assessed by RBM thickness, ASM mass and epithelial shedding. There was 
no association between BAL VDBP and RBM thickness (r 0.18, p 0.2), ASM 
mass (r -0.14, p 0.5) or epithelial shedding (r 0.12, p 0.9) (Table 6.4)  
 
Table 6.3 No relationship between BAL VDBP and airway inflammation  
Marker of inflammation  Spearman r  P value 
Sputum neutrophils 0.28 0.1 
Sputum eosinophils -0.20 0.5 
BAL neutrophils 0.048 0.8 
BAL eosinophils -0.15 0.5 
BAL macrophages -0.01 0.9 
Submucosal neutrophils 0.08 0.7 
Submucosal eosinophils 0.3 0.2 
 
Table 6.4 No relationship between BAL VDBP and airway remodelling  
Marker of inflammation  Spearman r  P value 
RBM thickness  0.18 0.2 
ASM mass (Vv) -0.14 0.5 
Epithelial shedding 0.12 0.6 
PCNA -0.04 0.9 
Vv, Volume faction of smooth muscle indexed to volume of submucosa tissue 
=smooth muscle (SM)/SM+submucosa 
PCNA, positive cell nuclear antigen positive smooth muscle cells=PCNA SM cells/ 
SMcells (%)  
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6.4 Discussion  
6.4.1 Principle findings  
The work of this chapter has shown for the first time that the local (BAL), but 
not systemic (serum), levels of VDBP are significantly higher in children with 
STRA as compared to the MA and non-asthmatic controls and that BAL 
VDBP levels inversely correlate with asthma severity, as assessed by ACT, 
spirometry, and inhaled corticosteroid usage.  Serum VDBP status did not 
correlate with any of these parameters of asthma control nor did it correlate 
with serum vitamin D levels or BAL VDBP levels.  
 
6.4.2 Strengths and weaknesses 
These data highlight the potential importance of the vitamin D axis, beyond 
vitamin D itself, in children with asthma. The cross-sectional design of this 
study cannot attribute causality, but strongly suggests that further study of 
local (pulmonary) vitamin D axis as a potential biological modulator is 
warranted. Functional work to clarify how VDBP may contribute to asthma 
severity should be a key part of any future investigation of the vitamin D axis, 
as well as a study of the mechanisms of any beneficial effects of 
supplementation of vitamin D in lung disease. 
 
Dexamethasone has previously been reported to increase VDBP gene 
transcription approximately two-fold in a cultured human hepatoma cell line 401 
and to increase airway (BAL) VDBP protein levels in a mouse asthma model 
400 suggesting a potential iatrogenic cause of these cross-sectional 
observations. The current findings indicate no modulation of VDBP expression 
by total BAL cell culture of 7 STRA children exposed to dexamethasone in 
vitro. However, it was not possible to exclude a dose effect because of limited 
sample size so an in vitro dose titration with dexamethasone was not 
performed. Another limitation of this work is that the effects of dexamethasone 
were not studied in MA and controls and importantly, it is not known which 
cells are producing VDBP in the airways of children with STRA. This limits any 
firm conclusions.  
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Interestingly, in children with STRA no association between inflammatory cells 
quantified (eosinophils or neutrophils cells) and BAL VDBP levels was noted 
and this may be related to relatively small numbers. However, it is also 
possible that the substantial anti-inflammatory treatment prescribed for these 
children may have masked a relationship between VDBP and airway 
inflammation in STRA.  
 
A weak but significant positive association (Spearman r=0.29, p<0.01) 
between serum VDBP and serum vitamin D levels has been reported in 469 
adults.402 Interestingly, there was no association between serum VDBP and 
serum vitamin D levels in the current chapter, and this may be related to small 
numbers. Importantly, there was also no association between BAL VDBP and 
serum VDBP and this stresses the importance of studying the vitamin D axis 
closer to the site of disease (locally) rather than just in peripheral blood."
 
6.4.3 Possible mechanisms by which excessive VDBP in the airway 
may limit vitamin D bioactivity with potential immunological 
consequences 
The vast majority of circulating vitamin D, both 25(OH)D3 and 1α,25VitD3, is 
bound to VDBP, which circulates at levels that far exceed those of its ligand. 
Cellular uptake of vitamin D can occur via both VDBP-independent and -
dependent pathways, although the biological significance of signaling via 
these different pathways is not known.  In vitro addition of VDBP to monocyte 
cultures impairs vitamin D responsiveness403 presumably by limiting free 
diffusion of unbound vitamin D into the cells.  This may represent one 
mechanism by which excessive VDBP in the airway may limit vitamin D 
bioactivity with potential immunological consequences. 
 
An alternative explanation may relate to the effects of VDBP on innate 
immune cell function.  VDBP augments the chemotactic effect of complement 
derived peptides (C5a) and together with macrophage activating factor drives 
macrophage activation in vitro towards a highly phagocytic phenotype with 
increased superoxide generation.299, 304 Alveolar macrophages are almost 
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invariably the most abundant cell type in the airway lumen, and exhibit 
phenotypic changes in asthma.404 In health, local signals may restrain these 
cells, making them relatively unresponsive to inflammatory stimuli, believed to 
be important for the prevention of airway hyperreactivity.404  It is plausible that 
in asthma excessive airway VDBP drives alveolar macrophages into a more 
inflammatory state, diverting them from their tolerogenic role. The final 
possible interpretation of these data could simply be that raised airway VDBP 
is a marker /mediator of steroid resistance. BAL VDBP levels were positively 
associated with prescribed ICS dose and it would have been interesting to 
assess relationship between BAL VDBP and steroid response. However, 
sample size was too small to assess the relationship between BAL VDBP and 
steroid response in children with STRA and this hypothesis still needs to be 
proven in larger cohort.  
 
6.4.4 Meaning of the results 
Having established a link between local (BAL) VDBP and asthma control, 
spirometry and prescribed inhaled corticosteroid dose in this chapter, it is 
logical to support further functional work in investigating BAL VDBP as a 
biological mechanism or marker of disease severity and/or steroid resistance 
and how it relates to vitamin D axis, and supplementation of vitamin D. This 
chapter also emphasizes the importance of studying mechanisms in the hope 
of finding therapeutic interventions locally (BAL), not just systemically 
(peripheral blood) in children with STRA. For example from this work totally 
different conclusions would have been reached if BAL VDBP was not studied.  
  
6.4.5 Summary  
The original hypothesis, that children with STRA have higher levels of VDBP 
in serum and BAL than non-asthmatic controls and VDBP levels are 
associated with clinical parameters of asthma control, has not been 
confirmed. In this cross-sectional study, only BAL VDBP levels were elevated 
in children with STRA, and inversely correlated with asthma control, 
spirometry and corticosteroid usage. Since the study was cross-sectional, any 
conclusions must be tentative but nevertheless, this chapter highlights the 
importance of (a) evaluating not just vitamin D but also other elements of 
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Vitamin D pathways; and (b) studying these pathways locally within the airway 
as far as possible, and not relying on peripheral blood. This is discussed in 
more depth in the next chapter, which also discusses the overall meaning of 
the study, the strengths and limitations, and what avenues for further work 
have been opened up. 
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Chapter 7 Discussion "
7.1 Main Findings  
The main findings reported in this thesis are as follows;  
(1) Children with STRA have significantly lower serum vitamin D levels than 
MA and controls. Lower serum vitamin D levels were associated with 
worse lung function, poorer asthma control and more inhaled steroid use 
in MA and STRA. Importantly, within the STRA group, low serum vitamin 
D levels were associated with increased ASM mass.  
 
(2) Reduced IL-10 protein concentration in PBMC cultures and BAL 
supernatant was found in children with asthma. Moreover, in vitro 
dexamethasone induced IL-10 secretion in the peripheral immune cell 
cultures was significantly lower in both STRA and MA compared to non-
asthmatic controls. The addition of vitamin D to PBMC cultures 
enhanced IL-10 responses to dexamethasone.  
 
(3) In children with STRA, BAL fluid IL-10 levels were significantly lower 
than in MA and non-asthmatic controls. Levels of serum vitamin D 
directly correlated with IL-10 levels and CD4+FoxP3+ cells in the BAL.  
 
(4) BAL, but not serum levels of VDBP were significantly higher in STRA, 
and BAL VDBP levels inversely correlated with asthma severity, as 
assessed by ACT, spirometry, and inhaled corticosteroid usage.  
 
7.2 Original hypotheses  
The hypotheses underpinning this work were as follows 
1. Children with STRA have lower serum vitamin D levels than MA and 
non-asthmatic controls, and these are associated with worse clinical 
parameters of asthma control including lung function and symptoms, and 
worse pathological markers of asthma severity including airway remodelling. 
 
2. In vitro, steroid responsiveness of PBMCs from children with STRA can 
be improved by addition of Vitamin D. 
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7.2.1 Hypothesis 1  
The first part of the hypothesis was proven: children with STRA had a higher 
prevalence of vitamin D deficiency even after adjusting for confounding 
factors (age, sex, % predicted FEV1 & FVC, body mass index and ethnicity) 
by multivariate analysis. There was no significant impact of season of sample 
collection on serum vitamin D level in the three groups. The cross-sectional 
design of this thesis made it impossible to determine whether low vitamin D 
levels result in severe asthma in children, or whether children with severe 
asthma have low vitamin D levels because, for example, they are unable to go 
outside and exercise normally. Furthermore, because by definition, STRA 
children were prescribed more medication than MA, it is virtually impossible to 
determine whether this was related to treatment or asthma severity, and also 
whether any of the subsequent associations described here were related to 
treatment or vitamin D levels. There were insufficient STRA children who were 
vitamin D sufficient for the interactions between STRA, steroid treatment and 
vitamin D levels to be unpicked. 
 
The second part of this hypothesis was that lower serum vitamin D levels in 
children with asthma are associated with worse clinical parameters of asthma 
control and this was partially confirmed.  This study has shown that even after 
adjusting for confounding factors including age, sex, body mass index, FEV1 
and ethnicity, a significant relationship between serum vitamin D levels and 
asthma control, exacerbations, inhaled and oral steroid use and positive BDR 
remained. Importantly, within STRA, low vitamin D levels were associated 
with increased ASM mass, but not with other parameters of airway 
remodelling. Surprisingly, there was no association between any of the 
inflammatory cells quantified (eosinophils, neutrophils or mast cells) and 
serum vitamin D levels. This remained true for both luminal inflammation (BAL 
and sputum) and tissue inflammation (EB). This may be related to the 
relatively small numbers, although this study is comparable in size with other 
airway biopsy studies. It is also possible that the substantial anti-inflammatory 
treatment prescribed for these children may have masked a relationship 
between vitamin D and airway inflammation in STRA. So, for example, the 
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closest relationship between induced sputum eosinophils and FeNO50 is in 
steroid naïve asthmatics.405 The negative association between serum vitamin 
D levels and ASM mass noted in this thesis may be consequence of 
confounding factors but with relatively small numbers it was not possible to do 
multivariate analysis. Ideally it would have been useful to repeat the flexible 
bronchoscopy 4 weeks later with stage 3 investigations, but this was not 
thought to be ethical. The cross-sectional nature of the biopsy data prevents 
certainty as to whether the relationship between increased ASM mass and 
vitamin D is a result of severe asthma, or whether the increased ASM mass 
may have been present before the development of disease and caused the 
asthma, although the findings from the biopsy studies369 of others militate 
against this second explanation.  
 
7.2.2 Hypothesis 2  
The second hypothesis in this thesis was that in vitro, steroid responsiveness 
of peripheral immune cells from children with STRA can be improved by 
addition of vitamin D. This study has shown that children with STRA have 
reduced IL-10 protein concentration in both PBMC cell cultures and BAL 
supernatant. Addition of vitamin D to PBMC cell culture enhances 
dexamethasone induced IL-10 secretion. These data were complimented by 
evidence for a positive correlation between BAL IL-10 and the percentage of 
CD4+Foxp3+ T cells with the systemic (serum) vitamin D status of the host. 
As discussed in chapter 1 section 1.3.3, reduced IL-10 protein levels and 
Tregs may be related to steroid resistance. Vitamin D may therefore improve 
steroid responsiveness in children with STRA. However, there may also be 
additional uninvestigated mechanisms of steroid resistance in the STRA 
group. The lack of functional and mechanistic experiments (for example how 
steroids and vitamin D interact at a molecular level) limits the ability to confirm 
that these mechanisms are of in vivo clinical significance. Nevertheless, the 
data supports the need for clinical and immunological data from interventional 
studies in this important patient cohort to confirm the benefit of 
supplementation with vitamin D.  
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7.3 Strengths of the study  
This is the most extensive study of vitamin D and immune-pathophysiology in 
children with STRA. A major strength of this study is the very detailed 
evaluation of potentially reversible factors to ensure as far as possible that the 
children had truly severe therapy resistant disease. The detailed multi-
disciplinary assessment to ensure, as far as possible, that basic management 
is correct is one of the novel features of this study. Adherence was assessed 
by checking prescription pick up. Paediatric respiratory nurses checked the 
location and availability of medications in the home and school.136 As a part of 
the clinically indicated stage 1 difficult asthma investigations (see chapter 1, 
Text box 1.3) the paediatric respiratory nurses also checked for allergen and 
environmental tobacco smoke exposure in the home and asked the children 
and family to fill in psychosocial questionnaires, and referred those with 
significant morbidity for professional help. All these assessments had to be 
completed prior to invasive assessments (stage 2 & 3 investigations, details in 
chapter 1). This is really important, because for example if apparent steroid 
resistance is caused by the steroids not being inhaled, vitamin D related 
mechanisms are unlikely to be relevant. It should be noted that no 
assessment is perfect, and there may still be some children in the group who, 
for example, had undetected poor adherence. The result of this would have 
been to reduce the chances of finding differences in STRA children, because 
the group would have been diluted by non-STRA subjects. 
 
Airway inflammation was assessed extensively in children with STRA both 
non-invasively and invasively with a range of techniques, including induced 
sputum, BAL and EB. Tissue sections were assessed for markers of 
remodelling and inflammatory cells. Importantly, the measurements of airway 
inflammation and remodelling were performed prior to the steroid trial. Rather 
than an oral steroid trial that relies on adherence from the patient, the steroid 
trial was given as an intramuscular injection to eliminate adherence from the 
equation. All but the invasive measurements were repeated 4 weeks after the 
steroid dose, and used to assess steroid responsiveness (ideally 
bronchoscopy would have been repeated, but this was not thought to be 
ethical). A true definition of steroid responsiveness is not known in children, 
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so rather than relying on the measurement of change in just FEV1 which can 
be insensitive in children with severe asthma,406 the response was measured 
in four different domains.134 Cytokines were measured in BAL and serum as a 
first step in determining the relationship between vitamin D and airway 
inflammation and remodelling. An additional strength of the study is the best 
use of these valuable and limited samples collected from an uncommon group 
of children who are relatively very difficult to study. However, there are 
inevitable inherent limitations, which are discussed in the next section.  
 
7.4 Limitations of this study  
It is important to recognise that, in establishing the link between vitamin D and 
asthma, there are several challenges. In spite of a wealth of data showing 
epidemiological associations, we still have a poor understanding of the 
potential mechanisms due to the complex nature of the pathways involved, 
the widespread expression of the vitamin D receptor across different cell 
types, the capacity to synthesize the active form of vitamin D locally and the 
genetic basis of inter-individual variability in vitamin D status. The majority of 
the body’s vitamin D is produced by exposure to UV-B radiation and UV-B 
radiation is also known to be an important immunomodulator and can exert its 
effects through several non-vitamin D dependent pathways.407 It is possible 
that serum vitamin D levels are simply a surrogate marker for UV-B exposure 
and vitamin D is not a causative pathway for disease outcomes. In the 
background of asthma, the potential relationship with vitamin D deficiency is 
further confounded by the strong association between physical activity, which 
is linked to an individual’s level of sun exposure229 and disease severity, 
which means that it is unclear if vitamin D is simply an indirect marker of 
physical activity or disease severity and, therefore, is an innocent spectator in 
disease pathogenesis. However, the experimental work of this thesis and 
independent adult and animal studies gives biological credibility to the effects 
of vitamin D being important. Also, whether there is a direct effect of 
inflammation in asthma on circulating vitamin D levels is not known, it is 
possible that in the setting of chronic airway inflammation systemic vitamin D 
levels may be reduced as a direct result of the inflammatory response itself,230 
which further confounds the positive association between vitamin D 
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insufficiency and disease severity.230 Therefore the cross-sectional design of 
this thesis made it impossible to determine whether low serum vitamin D 
levels result in severe asthma in children, or whether children with severe 
asthma have low serum vitamin D levels because, for example, they are 
unable to go outside and exercise normally. The level of physical activity and 
sunshine exposure were not recorded in this thesis, and this is acknowledged 
as a weakness, which therefore limits the ability to investigate for reverse 
causation. Also, it was not possible to adjust for potentially important factors 
such as the association between atopy and serum vitamin D with relatively 
small n numbers and non-normal distribution of data. Association does not 
prove causation and other explanations remain a possibility. Low serum 
vitamin D levels may contribute to asthma severity in children, or 
corticosteroid usage might result in low serum vitamin D levels228 ; or asthma 
severity, steroid usage, and low vitamin D levels may be caused 
independently by another as yet undetermined factor. By definition, children 
with STRA will always be on more treatment than children with MA, and this is 
inevitable. To unpick the interactions between vitamin D, asthma severity and 
corticosteroid usage, either a prospective study is needed, enrolling subjects 
with asthma before initiation of any treatment to see if those who eventually 
prove to have STRA had lower vitamin D levels from the outset; or, more 
practically, to show that supplementing children with established STRA with 
vitamin D improves asthma control and reduces exacerbations. Another 
limitation is the poor matching of BMI and race/ethnicity in STRA children with 
non-asthmatic controls. "
The assessment of bronchial responsiveness consisted of acute BDR rather 
than a formal airway challenge, which is often performed in adult studies. 
Ideally, both direct and indirect airway challenges would have been 
performed. Airway hyperresponsiveness assessment was considered not to 
be ethical as it is potentially dangerous in childhood STRA. A further limitation 
of this study was that BDR and ACT scores were not performed in normal 
controls. There was a lack of STRA children with normal vitamin D levels and 
thus it could be postulated that STRA, low vitamin D levels, high corticosteroid 
usage, high ASM mass and bad outcomes all cluster together and vitamin D 
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is not a causal factor. A steroid trial was not performed in MA and in fact it 
would be unethical to perform a high dose steroid response study in a group 
of mild-moderate asthmatics.  
 
There was no association between airway inflammation and serum vitamin D 
levels and this may be related to relatively small numbers or the substantial 
anti-inflammatory therapy prescribed to the STRA children. It is also possible 
that airway inflammation would correlate with pulmonary vitamin D levels, but 
we were unable to quantify this in BAL. An attempt was made to measure 
vitamin D levels in the airway (BAL) with the help of senior clinical biochemists 
at Homerton Hospital (Dr Peter Timms) and RBH (Dr Jackie Donovan). 
However, in preliminary work, vitamin D could not be reliably detected in 
unconcentrated BAL fluid. The presence of vitamin D in the BAL was noted 
using a 2 dimensional high performance liquid chromatography system - 
tandem mass spectrometry (2D LC-MS-MS) but was below the limit of 
detection of 3nmol/L. Unfortunately, not enough resources and in particular 
spare BAL samples were available for this study to develop efficient BAL 
concentration and purification techniques. The inability to measure BAL 
vitamin D levels remains a limitation of this work. 
 
A considerable effort was made to assess the patients before subjecting them 
to more invasive investigations, but even with this adherence could not be 
completely assured in the STRA group. Ideally directly observed therapy, or 
smart inhalers that automatically record when medication is taken would have 
been employed but unfortunately such resources were not available for this 
study. Allergen exposure is linked to poor asthma control and 
exacerbations,408 therefore a respiratory nurse assessed allergen exposure 
subjectively at the home visit but environmental sampling was not performed.  
 
Additionally the recruitment of controls and MA for bronchoscopies is difficult.  
All bronchoscopies undertaken at our centre are performed under general 
anaesthesia; it is therefore unethical for children to have these performed 
solely for research purposes. Children having clinically indicated 
bronchoscopies by definition have respiratory conditions and therefore very 
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rarely are completely healthy controls, albeit they are non-asthmatic. Similarly, 
bronchoscopy is only justified in a mild-moderate asthmatic if they have 
another condition. The ideal study would have involved recruiting totally 
healthy children, and well-controlled mild asthmatics, but this was not ethically 
feasible. However, we have previously found differences between asthmatics 
and these best possible controls, and again in this study, despite the 
limitations, differences were apparent between children with STRA and 
controls.  
 
There is emerging evidence that low serum vitamin D levels are associated 
with more viral respiratory infections, especially among patients with asthma, 
329 and with increasing asthma severity.183 Importantly, viruses often trigger 
exacerbations in STRA, and are thought to reduce steroid sensitivity in adult 
asthma.152 In the present study it was not possible to study this association 
because as far as possible, for safety reasons, bronchoscopies in STRA had 
to be performed only when the children were free of a clinically diagnosed 
viral infection in the 2 weeks prior to bronchoscopy.  
 
The requirement to draw only small volumes of peripheral blood (unavoidable 
as rightly limited by ethics committee), after the samples for clinical purposes 
had been taken, precluded thorough functional and mechanistic experiments, 
for example in vitro confirmation of the cellular source of IL-10 and the 
regulatory activity of IL-10-secreting cells. It was not possible to assess dose 
titrations with multiple concentrations of dexamethasone and vitamin D. 
Therefore, more patients are needed to delineate any associations between 
steroid responsiveness and the IL-10 studies.  
 
This work examined peripheral cytokine production by CD8-depleted PBMC 
cell cultures following activation by a T cell specific stimulus. PBMCs include 
CD8 T cells, CD4 T cells, B cells, monocytes, dendritic cells, natural killer 
cells, gamma-delta T cells, and innate lymphoid cells. Thus, the cell 
preparation used for the study cannot be defined as pure CD4+ T cells. 
However evidence from adult studies suggests that CD4+ T cells are an 
important source of IL-10 under comparable culture conditions.163, 171, 273 Also, 
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the percentage of all the populations prior to activation and after the 9 days in 
culture for each group was not assessed and remains a limitation of the in 
vitro work. It was not possible to exclude in vitro effect of dexamethasone and 
vitamin D on cells other than on T cells. 
 
The observed difference in median values of BAL fluid IL-10 between the 
three groups is significant although small and may be difficult to associate 
with meaningful clinical functional differences. On the other hand the 
observed difference between BAL IL-17 levels are higher, but were not found 
to be statistically significant. This may be related to relatively low patient 
numbers. Although a strict protocol for the BAL (including volume and number 
of aliquots instilled) was followed in all the children, the effect of dilution 
cannot be excluded. In this thesis, vitamin D, VDBP, and cytokines levels 
were not measured in sputum supernatant of the children with STRA. It was 
also not possible to assess the source of VDBP detected in the BAL or 
perform functional work to clarify whether, and if so, how VDBP contributes to 
asthma severity or steroid resistance.  
 
The subgroup analyses were often underpowered (for example when steroid 
response was assessed). In this thesis, it was not possible to determine the 
stability of the clinical measurements and vitamin D status to assess the 
significance of any changes reported. It would also have been ideal to repeat 
the bronchoscopy 4 weeks after the steroid injection to assess change in the 
vitamin D status, BAL and biopsy inflammation and remodelling to be 
assessed following the steroid trial. It is however unethical to repeatedly 
perform bronchoscopy in children, as it is an invasive procedure requiring a 
GA. 
 
Finally, this thesis has generated a large number of data points, meaning that 
a very large number of comparisons have been made. It is important to 
distinguish findings from pre-test hypotheses and pre-set analyses, from 
those, which appeared significant in post-hoc reviews. Post-hoc results will 
need testing in a prospective cohort. 
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7.5 Strengths and weaknesses in relation to other studies  
Some of the findings of this thesis concur with previous reports both in 
children and adults with much less severe asthma. These include the 
associations found between low serum vitamin D levels and lower lung 
function,172, 173, 221, 222, 372 increased reversibility to bronchodilator183, 372 and 
greater anti-inflammatory medication (ICS and oral steroid) usage.173, 183  
 
The strong relationship between low serum vitamin D levels and poor asthma 
control (assessed by ACT) and frequent exacerbations noted in this thesis is 
supported by previous reports.183, 222, 371 The association between vitamin D 
deficiency and asthma exacerbations was first noted by Brehm et al,214 in an 
investigation of data gathered in 1024 children of the Childhood Asthma 
Management Program, a randomized controlled trial of comparison of inhaled 
budesonide, inhaled nedocromil and placebo in children with mild-moderate 
asthma.409 They noted that vitamin D insufficiency (<75nmol/L) is related to an 
increased risk of asthma exacerbations. In another study, Searing et al167 
showed an inverse correlation between serum vitamin D levels and use of 
corticosteroids in a cross-sectional study of 100 asthmatic children. They also 
showed that vitamin D augmented glucocorticoid induced IL-10 synthesis in 
PBMC cell cultures. Chinellato et al351 have also recently reported an 
association between lower vitamin D levels and poor asthma control in 75 MA 
children aged 5-11 years.351 In another study410 48 asthmatic children on 
inhaled corticosteroids were randomized to either inhaled budesonide and 
500 IU of cholecalciferol per day or inhaled budesonide and placebo for 6 
months. Significantly fewer children assigned to the vitamin D arm had an 
asthma exacerbation, despite the fact that there were no significant 
differences in the levels of vitamin D achieved in the two groups after 6 
months.410 However, in this relatively small study there was no definition of 
what represented an asthma exacerbation. There is convincing data that 
many of the mechanisms modulated (summarized in Figure 7.1) by vitamin D 
are likely to prevent disease exacerbation, however larger clinical trials of 
sufficient duration are needed to determine whether vitamin D 
supplementation affects markers of disease severity. 
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Two recently published animal (mouse) studies support the findings of this 
thesis. In the first study, Lai et al316 showed that in a mouse model of allergic 
airway inflammation, vitamin D treatment attenuated established structural 
changes of the airways. Importantly, they showed that vitamin D treatment 
could efficiently reduce ASM mass, subepithelial collagen deposition, 
epithelial thickening and prevent goblet cell hyperplasia.316 In the second 
study, Agrawal and colleagues317 examined the effects of dietary 
supplementation with vitamin D in a murine model of allergic airway 
inflammation. By dietary intervention, mice were made vitamin D deficient, 
vitamin D sufficient or further supplemented with vitamin D. Serum vitamin D 
levels were measured at 6 and 13 weeks of age and the values were similar 
to levels measured in humans317 with vitamin D deficiency (15 nmol/L), 
sufficiency (78 nmol/L), and in the third group of mice (supplemented group) 
had serum vitamin D levels of 163 nmol/L. At 6 and 8 weeks of age 
(adulthood) the mice were sensitized to ovalbumin and lung function (airway 
hyperresponsiveness, whole body plethysmography and airway resistance) 
was measured. The lungs were then lavaged to obtain BAL for quantification 
of inflammatory cells and cytokines, lung tissue was isolated and fixed for 
histological assessment and blood taken for circulating Tregs. As expected, 
sensitization to ovalbumin significantly increased airway 
hyperresponsiveness, however in vitamin D deficient mice it was significantly 
higher and in vitamin D supplemented mice airway hyperresponsiveness was 
significantly lower. Importantly, airway hyperresponsiveness was significantly 
higher in vitamin D supplemented as compared to non-sensitized mice, 
suggesting that vitamin D could only partially attenuate changes due to 
allergen sensitization or alternatively, vitamin D supplementation was 
inadequate.318 Lung histopathology showed the expected evidence of airway 
remodelling in sensitized mice with increased collagen deposition and 
enhanced mucus production. Evidence of more severe airway remodelling 
(marked epithelial cell hypertrophy indicated by an increase in epithelial cell 
height, airway occlusion, and mucus staining and collagen deposition) was 
noted in the vitamin D deficient group as compared to vitamin D sufficient 
group. Importantly, the lungs of vitamin D supplemented mice exhibited the 
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mildest features but still had evidence of airway remodelling. As expected, 
ovalbumin sensitization increased eosinophils and IL-5, IL-13 and IL-6 in the 
BAL fluid; they were highest in vitamin D deficient group, and significantly 
reduced (but not to levels measured in non-sensitized mice) in vitamin D 
supplemented mice. Importantly, levels of IL-10 protein in the BAL and Treg 
cells in the blood decreased with sensitization, except when the mice were 
supplemented with vitamin D. For example, in the blood of vitamin D sufficient 
mice, Treg cells (CD4+CD25+T cells) comprised of 3.4%, decreasing to 2.2% 
in deficiency and increasing to 5.5% in the mice with supplemented levels of 
vitamin D. Additionally, for all of the markers that changed with serum vitamin 
D levels, there was a clear dose-dependent effect of vitamin D. Vitamin D 
deficiency was associated with BAL eosinophilia317 and the percentage of 
eosinophils in the BAL were significantly reduced in the vitamin D 
supplemented group. The results of this thesis are partly in agreement with 
the mouse work of Agrawal and colleagues (discussed above),317 who found 
that reduced levels of serum vitamin D are associated with positive BDR, low 
BAL IL-10 protein and Tregs and worse airway remodelling. However, no 
association was found herein between vitamin D and Th2 cytokines and 
eosinophilia, which may be related to disease severity or substantial anti-
inflammatory treatment prescribed for these children. 
 
Total serum IgE levels and specific IgE to cat, dog, pollen, Dermatophagoides 
pteronyssinus and Aspergillus fumigatus were inversely related to vitamin D 
levels in the patients reported here. Some,173, 183 but not all 222 investigators 
have found correlations between lower vitamin D levels and markers of allergy 
in childhood asthma. A U-shaped association between low and high vitamin D 
levels and serum total IgE levels has been demonstrated by Hypponen et al202 
Recently Sharief et al373 noted an interesting association between vitamin D 
deficiency and increased sensitization to aero- and food allergens in children 
(n=3136), but not in adults (n=3454).373 In particular, serum vitamin D values 
of less than 15 ng/mL (36 nmol/L) were associated with peanut (odds ratio, 
2.39), ragweed (odds ratio, 1.83), and oak (odds ratio, 4.75) allergy.373 An 
association between serum vitamin D levels and atopy in children but not 
adults, points to the potential plasticity of vitamin D mediated responses in 
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children, as atopy markers may be more sensitive to serum vitamin D levels in 
children as compared to adults.  
 
High BMI has been linked to vitamin D deficiency411 and steroid resistance in 
adults36, 37 however, there was no link between BMI and vitamin D deficiency 
in the results from the present study, but this may be because of the small 
sample size and the BMI (median 19.5 Kg/m2, interquartile range 16-24) of 
children was not high enough to find a significant difference. The study design 
precluded assessing this possible effect. 
 
Recently Zosky and coworkers412 provided important evidence of the role of 
vitamin D in reducing lung function in a murine model. Female mice were 
made vitamin D deficient or sufficient by dietary manipulation and then mated 
with vitamin D sufficient males. Lung volumes and function were studied in 
offspring by plethysmography, forced oscillometry, thoracic gas volume and 
lung mechanics were determined. Importantly, lung structure was assessed 
histologically including quantitating alveolar numbers.412 They noted that the 
offspring from vitamin D deficient mothers had reduced lung function and 
volume and also a borderline reduced number of alveoli compared with the 
offspring from vitamin D sufficient mothers. There was no difference in the 
somatic growth. Zosky and coworkers412 claimed that this study provides the 
first direct mechanistic evidence for linking vitamin D deficiency and lung 
development. The reduced alveolar numbers could lead to reduced alveolar 
tethering points and potentially airway instability.413 Also, this work provides a 
relatively poor physiologic link to asthma, which is primarily thought of as a 
disease of the airways and bronchial smooth muscle, not of reduced lung 
volumes or reduced alveoli (alveolar simplification) as seen by Zosky and 
colleagues.374, 412 It could be postulated that the vitamin D pathway plays an 
important role in in utero pulmonary development and maternal vitamin D 
deficiency contributes to the structural defects of the airway wall in children 
with STRA. .  
 
Eosinophils are major effector cells in the pathophysiology of allergic asthma 
and in response to allergic stimuli, eosinophils migrate from circulation the site 
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of inflammation where they secrete a range of cytokines, chemokines and 
mediators. Recently Hiraguchi et al414 investigated the direct effect of vitamin 
D on eosinophils in peripheral blood from healthy adults. They noted that in 
vitro eosinophils express vitamin D receptor and vitamin D prolonged 
eosinophil survival and upregulated eosinophil surface expression of the C-X-
C chemokine receptor 4 (CXCR 4) (the putative inhibitory chemokine receptor 
for eosinophils) as compared to the non-treated cells. Also, vitamin D 
counteracted the suppressive effect of IL-5 on CXCR4 while sharing the 
survival enhancing effect.414 Steroids have also been shown to upregulate 
CXCR4 expression in eosinophils.415 Thus, it has been postulated that vitamin 
D may synergistically promote the anti-inflammatory action of steroids by 
recruiting eosinophils away from the site of inflammation via CXCR4 
upregulation.188, 414, 415 Airway eosinophilia predominates in childhood 
STRA119 and the majority of children with STRA are vitamin D deficient. 
Surprisingly, there was no relationship between serum vitamin D and serum, 
BAL or biopsy eosinophils in this thesis. This may be because most children 
with STRA are highly atopic, and the majority of STRA patients are vitamin D 
deficient. This may also be related to substantial anti-inflammatory treatment 
prescribed for these children or perhaps the local (BAL & mucosal) 
inflammation is related to the local (pulmonary) vitamin D axis rather than 
systemic (serum) vitamin D levels. This hypothesis needs to be tested in a 
larger cohort of children with STRA.  
 
Chi et al416 in a recent study investigated effects of vitamin D in cord blood on 
immune function parameters. They used participants who were recruited as 
part of a prospective birth-cohort study designed to evaluate the 
environmental and immunologic causes of asthma in children. In the subset of 
participants at the Boston site, regulatory T-cells (CD4+CD25+FoxP3) were 
also quantified in 55 cord blood samples. The cord blood vitamin D levels 
were inversely related to the proportion of CD4+CD25+, and 
CD4+CD25+FoxP3 Treg cells. These results are different from the positive 
relationship between serum vitamin D and BAL CD4+FoxP3 cells found in 
children with STRA and in adults with moderate to severe asthma.181 These 
differences may be related to the distinct effects and requirement of vitamin D 
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in the prenatal period and in childhood. Chambers et al181 have recently 
shown in a cross sectional study that the frequency of circulating CD4+FoxP3 
Treg cells in peripheral blood is significantly lower in steroid resistant than in 
steroid sensitive adult asthmatics with comparable disease severity. 
Moreover, the majority of adults with severe asthma had vitamin D deficiency 
and importantly serum vitamin D levels strongly correlated with Foxp3+ Treg 
cell numbers in the peripheral blood. These data support the work of this 
thesis and suggest a strong positive correlation between systemic vitamin D 
status and circulating Tregs181 and local (BAL) Tregs. These paediatric and 
adult studies provide important in vivo validation of previous in vitro studies 
with human cells and evidence from animal models179, 417 suggesting that the 
vitamin D pathway plays an important role in enhancing the frequency of the 
CD4+Foxp3+ Treg cell compartment in humans.  
 
In an adult study, Xystrakis and colleagues163 obtained peripheral blood 
CD4+T cells from steroid sensitive and resistant asthmatics. They noted that 
the addition of vitamin D to peripheral cultures from steroid resistant 
asthmatics restored IL-10 secretion in response to dexamethasone to levels 
seen in steroid sensitive asthmatics. More importantly, they also showed that 
oral treatment with vitamin D (0.5mcg calcitrol once daily for 7 days) in steroid 
resistant asthmatics restored IL-10 responses to dexamethasone.163 In this 
thesis, an inverse association between serum vitamin D levels and the use of 
inhaled and oral corticosteroids has been shown in children with STRA. 
Children with the lowest serum vitamin D levels were prescribed significantly 
higher doses of ICS to control their symptoms. It could be postulated that 
lower vitamin D levels contribute to increasing asthma severity resulting in a 
concomitant need to escalate pharmacologic intervention. Reduced IL-10 
protein expression found in the supernatant of peripheral cultures from 
paediatric asthmatics (MA and STRA) in this study is consistent with the 
defective IL-10 expression observed in adult asthma.379, 394 By definition 
children with STRA are steroid resistant and it was interesting to note that 
there was no significant difference in IL-10 secretion by PBMC between MA 
and STRA. In the present study a significant dexamethasone-induced IL-10 
response was found in STRA, however in the adults163 responses were 
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lacking in steroid resistant asthmatics.162 In this thesis, addition of vitamin D in 
peripheral culture significantly enhanced IL-10 responses to dexamethasone, 
similar to the adult study. Importantly, in the present study, STRA children 
were further sub-classified according to their clinical response to a single dose 
of an intramuscular steroid (triamcinolone), as suggested by Bush et al134 
using lung function response, symptom response and inflammatory response. 
Non-responders (SR) were classified as no improvement in any of the three 
domains; partial response (partial responders, PR) was improvement in one 
or two domains; and complete response (SS) was normalisation in all three 
domains.134 Stratification of in vitro responses in this manner revealed that IL-
10 potentiation by vitamin D was highest in SS STRA, but still apparent in SR 
and PR as well. Xystrakis and colleagues noted an increase in IL-10 secretion 
with a combination of vitamin D and dexamethasone in culture of peripheral 
immune cells of steroid resistant asthmatics to the level seen in the steroid 
sensitive asthmatics. Interestingly, in this thesis, IL-10 production achieved 
with the combination of vitamin D and dexamethasone from PBMC culture of 
SR STRA remained less than that seen in cultures of cells from SS STRA. 
Further stratification of IL-10 secretion according to all 4 individual responses 
(symptom, lung function, FeNO50 and sputum eosinophils) after intramuscular 
triamcinolone revealed similar trends. It was interesting to note that the IL-10 
response was most marked in non-asthmatic controls and SS STRA. The 
differences between the adult and paediatric studies could be secondary to 
other factors (e.g. genetic) for defective IL-10, or perhaps dose, duration or 
route of vitamin D exposure (in vivo versus in vitro) may be important. The 
difference may also be related to different adult and paediatric phenotypes. 
CD8 depleted PBMC cell cultures employed here do have predominant CD4+ 
T cells but also other cells, including some antigen presenting cells, gamma-
delta T cells, B cells, monocytes and dendritic cells, which may have been 
important in the results. The variations in the genes regulating steps in the 
vitamin D axis pathway could also explain differences between paediatric and 
adult studies. However, the number of children studied in this thesis was too 
small to look for genetic associations. Goleva et al418 showed that serum 
vitamin D status in asthmatic children correlated inversely with both ICS dose 
and in vitro steroid responsiveness but no significant association was seen for 
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adult asthmatics. This perhaps suggests that the effects were stronger in 
childhood asthmatics. This study was the first to compare an age-specific 
relationship between serum vitamin D levels and cellular sensitivity to in vitro 
steroid responsiveness in 53 children and 50 adult asthmatics. Although 
severity of asthma was not mentioned, 25% of subjects were not prescribed 
ICS and the remaining were on moderate dose of ICS (median daily dose of 
320 microgram), suggesting they were mild-moderate asthmatics. The 
difference between the results reported in this thesis and the adult (Xystrakis 
et al163) study and Goleva et al418 study suggest adult data should not be 
directly extrapolated to children and findings from oral vitamin D 
supplementation trials in adult asthmatic patients might not necessarily be 
applicable to children with asthma.      "
From this work it was difficult to elucidate whether IL-17A caused disease or 
had a protective role. Nanzer et al164 and Chambers and Hawrylowicz 
(unpublished data) have shown that steroids enhance IL-17A synthesis in 
CD4+ T cell culture from adult asthmatics. Also, in a retrospective analysis of 
the data, Nanzer et al164 observed a positive association between inhaled 
corticosteroid dosages and the amounts of blood PBMC IL-17A released 
in vitro (Pearson correlation r = 0.5, P <0.05), supporting the possibility that at 
least some of the IL-17A produced by PBMCs in adult asthmatic patients 
results from corticosteroid exposure. In the work of this thesis, IL-17A 
secretion was significantly enhanced by dexamethasone treatment in vitro in 
STRA peripheral immune cell cultures. This is interesting given the successful 
use of steroids to control a large proportion of steroid-responsive asthmatic 
disease and it could be postulated that IL17A is protective in children with 
STRA. The exact role of IL-17A in asthma is also yet to be fully defined, with 
data from murine models indicating that IL-17A from gamma-delta T cells is 
protective in the resolution of acute airway inflammation.67 Importantly, the 
CD8-depleted PBMC cell culture employed in this thesis contains gamma-
delta T cells, and they cannot be ruled out as a source of steroid-induced IL-
17A. The work of this thesis suggests further investigation of the relationship 
between IL-17A and vitamin D in children with STRA is warranted. 
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In this thesis, serum vitamin D was positively associated with BAL IL-10 
levels. This is the first in vivo study to demonstrate this association. Both 
corticosteroids and vitamin D have been proposed as therapeutic candidates 
to drive IL-10 expression in asthma.92 However it was not possible to identify 
the source of IL-10 detected in the BAL or perform functional work to clarify 
how reduced IL-10 levels in the BAL may contribute to asthma severity or 
steroid resistance. No other cytokines (IL-6, IL-17A, Th2 cytokines) measured 
in the BAL significantly correlated with serum vitamin D levels. Signature Th2-
associated cytokines in BAL, for example IL-5 and IL-13 were largely 
undetectable. This is consistent with observations made in similarly 
characterised paediatric asthmatics, where Th2 cytokines were not prevalent 
and could only be detected in a small subgroup of individuals.44, 119  
 
VDBP is a multifunctional transport protein and is bound via chrondroitin 
sulfate proteoglycans with the surfaces of a large number of cells including 
neutrophils, fibroblasts, B cells, T cells and smooth muscle cells.419 VDBP has 
direct effects299 and also influences vitamin D availability. The influence of 
VDBP on vitamin D availability is complex and whether variation in the 
amount of circulating VDBP affects metabolism and availability of vitamin D is 
still not established. Direct effects of VDBP are known to influence immune 
functions including macrophage activation304 and neutrophil chemotaxis.299 
Very little is known about the role of VDBP in asthma and atopy but it was 
reported to be significantly elevated in a mouse model of allergic asthma.420 
The work of this thesis has shown for the first time that local (BAL), but not 
systemic (serum), levels of VDBP are significantly higher in children with 
STRA and that BAL VDBP (but not serum VDBP) levels inversely correlate 
with asthma severity, as assessed by ACT, spirometry, and inhaled 
corticosteroid usage. The implications of these results with regard to vitamin D 
deficiency in STRA are unclear. It is known that polymorphisms in the VDBP 
gene are determinants of vitamin D status421 and importantly VDBP can 
regulate the bioavailability of vitamin D to cells.403 Polymorphisms of VDBP 
genes determine the activity of vitamin D on monocytes in vitro.403 Recently 
Lee et al419 have shown that proteomic analysis of BAL fluid from 67 mild to 
moderate adult asthmatics identified increased (more than fivefold) 
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concentrations of a VDBP when compared to BAL fluid from 22 adult controls. 
This is in agreement with the work of this thesis. Looking at the individual 
cells, the BAL VDBP levels of adults with asthma was very weakly positively 
correlated with BAL neutrophils (r2=0.2) but not with BAL eosinophils or 
macrophages.419 However, mixed BAL inflammation (BAL eosinophils>3% 
and BAL neutrophils >10%) was associated with the highest VDBP levels and 
pauci-cellular (BAL eosinophils<3% and BAL neutrophils <10%) had lowest 
VDBP concentration.419 However, no correlation between airway inflammation 
(sputum/EB/BAL neutrophils or sputum/EB/BAL eosinophils) or BAL Th1, Th2, 
Th17 cytokines and BAL VDBP was noted in this study. As discussed earlier, 
this may be related to relatively small numbers and it is also possible that the 
substantial anti-inflammatory treatment prescribed for these children may 
have masked a relationship between VDBP and airway inflammation. 
Importantly, in a murine model, Lee et al419 also showed that VDBP mRNA 
and protein levels were elevated in ovalbumin challenged mice and intranasal 
administration of anti-VDBP antibody dose-dependently reduced the 
ovalbumin induced enhancement of airway hyperresponsiveness. The 
neutralization of VDBP with anti-VDBP antibody led to significant 
improvements in airway (BAL) inflammatory cell recruitment, including 
eosinophils, neutrophils and lymphocytes, and decreased peribronchial 
infiltration of inflammatory cells and numbers of goblet cells, in a dose 
dependent manner. Anti-VDBP antibody also significantly reduced levels of 
BAL Th1 cytokine (IFNγ) and Th2 cytokines (IL-5, IL-5, IL-13). As blockage of 
VDBP with anti-VDBP antibody attenuated airway inflammation (both 
eosinophilic and neutrophilic), it could be postulated that VDBP is one of the 
global factors involved in asthma rather than restricted to neutrophil activation. 
This hypothesis was further supported by the finding inhibition of Th2 and Th1 
cytokines by the anti-VDBP antibody. It was interesting to note global effects 
of VDBP blockade on airway inflammation and airway hyperresponsiveness 
but the underlying mechanisms are poorly understood. It could also be 
postulated that the changes in quantity or function of the VDBP could be 
accompanied by changes in the relative proportions of free and bound 25-
hydroxyvitamin D, with the free proportion being the potential rate-limiting 
factor for 1α,25VitD3 production421 and thus influencing the availability of 
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vitamin D to local tissues (for example airway). As discussed before, vitamin 
D has immunomodulatory properties and can modulate allergic inflammation 
and the modulation of vitamin D by VDBP in the airways is a possible 
explanation for some of the effects of VDBP in asthma. The authors also 
postulated an interaction of VDBP with the complement pathway in the 
airways. VDBP is known to act with neutrophils to increase their chemotaxis 
to C5a peptide (discussed in chapter 6) Thus, airway neutrophilic 
inflammation induced by C5a may be dependent on the presence of VDBP in 
the airways.419 The modulation of vitamin D by VDBP in the airways is a 
possible explanation for the effects of VDBP in asthma. In summary, Lee et 
al’s419 work confirms the contribution of VDBP to allergic airway inflammation 
and remodelling and provides a new hypothesis which should lead to a study 
of the effects of blocking VDBP (perhaps with local pulmonary delivery only) 
as a therapeutic strategy. However, further studies are needed to fully 
understand the relationship of vitamin D and VDBP both locally in the lungs 
and systemically, in children with asthma.    
 
7.6 Future work 
 
Need for double blind randomized placebo-controlled clinical trial of 
vitamin D supplementation in children with STRA"
This work shows very interesting associations between the vitamin D axis and 
the pathophysiology of asthma and strongly supports the need for a double 
blind, randomized, placebo-controlled clinical trial of vitamin D 
supplementation in children with STRA. This work also suggests the findings 
from vitamin D supplementation in adult asthmatic patients might not 
necessarily be generalized to children with STRA. Recently an IOM 
Committee203 conducted a comprehensive review of the evidence for both 
skeletal and extraskeletal outcomes of vitamin D supplementation. The 
Committee concluded that available scientific evidence supports a key role for 
vitamin D in skeletal health, however, for other outcomes the evidence was 
inconsistent and inconclusive as to causality, and insufficient to inform 
nutritional requirements. It was stated that clinical trial evidence for these 
223" "
extraskeletal outcomes was limited and generally uninformative.203 The panel 
concluded that more research and reassessment of laboratory ranges for 
serum vitamin D should be done to avoid problems of both under and 
overtreatment.203 
      
The primary end point of the clinical trial should be whether vitamin D 
supplementation improves asthma control and reduces exacerbations in 
children with STRA. As discussed earlier in this chapter, vitamin D deficiency 
is associated with more viral respiratory infections in patients with asthma,183, 
329 and viruses often trigger exacerbations in STRA, and may even reduce 
steroid sensitivity.152 This work has shown an association between low serum 
vitamin D levels and acute exacerbations in children with STRA, however 
whether this is due to an altered response to infections is yet to be elucidated. 
Bronchial epithelial cells cultures from STRA children have profoundly 
impaired interferon-β and interferon-λ mRNA and protein in response to 
rhinovirus as compared to the healthy controls suggesting innate anti-viral 
responses to rhinovirus are impaired in the STRA.422 It would be interesting to 
investigate the effect of adding vitamin D to bronchial epithelial cell cultures 
from children with STRA and determine anti-viral responses. Interventional 
studies are also needed to study the interaction between viruses, vitamin D 
and asthma exacerbations in children with STRA during an acute 
exacerbation using either blood or sputum to assess the primary role of 
vitamin D in modulating the severity and/or duration of illness. 
 
The clinical trial would likely have to be a multi-centre UK study. This thesis 
and previous work119, 134, 136 also reinforces the need for a very detailed 
evaluation of potentially reversible factors (e.g allergen exposure, compliance) 
to ensure as far as possible that the children have truly severe therapy 
resistant disease. Compliance needs to be evaluated by prescription pick up 
and either directly observed therapy or inhalers with microchips which show 
exactly when doses were taken would have been used. Paediatric respiratory 
nurses also need to check for the availability and utilisation of medications in 
the home and school.136 Also, allergen exposure and passive smoke 
exposure needs to be assessed by a scientific sampling. This detailed 
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assessment is similar to the recently proposed international approach.423-425""
From the work of this thesis, it was difficult to propose a unifying hypothesis to 
account for the effects of vitamin D; it would be pertinent to study 
immunopathology following vitamin D supplementation. However it is 
important to recognize that simple deficiency of serum vitamin D does not 
necessarily result in loss of activity of genes activated by the active form of 
vitamin D.426 For example, as discussed in chapter 1 section 1.4.12 the 
antimicrobial peptide cathelicidin is present in skin, monocytes and lung and is 
strongly induced by increased vitamin D in cell culture. However, low vitamin 
D levels are associated with increased parathyroid hormone levels (discussed 
in chapter 1 section 1.4.2) and recently, parathyroid hormone has also been 
found to induce cathelicidin, thus counteracting the potential for decreases in 
levels of this antimicrobial peptide and maintaining appropriate immune 
defence against infection.426, 427 This hypothesis of the existence of systems 
to compensate for local vitamin D insufficiency in airways and immune 
function supports the important role of this molecule in immunity and sheds 
light on the difficulty in consistently detecting clinical phenotypes associated 
with specific systemic serum vitamin D values.426, 427 Paul et al409 recently 
reviewed the potential protective effects of vitamin D on asthma morbidity, 
and these are summarized in Figure 7.2. "" "
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Figure 7.2 Potential protective effects of vitamin D against asthma 
morbidity. Reproduced from ‘Vitamin D and Asthma’409 
 
 
 
 
The question of how much vitamin D is needed to maintain pulmonary health 
should also be investigated further in clinical trials in children. It should be 
noted that there may be different levels appropriate for different organ 
systems, and it is not right to extrapolate between systems. It will be helpful 
when technology is available to readily assess vitamin D and other 
metabolites of the vitamin D axis locally in BAL, sputum and EB. Vitamin D 
deficiency is defined by most experts as a 25[OH]D3 level of less than 50 
nmol/L (20ng per milliliter) which is based entirely on the levels required to 
maintain bone health.185, 190-194 The current IOM guidelines from 2011 
recommended a lower limit of 50 nmol/L (20 ng per milliliter) and an upper 
limit of 125 nmol/L (50 ng/ml).203 This upper limit was not based on concern 
for outright vitamin D toxicity which only occurs at much higher levels.428 
Rather, the recommendation is based on the U-shape of some studies 429-431 
where both vitamin D levels at the low end and high end exhibited elevated 
risks of health outcomes (neonatal vitamin D status and risk of 
schizophrenia429; serum vitamin D levels and risk of pancreatic cancer430 and 
serum total IgE levels 202). The capacity to compensate for lower vitamin D 
levels results in a nonlinear relationship between intake and biological 
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effects,426 however, explaining these findings is challenging432, 433 and needs 
further investigations in a large prospective controlled study in children with 
asthma. Again, this study would have to be a multi-centre study, across the 
UK, and likely international.  
 
The doses of supplementation should ideally not be chosen randomly but 
pragmatically stratified based on individual vitamin D status or genotype and 
response to supplementation should also be monitored. The optimal dose of 
vitamin D to maintain pulmonary health in children with STRA perhaps needs 
to be tested first by more mechanistic studies in peripheral and local (BAL & 
bronchial) cell cultures  (in vitro and in vivo). This will ensure negative results 
are not related to inadequate supplementation.  "
Further mechanistic work "
The interactions of vitamin D with cells of immune system are summarized in 
Figure 7.3 
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Figure 7.3 Overview of vitamin D and its interactions with cells of 
immune system. Reproduced from ‘Vitamin D in Allergic disease”426 
 
 
 
Measuring vitamin D levels in BAL and sputum 
The synthesis of active form of vitamin D, 1α,25VitD3 is dependent on serum 
25(OH)D3 levels, the primary circulating form of vitamin D.185 Until recently, it 
was thought that the conversion to 1α,25VitD3 occurred only in the kidneys, 
but increasing evidence indicates that the cells of most organs express the 
vitamin D receptor and have the capacity to synthesize vitamin D locally.185 
The enzyme (25-hydroxyvitamin D-1alpha-hydroxylase) has also been 
recently found in epithelial cells of the lung, immune cells such as lung 
macrophages, monocytes, dendritic cells, and T lymphocytes266, 434, 435 As a 
result, there are several pathways that can influence an individual’s ability to 
produce and respond to adequate local quantities of the active form of vitamin 
D which is probably the true determinant of physiological function.  However, 
very little is known regarding the levels and clinical significance of vitamin D 
within lung tissues or along mucosal surfaces. It would be important to 
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determine the clinical significance of local activation and vitamin D levels in 
children and the relationship to circulating levels. Importantly, in this thesis 
local (BAL) VDBP not systemic (serum) VDBP was associated with asthma 
severity in children with STRA, reinforcing the importance of assessing the 
vitamin D axis locally. Recently, Liu et al 436 have developed techniques to 
measure vitamin D levels in BAL. They noted an association of vitamin D with 
airway (BAL) inflammation following allergen challenge in adults.436 Also, 
Wood et al have recently developed techniques to measure VDBP in sputum 
of adults with COPD.304 It would be valuable to measure vitamin D (both 
25(OH)D3 and 1.25(OH)D3, although technical challenges still remain) levels 
locally in the BAL and sputum and assess relationships with airway 
inflammation, remodelling and steroid responsiveness.  "
Importance of raised BAL VDBP in STRA "
The cross-sectional design of this study cannot attribute causality, but strongly 
suggests that further study of VDBP as a potential biological modulator and 
functional work to clarify how VDBP may contribute to asthma severity should 
be a key part of the future investigation of supplementation of vitamin D in 
lung disease. It could be that VDBP is a marker of disease severity and/or 
steroid resistance, and this possibility needs to be investigated. It is plausible 
that in asthma excessive airway VDBP drives alveolar macrophages into a 
more inflammatory state, diverting them from their tolerogenic role. This could 
be investigated by using an efferocytosis assay,304 which assesses 
macrophage activation by measuring the proportion of macrophages that 
engulf apoptotic neutrophils. As discussed earlier, VDBP had dual potential 
functions (regulating vitamin D availability and own direct immunological 
effects). The influence of VDBP on vitamin D availability is complex and is still 
poorly understood and further studies are needed to assess the effects of 
variation in concentrations of airway (sputum) VDBP.  
 
Focusing exclusively on total serum or other fluid vitamin D levels is too 
simplistic, and overlooks the role of VDBP in determining free vitamin D 
levels, a consequence of the basic biochemical properties of VDBP. It would 
be valuable to assess the impact of VDBP on free and total vitamin D levels. It 
229" "
could be postulated that the high VDBP levels might lead to a reduction in free 
vitamin D levels leading to the increased risk. Under these kinds of 
circumstances, total vitamin D levels would not provide a complete picture of 
the vitamin D status of the individual. "
IL-17A and vitamin D in children with STRA"
A further pathway that should be explored in children with STRA is the Th17 
axis and its relationship with vitamin D. There was a trend (non-significant) for 
IL-17A to be elevated in BAL of some children with STRA, and IL-17A 
secretion in STRA PBMC was significantly enhanced by dexamethasone 
treatment in vitro and there is recent evidence that this may drive steroid 
resistant disease.35, 165, 437 Nanzer and colleagues have shown that adults with 
severe asthma exhibit increased levels of Th17 cytokines, which are not 
inhibited by steroids, and vitamin D inhibited Th17 cytokine production 
identifying novel properties of vitamin D in adult asthmatic patients. 
 
A study specifically investigating the role of IL-17A and vitamin D in paediatric 
STRA and their impact on steroid responsiveness needs to be undertaken in 
a larger cohort of childhood STRA. The cellular source of IL17A needs to be 
identified by flow cytometry in BAL and immunohistochemistry in EB and its 
secretion from epithelial cell cultures would help to elicit whether it is only 
released from inflammatory cells or whether structural cells also contribute to 
its production in STRA. This is particularly important because a number of 
anti-IL17 antibody strategies are being trialed in rheumatoid arthritis and adult 
asthma.438 However, before this approach is extended into paediatric asthma, 
it is important to determine whether IL-17A is driving asthma, or in fact may be 
protective. It may well be that the cellular source of IL-17A is important in 
determining its effects. 
 
7.7 Summary!
In summary, the work of this thesis highlights the potential pathophysiological 
importance of vitamin D in children with STRA. The original hypotheses of this 
thesis were partly proven, in that children with STRA have significantly lower 
serum vitamin D levels and these were associated with worse lung function, 
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poorer asthma control and more steroid use. Importantly, low serum vitamin D 
levels were associated with increased ASM mass. Defective IL-10 protein 
expression in BAL and peripheral immune cell cultures was noted in children 
with asthma. The circulating levels of serum vitamin D directly correlated with 
IL-10 levels and CD4+FoxP3+ cells in BAL. Moreover, the inclusion of vitamin 
D in PBMC culture enhanced IL-10 responses to dexamethasone 
 
This work also highlights the importance of evaluating not just systemic 
(serum) vitamin D but also the pulmonary vitamin D axis. Other findings are 
hypothesis generating, and need to be validated by larger and more extensive 
studies. These include the role of IL-17A and vitamin D in children with STRA, 
and the role of pulmonary VDBP as a therapeutic target. 
 
This thesis has prepared the ground for a double blind, randomized, 
controlled clinical trial of vitamin D supplementation in children with STRA in 
collaboration with other centres to allow recruitment of sufficient numbers of 
children. Realistically, this will be the best test of whether the vitamin D axis is 
relevant to the pathophysiology of STRA, or whether the associations 
described here and elsewhere are in fact of no clinical significance.  
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Appendix 2.  Sputum Processing Form "
"
!Tube"weight" !Total"weight"(tube"+"sample)"
!Sample"weight"
""""""Whole"sputum"(g)" ! ! !!!!!A!!!!
"Selected"sputum"–"tube"1"(g)" ! ! !!!!B!!!!
""""""Volume"of"DTT"added"(ml)" !!!!4!x!B!!.!!!!!! !!
"""""Volume"of"PBS"added"(ml)"[total"of"1"in"9"dilution]"" !!4!x!B.!!!!!!
!
Counts: Improved Neubauer Haemocytometer Resuspend"cell"pellet" in"1ml"of"PBS," then"dilute"10µl" into"a"know"volume"of"Trypan"Blue"e.g."10µl" cells"+"40µl"Trypan"Blue"for"a"1"in"5"dilution"(i.e.&dilution&factor&=&5)"or"in"10µl"Trypan"blue"(dilution"factor"=2)""
Dilution!factor!! !!!a!!.!!!" """"Viable""""Leukocytes" """""Dead"""leukocytes" ""Squamous""""""""""Cells"Lower"left"4x4" " " "Middle"5x5" " " "Upper"right"4x4" " " "
Average! !!!b!!.!! !!!c!!.! !!!d!!.!
Average!
!leukocyte!count!
!!e!=!b!+!c!.!!!!!!
&
!
!
!
! Leukocyte"count"(x"104/ml)" a!x!e.!
!
!
!
!
Leukocyte!viability!(%)! !!(b!/!e)!x100!.!
!
!
!
!
Squamous!cells!(%)! (d/!(d!+!e))!x!100!.!
Cytospin preparation  Dilution"required"to""prepare"2x105"leukocytes/ml"" "100µl"of"cells"at"2x105"leukocytes/ml"in"PBS"per"cytospin"block""" Number"slides"unfixed/"^70°C" "slides"MeOH/Diff^Quik/mount"" """""" "
Specimen Identification 
Number 
R"Epi"Lymp"Mac"Neuts"Eos" %"%"%"%"%"
Cell Differential 
 
counts for 400 leukocytes 
% of 400 leukocytes""
%"of"Total"Absolute"Count"
Number"
________ul""sputum"supernatants"store"at"–80oC" "
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Appendix 3  Parent information (asthma) 
 
PARENT/GUARDIAN INFORMATION SHEET 
 
 
Vitamin D level and asthma control in children  
 
Thank you very much for taking the time to read this leaflet. 
 
We would be very grateful if you would consider allowing your child to 
take part in a research study. Before you decide whether your child should 
take part, it is important for you and your child to understand why the 
research is being done and what it will involve. We would therefore be 
grateful if you would take the time to read the following information and 
discuss it with your child, friends, relatives and your child’s GP if you wish. 
Also, please feel free to ask the doctor doing this research or your child’s 
consultant here at the Brompton Hospital if there is anything that is not 
clear, or if you would like more information.  
 
Why is the study being done? 
This study will look at ways to improve asthma control in children with 
severe disease that is unresponsive to steroid treatment. 
 
Inhaled steroids are the main treatment that we use for asthma. However, 
they do not always work well in children with severe asthma. These 
children often have a poor quality of life because of inadequate asthma 
control. Making steroids work better in these children would represent a 
major medical advance. We do not know why steroids work so badly in 
some children with severe asthma. We know that adults with severe 
asthma produce lower levels of a natural chemical messenger, interleukin-
10, in response to steroids. Also, when vitamin D (sometimes called 
sunshine vitamin) is added with steroids to blood cells from severe 
asthmatics they respond better to steroids. However, this work has not 
yet been done in children.  
 
In this study, we hope to find out how much of the chemical interleukin 10 
is produced in response to steroids in children with severe asthma and 
compare that to children without asthma.  We also want to find out 
whether addition of vitamin D to blood cells from children with severe 
275" "
asthma increases the production of the helpful Interleukin -10 messenger. 
If increased production of Interleukin-10 is achieved in the presence of 
vitamin D, then this may result in severe asthmatic children becoming 
more responsive to steroid treatment. If successful, then the experiments 
proposed in this study may lead to a new treatment (vitamin D 
supplementation) for children with severe, steroid resistant asthma.  
 
Why has my child been asked to take part? 
We would like to invite your child to participate in this study because 
he/she has severe asthma and is looked after by the doctors at Royal 
Brompton Hospital which is where this study is being done. "
What does the study involve? 
If you are happy for your child to take part in this study, we will do a 
blood test and take up to 5 teaspoons of blood from your child. We will try 
to take the blood whilst they are undergoing a general anesthetic (for 
their operation) or at the same time as they are having any planned blood 
tests (clinically indicated) so as to avoid any additional distress to your 
child. If your child is not anaesthetized when we do the blood test we will 
use an anaesthetic (numbing) cream on their skin (like EMLA or AMETOP) 
to minimize any pain or discomfort.  
 
This blood will be taken to the laboratory to analyze levels of various 
chemical messengers and molecules like interleukin-10 and vitamin D 
levels. We will also perform tests in the laboratory to find out whether the 
active form of vitamin D can magnify the helpful (interleukin-10) 
messenger response when steroids are given. 
 
We will also ask you some questions about your child’s diet in order to get 
an idea of their daily Vitamin D intake. As vitamin D status in children is 
affected by developmental status, we will also ask your child to indicate 
which developmental stage they are at using a short picture 
questionnaire.  
 
 
Are there any risks or side effects involved in taking part?  
The main risks with blood tests are pain, discomfort or bruising at the site 
where the needle goes in. These complications are usually minor and go 
away shortly after the tests are done. As the amount of additional blood 
needed is small, it will not adversely affect your child. Your child’s 
treatment will be unaffected regardless of whether he/she takes part in 
the study.  
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Who is organizing and funding the research? 
This study is organized by the doctors from Royal Brompton Hospital and 
Imperial College, London in collaboration with Kings College, London. 
Equipment needed for the study is funded by a research grant from The 
British Medical Association. No doctor conducting the research will be 
given any remuneration for including your child in this study 
 
What does my child gain from being in the study? 
There is no immediate benefit to your child from taking part in this study. 
 
What happens when the research study stops? 
Your child’s treatment will be continued during and after this study and 
will not be affected by your child’s participation in this study.  
 
What if something goes wrong? 
Imperial College holds insurance policies which apply to this study.  If 
your child experiences harm or injury as a result of taking part in this 
study, you and your child will be eligible to claim compensation without 
having to prove that Imperial College is at fault.  This does not affect your 
legal rights to seek compensation. 
If your child is harmed due to someone's negligence, then you may have 
grounds for legal action.  Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been treated 
during the course of this study then you should immediately inform the 
Chief Investigator (Dr Atul Gupta telephone number 02073528121, extn 
2257).  The normal National Health Service complaints mechanisms are 
also available to you.  If you are still not satisfied with the response, you 
may contact Imperial College Clinical Research Governance Office.  
 
Will my child’s taking part in this study be kept confidential? 
All information which is collected about your child during the course of the 
research will be kept strictly confidential.  Any information about your 
child which leaves the hospital will have your name and address removed 
so that your child will not be identified. 
 
Your child’s GP will be notified of their participation in the trial but we will 
seek your agreement prior to doing this.   
 
What will happen to the results of the research study? 
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The results of the research will be analysed by the research team and will 
be presented at research meetings.  The results will be published in 
medical journals but without identification of any participants in the 
report. All information collected will be confidential, and no information 
will appear in any medical publication that will allow your child to be 
identified.  
 
If you would like to find out about the publication, please let us know and 
we will send you a copy once the results are published. Please remember 
that it can take at least a year after the end of the study to have the 
results published.  
 
Who has reviewed the study? 
The study has been given a favourable opinion by the Brompton, Harefield 
and NHLI Research Ethics Committee. 
 
Does my child have to take part? 
It is up to you and your child to decide whether or not to take part. If you 
and your child do decide to take part you will be given this information 
sheet to keep and you will be asked to sign a consent form. If your child 
decide to take part you are still free to withdraw your child from the study 
at any time without giving a reason. The care and the management your 
child will receive will be exactly the same and will not be affected by your 
participation in this study.  
 
Who can I contact for further Information? 
If you need further information about this study, you can contact Dr Atul 
Gupta on 02073528121, extn 2257. 
 
Thank you for reading this document. You and your child are encouraged 
to ask any questions you may have. Please remember that you may 
withdraw from this study at any time and without giving any reason. 
Please understand that your child need not take part in this trial if you do 
not wish to. If your child does take part, they may withdraw at any time, 
and does not need to give any reason for doing so.  
 
Thank you very much for your kindness in considering this project. 
 "" "
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Appendix 4  Parent information (control) 
 
 
PARENT/GUARDIAN INFORMATION SHEET 
 
 
VITAMIN D LEVEL AND ASTHMA CONTROL IN CHILDREN 
 
Thank you very much for taking the time to read this leaflet. 
 
We would be very grateful if you would consider allowing your child to 
take part in a research study. Before you and your child decide whether to 
take part, it is important for you and your child to understand why the 
research is being done and what it will involve. We would therefore be 
grateful if you would take the time to read the following information and 
discuss it with your child, friends, relatives and your child’s GP if you wish. 
Also, please feel free to ask the doctor doing this research or your child’s 
consultant here at the Brompton Hospital if there is anything that is not 
clear, or if you would like more information.  
 
Why has my child been asked to take part? 
As a parent of a non-asthmatic child, we would like to invite you to 
consider allowing your child to participate in a research project which is 
trying to find ways to improve asthma control in children with severe 
disease. In order for us to be able to fully understand and accurately 
interpret our results, it is essential that we compare the measurements 
we obtain from asthmatics to those made in non-asthmatic children. We 
would therefore be most grateful if you and your child would consider 
taking part in this project. 
 
Why is the study being done? 
This study will look at ways to improve asthma control in children with 
severe disease that is unresponsive to steroid treatment. 
 
Inhaled steroids are the main treatment that we use for asthma. However, 
they do not always work well in children with severe asthma. These 
children often have a poor quality of life because of inadequate asthma 
control. Making steroids work better in these children would represent a 
major medical advance. We do not know why steroids work so badly in 
some children with severe asthma. We know that adults with severe 
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asthma produce lower levels of a natural chemical messenger, interleukin-
10, in response to steroids. Also, when vitamin D (sometimes called 
sunshine vitamin) is added with steroids to blood cells from severe 
asthmatics they respond better to steroids. However, this work has not 
yet been done in children.  
 
In this study, we hope to find out how much of the chemical interleukin 10 
is produced in response to steroids in children with severe asthma and 
compare that to children without asthma.  We also want to find out 
whether addition of vitamin D to blood cells from children with severe 
asthma increases the production of the helpful Interleukin -10 messenger. 
If increased production of Interleukin-10 is achieved in the presence of 
vitamin D, then this may result in severe asthmatic children becoming 
more responsive to steroid treatment.  
What does the study involve? 
If you are happy for your child to take part in this study, we will do a 
blood test and take up to 5 teaspoons of blood from your child. We will try 
to take the blood whilst they are undergoing a general anesthetic (for 
their operation) or at the same time as they are having any planned blood 
tests (clinically indicated) so as to avoid any additional distress to your 
child. If your child is not anaesthetized when we do the blood test we will 
use an anaesthetic (numbing) cream on their skin (like EMLA or AMETOP) 
to minimize any pain or discomfort.  
 
This blood will be taken to the laboratory to analyze levels of various 
chemical messengers and molecules like interleukin-10 and vitamin D 
levels. We will also perform tests in the laboratory to find out whether the 
active form of vitamin D can magnify the helpful (interleukin-10) 
messenger response when steroids are given. 
 
We will also ask you some questions about your child’s diet in order to get 
an idea of their daily Vitamin D intake. We will also ask you some 
questions about your child’s diet in order to get an idea of their daily 
Vitamin D intake. As vitamin D status in children is affected by 
developmental status, we will also ask your child to indicate which 
developmental stage they are at using a short picture questionnaire.  
 
We will also do a blowing test (basic lung function test ‘spirometry’) to 
measures how much air your child breathes in and out and how fast 
he/she blows it out. During the test, we will ask your child to take a deep 
breath in and then blow as hard as he/she can into a tube connected to a 
small machine. Spirometry (blowing test) is done to look for diseases and 
conditions that affect how much air you can breathe in and to look for 
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diseases that affect how fast you can breathe air out. We will explain 
blowing test results to you and your child.  
  
Are there any risks or side effects involved in taking part?  
The main risks with blood tests are pain, discomfort or bruising at the site 
where the needle goes in. These complications are usually minor and go 
away shortly after the tests are done. As the amount of additional blood 
needed is small, it will not adversely affect your child. Your child’s 
treatment will be unaffected regardless of whether he/she takes part in 
the study.  
 
Who is organizing and funding the research? 
This study is organized by the doctors from Royal Brompton Hospital and 
Imperial College, London in collaboration with Kings College, London. 
Equipment needed for the study is funded by research grant from British 
Medical Association. No doctor conducting the research will be given any 
remuneration for including your child in this study. 
 
What does my child gain from being in the study? 
There is no immediate benefit to your child from taking part in this study. 
 
What happens when the research study stops? 
Your child’s treatment will be continued during and after this study and 
will not be affected by your child’s participation in this study.  
 
What if something goes wrong? 
Imperial College holds insurance policies which apply to this study.  If 
your child experience harm or injury as a result of taking part in this 
study, you and your child will be eligible to claim compensation without 
having to prove that Imperial College is at fault.  This does not affect your 
legal rights to seek compensation. If your child is  harmed due to 
someone's negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns 
about any aspect of the way you have been treated during the course of 
this study then you should immediately inform the Chief Investigator (Dr 
Atul Gupta telephone number 02073528121, extn 2257).  The normal 
National Health Service complaint complaints mechanisms are also 
available to you.  If you are still not satisfied with the response, you may 
contact the Imperial College Clinical Research Governance Office.  
 
Will my child’s taking part in this study be kept confidential? 
All information which is collected about your child during the course of the 
research will be kept strictly confidential.  Any information about your 
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child which leaves the hospital will have your name and address removed 
so that your child will not be identified. 
 
Your child’s GP will be notified of their participation in the trial but we will 
seek your agreement prior to doing this.   
 
What will happen to the results of the research study? 
The results of the research will be analysed by the research team and will 
be presented at research meetings.  The results will be published in 
medical journals but without identification of any participants in the 
report. All information collected will be confidential, and no information 
will appear in any medical publication that will allow your child to be 
identified. If you would like to find out about the publication, please let us 
know and we will send you a copy once the results are published. Please 
remember that it can take at least a year after the end of the study to 
have the results published.  
 
Who has reviewed the study? 
The study has been given a favourable opinion by the Brompton, Harefield 
and NHLI Research Ethics Committee. 
 
Does my child have to take part? 
It is up to you and your child to decide whether or not to take part. If you 
and your child do decide to take part you will be given this information 
sheet to keep and you will be asked to sign a consent form. If you and 
your child decide to take part you are still free to withdraw your child from 
the study at any time without giving a reason. The care and the 
management your child will receive will be exactly the same and will not 
be affected by your participation in this study.  
 
Who can I contact for further Information? 
If you need further information about this study, you can contact Dr Atul 
Gupta on 02073528121, extn 2257. 
 
Thank you for reading this document. You and your child are encouraged 
to ask any questions you may have. Please remember that your child may 
withdraw from this study at any time and without giving any reason. 
Please understand that your child need not take part in this trial if you do 
not wish to. If your child does take part, they may withdraw at any time, 
and does not need to give any reason for doing so.  
 
Thank you very much for your kindness in considering this project. 
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Appendix 5  Child information (control) 
 
 
VITAMIN D LEVEL AND ASTHMA CONTROL IN CHILDREN 
 
Young person Information sheet 
 
 
Thank you very much for taking the time to read this leaflet 
 
We would like to ask you to take part in a research study. Before you decide 
whether to take part, it is important for you to understand why the study is 
being done and what it will involve. We would therefore be grateful if you would 
take the time to read the following information and discuss it with your family, 
friends and your GP if you wish. Ask us if there is anything that is not clear, or 
if you would like more information.  
 
What is research?  
Research is done to try and find out answers to important medical questions.  
 
Why is the study being done? 
This study is being done to try and find ways to improve asthma control in 
children with severe disease. 
 
Steroids are the main treatment we use to control asthma symptoms. But some 
children have very severe asthma that does not respond to steroid treatment. 
These children remain poorly and have troublesome asthma. They also often 
have a poor quality of life because of inadequate asthma control. Making 
steroids work better in these children would be very helpful.  
 
It is known that adults with severe asthma produce lower levels of a special 
chemical called interleukin-10 in response to steroids. Importantly, when vitamin 
D (sometimes called sunshine vitamin) is added together with steroids to blood 
cells from these asthmatic adults their asthma responds better to steroids.  
 
In this study, we want to know whether this special chemical (interleukin 10) is 
also lower in children with severe asthma.  We then want to find out whether 
adding vitamin D to blood cells from children with severe asthma increases the 
production of this helpful chemical.  If this does happen, then giving vitamin D 
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to children with severe asthma may make their asthma respond better to 
steroids and make their asthma control better as well. 
Why have I been asked to take part in this study? 
In order for us to fully understand our results it is really important that we 
compare the findings from asthmatic children to those made in healthy children. 
We are therefore asking you as a non-asthmatic child to consider taking part in 
this study. 
 
What happens if I agree to take part? 
• If you are happy to take part in this study, we will need you to have a blood 
test. We can put ‘magic cream’ on your skin before the blood test to help to 
make it numb so that it does not hurt.  As the amount of blood we need is 
small, it will not affect you or harm you in any way. 
• This blood will be taken to the laboratory where the special tests for this 
study will be performed.  
• We will also ask you and your family a few questions to find out how much 
Vitamin D is in your daily food.  
• As vitamin D status is affected by development, we will also ask you to 
indicate which developmental stage you are at using a short picture 
questionnaire.  
• We will also ask you to do a blowing test. 
 
Do I have to take part? 
• It is up to you and your parents to decide whether or not to take part. You 
do not have to take part in the project, and you do not have to say why 
either. 
• The care and the management you will receive will be exactly the same and 
will not be affected by your participation in this study.  
 
Will your taking part in this study be kept confidential? 
All information which is collected during the course of the research will be kept 
strictly confidential.   
What will happen to the results of this study? 
The results of the research will be presented at research meetings.  The results 
will be published in medical journals. All information collected will be 
confidential, and no information will appear in any publication that will allow you 
to be identified.  
Who can I contact for further Information? 
If you need further information about this study, you can contact Dr Atul Gupta 
on telephone number 02073528121, extn 2257.   
Thank you for reading this document. You are encouraged to ask any questions 
you may have.  
Thank you very much for your kindness in considering this project  
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Appendix 6  Child information (asthma) 
 
 
VITAMIN D LEVEL AND ASTHMA CONTROL IN CHILDREN 
Young person Information sheet 
 
 
Thank you very much for taking the time to read this leaflet 
 
We would like to ask you to take part in a research study. Before you decide 
whether to take part, it is important for you to understand why the study is 
being done and what it will involve. We would therefore be grateful if you would 
take the time to read the following information and discuss it with your family, 
friends and your GP if you wish. Ask us if there is anything that is not clear, or 
if you would like more information.  
 
What is research?  
Research is done to try and find out answers to important medical questions.  
 
Why is the study being done? 
This study is being done to try and find ways to improve asthma control in 
children with severe disease. 
 
Steroids are the main treatment we use to control asthma symptoms. But some 
children have very severe asthma that does not respond to steroid treatment. 
These children remain poorly and have troublesome asthma. They also often 
have a poor quality of life because of inadequate asthma control. Making 
steroids work better in these children would be very helpful.  
It is known that adults with severe asthma produce lower levels of a special 
chemical called interleukin-10 in response to steroids. Importantly, when vitamin 
D (sometimes called sunshine vitamin) is added together with steroids to blood 
cells from these asthmatic adults their asthma responds better to steroids.  
In this study, we want to know whether this special chemical (interleukin 10) is 
also lower in children with severe asthma.  We then want to find out whether 
adding vitamin D to blood cells from children with severe asthma increases the 
production of this helpful chemical.  If this does happen, then giving vitamin D 
to children with severe asthma may make their asthma respond better to 
steroids and make their asthma control better as well. 
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Why have I been asked to take part in this study? 
We would like you to take part in this study as you have severe asthma and you 
are being looked after by the doctors at the Royal Brompton Hospital which is 
where this study is being done.   
 
What happens if I agree to take part? 
• If you are happy to take part in this study, we will need you to have a blood 
test. We can put ‘magic cream’ on your skin before the blood test to help to 
make it numb so that it does not hurt.  As the amount of blood we will take 
is small, it will not affect you or harm you in any way. 
• This blood will be taken to the laboratory where the special tests for this 
study will be performed.  
• We will also ask you and your family a few questions to find out how much 
Vitamin D is in your daily food.  
• As vitamin D status is affected by development, we will also ask you to 
indicate which developmental stage you are at using a short picture 
questionnaire.  
 
Do I have to take part? 
• It is up to you and your parents to decide whether or not to take part. You 
do not have to take part in the project, and you do not have to say why 
either. 
• The care and the management you will receive will be exactly the same and 
will not be affected by your participation in this study.  
 
Will your taking part in this study be kept confidential? 
All information which is collected during the course of the research will be kept 
strictly confidential.   
 
What will happen to the results of this study? 
The results of the research will be presented at research meetings.  The results 
will be published in medical journals. All information collected will be 
confidential, and no information will appear in any publication that will allow you 
to be identified.  
If the results of this study show that vitamin D can help children with severe 
asthma respond better to steroids, then we hope to look at vitamin D as a 
possible additional treatment in severe asthma. 
 
Who can I contact for further Information? 
If you need further information about this study, you can contact Dr Atul Gupta 
on telephone number 02073528121, extn 2257.  
Thank you for reading this document. You are encouraged to ask any questions 
you may have.  
Thank you very much for your kindness in considering this project 
